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Status epilepticus (SE) is a major clinical emergency resulting in continuous 
seizure activity that can cause brain injury and many molecular and pathophysiologic 
changes leading to neuronal plasticity.  The neuronal plasticity following SE-induced brain 
injury can initiate epileptogenesis and lead to the ultimate expression of acquired epilepsy 
(AE), characterized clinically by spontaneous, recurrent seizures.  Epileptogenesis is the 
process wherein healthy brain tissue is transformed into hyperexcitable neuronal networks 
   
 xix 
that produce AE.  Understanding these alterations induced by brain injury is an important 
clinical challenge and can lend insight into possible new therapeutic targets to halt the 
development of AE.  Currently there are no means to prevent epileptogenesis following 
brain injury; thus, the elucidation of mechanisms of epileptogenesis will be useful in 
preventing the long-term clinical sequela.  It has been demonstrated in vivo that calcium 
(Ca2+) dynamics are severely altered during SE and that elevations in intracellular Ca2+ 
([Ca2+]i) in hippocampal neurons are maintained well past the duration of the injury itself 
(Ca2+  plateau).  Here we report that similar changes in [Ca2+]i are observed in the 
hippocampal neuronal culture model of SE-induced AE. As an important second 
messenger, the maintenance of a Ca2+ plateau following injury can lead to several changes 
in gene expression, neurotransmitter release, and overall, neuronal plasticity.  Thus, 
changes in post-SE [Ca2+]i and Ca2+ homeostasis may be important in understanding 
epileptogenesis and eventually preventing the progression to chronic epilepsy.  This 
dissertation examines the development and maintenance of the Ca2+ plateau after SE and 
demonstrates the novel finding that pharmacological modulation of [Ca2+]i following SE 
may inhibit epileptogenesis in vitro. 
  1 
 
 
 
 
Chapter 1: General Introduction 
 
 
Status Epilepticus and Acquired Epilepsy 
Epilepsy is one of the most common neurological conditions, affecting about 50 million 
people worldwide [1] and approximately 2.7 million Americans [2].  It results in an 
estimated annual cost of $15.5 billion [3] and thus, represents a significant clinical 
challenge. The condition is characterized by the presence of recurrent, spontaneous 
seizures, which stem from sudden neuronal hyperexcitability.  Approximately 60% of all 
cases of epilepsy are idiopathic, while the remaining 40% occur following neuronal injury 
and are thus, classified as acquired.  Acquired epilepsy (AE) is a neurological condition 
characterized by the development of spontaneous, recurrent seizures following a Central 
Nervous System (CNS) injury such as status epilepticus (SE), stroke, or traumatic brain 
injury (TBI) [4,5].  The process by which healthy brain tissue is transformed into a 
hyperexcitable circuit of neurons giving rise to seizures is called epileptogenesis [6,7].  
The focus of these studies will be on AE following SE, as 20-40 percent of all cases of SE 
develop this chronic condition [7,8].  Moreover, experimental models of SE-induced AE 
remain the most widely studied and best characterized examples of epileptogenesis.  
Ultimately, the AE produced in these models closely resembles the pathology observed in 
humans and has provided tremendous insight into molecular mechanisms of 
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epileptogenesis.  Understanding the pathophysiological mechanisms through which SE 
causes the development of AE would lend insight into mechanisms of neuronal plasticity 
and also aid in the elucidation of new therapeutic targets to prevent epileptogenesis.  
 
SE has been defined as a medical emergency constituting convulsive or non-convulsive 
seizures lasting for at least 30 minutes, or multiple seizures without regaining 
consciousness lasting the same duration of time [9,10].  The seizures can be behavioral or 
electrographic, which can be determined through electrophysiological monitoring using 
electroencephalograms (EEG).  This particular definition of SE, as described above, was 
reached following reports in experimental animal models that correlated seizure duration 
with degree of permanent brain injury; after 30 minutes, animal data indicated significant 
declines in brain oxygenation and increases in cardiovascular distress and refractoriness to 
treatment.  However, this definition has been revisited because from a treatment 
standpoint, after 5 minutes of ongoing seizures there is a high likelihood that the seizure 
will continue for at least 30 minutes and become increasingly difficult to treat [11].  In the 
United States, the frequency of SE is approximately 100,000-150,000 cases annually with 
almost 55,000 deaths per year [12].  Various processes can cause SE including metabolic 
disorders, drug toxicity, head trauma, hypoxia, and stroke.  Often chronic conditions such 
as pre-existing epilepsy, alcohol abuse, or CNS tumors can also precipitate SE [12-15].  
Therefore, experimental models are needed to study both SE and SE-induced AE to better 
understand mechanisms and develop treatments. 
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Models of SE-Induced AE Provide Important Tools to Study Epileptogenesis 
In vivo 
There are several different models utilized to study SE-induced AE (Table 1-1).  The 
development of these models has made SE-induced AE more accessible to study than AE 
caused by other brain injuries, such as stroke and TBI.  Moreover, models of AE following 
SE have provided insight into general mechanisms of neuronal injury [16].  
Chemoconvulsants such as pilocarpine and kainic acid, as well as prolonged hippocampal 
stimulation leading to the spontaneous development of epileptiform activity, are most 
commonly used to induce SE in animals [17,18].  Electrical stimulation can also be used to 
trigger SE and is often utilized as a model of epileptogenesis following SE.  The 
pilocarpine model has been used most often in the studies described in this dissertation; 
thus, in order to understand the model, it is useful to explore the experimental design.  
Briefly, rats are injected intra-peritoneally with scopolamine to block the peripheral effects 
of pilocarpine, a muscarinic agonist.  30 minutes later, the animals are treated intra-
peritoneally with pilocarpine to trigger SE.  The animals are allowed to seize for 1 hr 
before the seizures are terminated with a benzodiazepine, diazepam.  The animals are 
video-EEG monitored approximately 1 month following SE for the development of 
recurrent seizures, or epilepsy.   
 
The animal models that utilize chemicals such as pilocarpine follow a progression that 
correlates closely with the clinical presentation of SE in man. Following SE-induced brain 
injury, there is a latency period characterized by a lack of seizure activity [4,19,20].  This 
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period is then followed by the development of spontaneous, recurrent seizures.  The 
progression from SE to AE is thus, often divided into three stages [19,20]: induction or 
injury (the episode of SE), a latent period of epileptogenesis, and finally the development 
and chronic occurrence of AE (Figure 1-1, Figures from Chapter 1 are adapted from 
Nagarkatti et al. [21]).  The animal models also share several other characteristics with the 
human condition.  In the pilocarpine model, similarities including hippocampal neuronal 
death, astrocyte proliferation, and microglial activation are observed [18,22].  Although the 
in vivo models have the advantage of representing the clinical presentation in an intact 
animal, they also provide challenges in studying the mechanisms of epileptogenesis, since 
it is difficult to control many of the variables needed to conduct molecular biological 
studies in these complex, multi-dimensional systems.  Thus, the development of an in vitro 
model of epileptogenesis has proven to be a useful addition to understanding this clinical 
condition. 
 
In vitro 
Our laboratory has developed an in vitro cell culture model of SE and SE-induced AE 
using cultured hippocampal neurons plated on glial beds [23].  This model offers a 
powerful tool to evaluate potential molecular mechanisms underlying epileptogenesis, but 
has the disadvantage of not representing clinical epilepsy in an intact brain.  The in vitro 
model utilizes a buffer solution with no added magnesium (Mg2+), referred to as “low 
Mg2+” to trigger epileptiform discharges, the in vitro correlate to SE.  These cultures are 
treated with low Mg2+ for three hours (hrs), during which time they manifest continuous 
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epileptiform discharges as a result of removing the Mg2+ block on N-methyl d-aspartate 
receptor (NMDAR).  These discharges occur at a frequency greater than three hertz, 
consistent with the frequency and characteristics of seizure activity observed in clinical, 
electrographic SE.   
 
When the neurons are returned to normal, Mg2+-containing maintenance media and 
patched using whole-cell current clamp electrophysiology, they no longer manifest SE-like 
continuous epileptiform discharges, the neurons instead show only occasional 
depolarizations and short epileptiform discharges.  By 12 hrs post-low Mg2+, the neurons 
consistently exhibit spontaneous, recurrent epileptiform discharges (SREDs), characterized 
by bursts of action potentials over-riding paroxysmal depolarization shifts.  At this and all 
later time points, between six to nine distinct SRED episodes are observed per hour.  These 
SREDs meet the electrophysiological characteristics of seizure discharges observed in 
patients exhibiting seizure activity.  The SREDs persist for the life of the neurons in 
culture and are synchronous events between networked neurons.  Thus, this model utilizes 
an inciting injury that resembles SE to cause the subsequent development of SREDs, an in 
vitro correlate to AE.  The model exhibits several features consistent with the development 
of AE in both in vivo models and the clinical condition, including pharmacoresistance to 
anticonvulsants, cell death, homeostatic changes in Ca2+, and spike frequency [23,24].  
Moreover, the cell injury observed in the in vitro and in vivo models correspond to that 
seen in clinical studies documenting the relationship between SE and neuronal injury [25-
27].   
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The low Mg2+ in vitro model and the in vivo models of SE-induced AE are useful tools to 
study potential molecular mechanisms underlying the induction of AE; however, it is 
important to note that there are several limitations in these models.  Clear differences 
between the experimental models and the human condition include: duration of latency 
between SE and the development of epilepsy, percentage of SE cases that develop 
epilepsy, and comorbidities associated with the pathology [28].  Yet, despite these 
differences, these models have provided much insight on molecular mechanisms of 
epileptogenesis and have been useful tools in the elucidation of new therapeutic modalities.  
 
Ca2+ Dynamics in the Rat Pilocarpine Model of SE-Induced AE 
Both in vivo and in vitro models of SE-induced AE have provided tremendous insights 
into the molecular and cellular changes that occur during and following SE.  This research 
is important since the characterization of mechanisms that cause AE after brain injuries has 
significant implications on the development of new treatments to prevent the progression 
to AE.  Recently, several studies have highlighted the novel observation that intracellular 
Ca2+ ([Ca2+]i) dynamics change during an injury such as SE, stroke, or TBI [29-31].   
 
SE causes elevations in [Ca2+]i  
One landmark paper demonstrated changes in hippocampal neuronal Ca2+ during 
pilocarpine-induced SE and at various time points post-SE [32].  In brief, rats were treated 
with the muscarinic agonist, pilocarpine to induce SE.  The SE lasted for 1 hr before being 
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terminated by diazepam, a benzodiazepine.  Representative EEG recordings generated 
from control animals show ‘normal’ brain activity, whereas traces from animals in SE 
demonstrate the high frequency epileptiform discharges observed following treatment with 
pilocarpine (Figure 1-2 A). Using this model, it was possible to evaluate hippocampal 
neuronal Ca2+ levels during and after SE.  Thus, during and immediately following SE, the 
rats were sacrificed, hippocampal tissue was acutely isolated, various regions were 
dissected out, and neurons were dissociated.  [Ca2+]i levels were evaluated in these neurons 
using Ca2+ indicator dyes.  Significant elevations in [Ca2+]i were observed in hippocampal 
neurons from the CA1 region immediately following pilocarpine-induced SE but not in 
those isolated from vehicle-control animals, 850±59 nM and 90 ± 22 nM, respectively 
(Figure 1-2 B).  This represented a 9.4-fold increase in [Ca2+]i between post-SE neurons 
and control neurons.  These studies suggest that [Ca2+]i, increases during SE. 
 
The Ca2+ plateau following SE: Long-term elevations in [Ca2+]i 
This same paper identified the presence of a “Ca2+ plateau” that is maintained well past the 
duration of the injury itself in the same rat pilocarpine model of SE-induced AE [32].  
[Ca2+]i  was evaluated at 1, 2, 6, 10, and 30 days following SE in acutely isolated CA1 
hippocampal neurons (Figure 1-3).  Neurons from animals in the SE group exhibited 
markedly elevated [Ca2+]i  at each of these time points.  [Ca2+]i does decrease over time 
from the levels observed in neurons isolated from animals immediately after SE.  By 6 
days post-SE, the [Ca2+]i has leveled out but interestingly, is still significantly higher than 
concentrations recorded from neurons in the control group.  More studies are being 
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conducted to better characterize the Ca2+ plateau in this model so as to aid in our ability to 
understand the mechanisms responsible for this novel observation.  
 
SE causes long-term neuroplasticity changes including AE, elevated [Ca2+]i, and 
altered Ca2+ homeostatic mechanisms  
To determine whether the changes in Ca2+ dynamics were transient or more long-lasting, 
animals were treated with pilocarpine or vehicle to induce SE and were then maintained for 
one year post-SE [32].  These animals were evaluated for epilepsy using video-EEG and 
spontaneous, recurrent seizures were observed only in the pilocarpine group, as shown in 
representative EEG recordings from control and epileptic animals (Figure 1-4 A).  
Hippocampal neurons isolated from epileptic animals one year post-pilocarpine 
demonstrated markedly elevated [Ca2+]i (325 ± 35 nM)—more than double the values 
observed in control neurons (Figure 1-4 B). 
 
Neurons from animals displaying the epileptic phenotype were acutely isolated at one-year 
post-SE and also challenged with glutamate to evaluate whether homeostatic mechanisms 
were intact.  Glutamate, as an excitatory neurotransmitter, stimulates neurons so that Ca2+ 
is released into the cell.  Under normal conditions, neurons can recover from this challenge 
and restore [Ca2+]i to the concentration observed prior to the stimulation.  Neurons from 
epileptic animals were unable to restore [Ca2+]i to baseline levels as effectively as control 
neurons, therefore suggesting persistent alterations in homeostatic mechanisms at this time 
point (Figure 1-4 C).  The observation that neurons in animals from the pilocarpine-treated 
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group exhibited marked changes in both [Ca2+]i and Ca2+ homeostatic mechanisms one 
year after the initial injury suggests that Ca2+ dynamics post-SE affect plasticity changes 
and, ultimately, contribute to the maintenance of the chronic, epileptic phenotype.   
 
These studies demonstrated that [Ca2+]i was elevated and Ca2+ homeostatic mechanisms 
were altered well past the duration of neuronal injury.  These changes appear to play a 
significant role in the maintenance of the epileptic phenotype.  The elucidation of the 
specific mechanisms behind such long-lasting alterations remains an important area of 
research; moreover, understanding how these changes lead to development or maintenance 
of chronic epilepsy could provide new information for the development of better 
treatments or new preventative measures to halt epileptogenesis. 
 
Role of Ca2+ in Normal Cellular Physiology 
The importance of altered Ca2+ dynamics is largely based on Ca2+ being an important 
divalent, cationic charge carrier that serves as a second messenger in cell signaling [33].  
Under standard conditions, extracellular Ca2+ concentration is significantly higher than 
intracellular Ca2+ concentration ([Ca2+]i ) at approximately 1-2 mM and 100 nM, 
respectively.  Regulators of intracellular Ca2+ and of Ca2+ efflux pathways are primarily 
responsible for maintaining such low concentrations inside the cell [34].  
 
The large concentration gradient between extracellular and intracellular spaces allows for a 
high signal to noise ratio and thus, enables Ca2+ to serve as a second messenger even upon 
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the smallest of changes in its intracellular concentration.  Transient increases in [Ca2+]i are 
required for higher functions such as learning and memory consolidation through the 
cellular phenomenon of long-term potentiation (LTP) [35].  In addition, such ephemeral 
elevations are necessary for basic neuronal processes, and thereby play a significant role in 
synaptic activity and gene expression (Figure 1-5).  Moderate to severe injuries can lead to 
more sustained elevations in [Ca2+]i resulting in prolonged and often permanent alterations 
in cellular function—such increases can overwhelm the cell and regulators of cellular 
homeostasis, leading to the initiation of pro-apoptotic pathways and, ultimately, to cell 
death [4].  While it is well known that severe elevations in neuronal [Ca2+]i following 
injury can lead to both acute and delayed neuronal death [36], studies from our laboratory 
have demonstrated that the sustained elevations in [Ca2+]i observed in surviving neurons 
lead to altered neuronal function and induce neuronal plasticity [4].   
 
Ca2+, through second messenger effects, can alter gene expression, neurotransmitter 
release, basic cellular functions, and plasticity.  Thus, it is important to examine the 
implications of altered Ca2+ dynamics on the development and maintenance of AE in light 
of recent discoveries in this evolving field.  Further elucidating how the observed post-SE 
Ca2+ plateau contributes both to epileptogenesis and the maintenance of AE remains an 
important area of research.  Understanding the mechanisms responsible for the Ca2+ 
plateau may lead to therapeutic approaches to block this long-term elevation in Ca2+ after 
injuries such as SE, therefore leading to the prevention of AE.  Thus, learning more about 
the mechanisms responsible for altered Ca2+ dynamics after brain injury has potentially 
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important implications for both basic scientists and clinicians.  The following presents an 
overview of evidence documenting the development of altered Ca2+ dynamics and what is 
known on how the Ca2+ plateau following SE contributes to epileptogenesis and AE.  
 
Mechanisms Underlying Ca2+ Changes After SE 
Glutamate and NMDA receptors 
SE is an excitotoxic injury, meaning it triggers the release of large amounts of the amino 
acid neurotransmitter glutamate [37-39].  The degree and duration of SE directly affects 
the concentration of glutamate, which has been reported to exist at extracellular 
concentrations ranging from 1-5 µM under normal conditions. Excess glutamate following 
excitotoxic neuronal injuries such as SE causes the over-stimulation of glutamate 
receptors, including the NMDA receptor that is coupled with a Ca2+-permeable ion 
channel, thus leading to the excess movement of Ca2+ across the cell membrane into the 
cell (Figure 1-6). While glutamate acts at several receptors, it appears that the NMDA 
receptor contributes most significantly to the neuronal pathology and to Ca2+ changes 
observed post-injury, as confirmed by the ability of NMDA antagonists to offer 
neuroprotection when administered prior to injury despite an undiminished SE [40-42].  
Several studies have demonstrated that these elevations in glutamate cause neuronal death 
and that the inhibition of Ca2+ overload through the use of NMDA antagonists can prevent 
both the cognitive sequelae and epileptogenesis [41,43]. 
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A majority of the work demonstrating that epileptogenesis is Ca2+-dependent was 
performed in the hippocampal neuronal culture model of epilepsy as various 
pharmacological inhibitors were able to be utilized to tease out which systems were 
involved in the process.  One study correlated electrophysiological activity with 
intracellular Ca2+ imaging in the presence of various Ca2+ channel inhibitors in order to 
determine if any of these channels were contributing to the development of SREDs (Table 
1-2) [44].  During the 3 hour low Mg2+ treatment, cells were in the presence of either low 
Ca2+ (0.2 mM), 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate (BAPTA) (100µM), 
MK-801 (10µM), APV (25µM), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (10µM), 
2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) (10µM), or nifedipine 
(5µM).  No significant changes in spike frequency, intensity, or epileptic discharge 
duration were observed during in vitro SE under each condition [44].  However, both the 
Ca2+ chelating agent, BAPTA and the low-Ca2+ conditions prevented the development of 
SREDs 48 hrs post-in vitro SE, [44] demonstrating the overall importance of Ca2+ in 
causing SREDs.  Furthermore, NMDA receptor antagonists, including MK-801 and APV, 
exhibited similar effects wherein SE was unaffected but SREDs failed to develop 48 hrs 
following low Mg2+[44].  In contrast, the AMPA receptor antagonists CNQX and NBQX, 
as well as the antagonist of L-type voltage gated Ca2+ channels, nifedipine, failed to inhibit 
SREDs at this time-point [44].  Moreover, when Ca2+ imaging was performed on the 
neurons under each condition while the cells were in low Mg2+ it was demonstrated that 
only low extracellular Ca2+, NMDA antagonists, and BAPTA were able to prevent or 
diminish Ca2+ entry during SE [44].  Thus, this study demonstrated in vitro that Ca2+ is a 
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necessary component in the generation of SREDs post-SE and that the NMDA receptor in 
particular contributes to the Ca2+ entry involved in epileptogenesis.  
 
Intracellular regulators of Ca2+ 
Neurons have a network of endoplasmic reticulum (ER) which contributes to the overall 
levels of [Ca2+]i by acting to either release or sequester Ca2+ [45].  Ca2+ that is stored in the 
ER can be released through activation of the inositol triphosphate receptors (IP3R) or 
ryanodine receptors (RyR) [45,46].  These receptors gauge cytoplasmic Ca2+ and mediate 
Ca2+-induced Ca2+ release (CICR) from the ER; thus, the channels amplify the Ca2+ signal 
coming from outside the cell.  IP3 and cyclic ADP ribose, levels of Ca2+ in the ER, and 
other messengers can influence the sensitivity of these receptors.  The ER also has a 
sequestration mechanism through the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), 
which pumps Ca2+ back into the ER from the cytosol [46].  The ER is able to sequester 
large amounts of Ca2+ under normal conditions.  
 
Thus, SE causes glutamate release that stimulates Ca2+ entry into the cell, triggering the 
activation of CICR wherein RyR and IP3R are activated to release more Ca2+ from ER 
stores [47,48].  During the Ca2+ plateau, epileptic neurons show upregulation of CICR 
mechanisms when compared to control neurons [48].  Interestingly, one study 
demonstrated that the intracellular injection of IP3 causes epileptiform discharges in 
hippocampal neurons [49].  Therefore, several groups have examined the ability of anti-
epileptic drugs to inhibit IP3 or IP3R as a means to prevent epileptiform activity [50,51].  
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Moreover, it has also been demonstrated that SERCA is unable to effectively sequester 
Ca2+ in “epileptic” neurons, [48] thus suggesting that this mechanism may contribute to the 
Ca2+ plateau.  Future studies should further examine this relationship between SERCA 
uptake and CICR as they are interdependent processes.   
 
Ca2+ binding proteins 
Ca2+ binding proteins also play an important role in basic physiology further contributing 
to the maintenance of basal [Ca2+]i.  It has been hypothesized that the down-regulation of 
Ca2+ binding proteins also contributes to the elevated [Ca2+]i maintained during the Ca2+ 
plateau following SE [52].  Several studies utilizing human epileptic hippocampal tissue 
showed that calbindin levels in the dentate granule cells were diminished [53,54].  The 
pilocarpine model has yielded similar results wherein it has been demonstrated that at one 
month after pilocarpine-induced SE, epileptic animals demonstrated a 50% reduction in 
calbindin protein expression in the hippocampus [52].  These changes were observed up to 
two years after the initial SE [52]; moreover, calbindin mRNA expression was also 
decreased in these animals. 
 
These observations have also been noted a few months post-initial injury in other models 
of epilepsy including those utilizing kindling and kainic acid [55,56].  However, some 
studies have also shown that following kainic acid or electrically stimulated seizures, 
calbindin mRNA levels are unchanged or even increased [57-59].  Therefore, these data 
suggest that following a glutamate-induced Ca2+ influx, there is a transient compensatory 
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up-regulation in calbindin expression, but the long-term elevations in [Ca2+]i observed in 
epileptic animals may be attributed to overall down-regulation in protein expression.  This 
suggests that the maintenance of the post-SE Ca2+ plateau may be mediated in part by a 
decrease in Ca2+ binding proteins, which normally buffer elevations in Ca2+.    
 
Ca2+ regulated enzymes 
Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) is an enzyme that plays a 
major role in the modulation of neuronal excitability through its actions on Ca2+-dependent 
neuronal processes [60,61].  CaM kinase II has a widespread distribution throughout the 
nervous system and interestingly, comprises up to 2% of total hippocampal protein [62].  
 
Genetic studies have demonstrated that mice with a null mutation of the alpha-subunit of 
CaM kinase II show gene dose-dependent neuronal hyperexcitability and seizures [18].  In 
vitro molecular approaches have yielded supporting data by the demonstration that 
reduction of α-CaM kinase II levels through antisense oligonucleotides causes spontaneous 
epileptic discharges in culture [63].  While these studies have provided tremendous insight 
on CaM kinase II as a means of neuronal excitability, they have not examined whether 
CaM kinase II expression or activity was actually altered in neurons from epileptic animals 
or from cultures exhibiting in vitro epilepsy.  
 
In whole animal and slice models that use repeated hippocampal stimulation to elicit SE, 
decreased CaM kinase II activity has been shown to trigger epileptiform activity [64]. Both 
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pilocarpine and kainic acid models of SE-induced AE have shown decreased CaM kinase 
II activity and these results have also been observed in the low Mg2+ in vitro hippocampal 
culture model [65-67].  Interestingly, reduced CaM kinase II activity can be stopped by 
NMDA receptor antagonists administered prior to SE [61,67].  Thus, the change in CaM 
kinase II activity appears to be a consequence of NMDA receptor activation.  
Paradoxically, short-term NMDA receptor activation and the resulting elevations in 
intracellular Ca2+ lead to increased CaM kinase II activation and the translocation of the 
enzyme from the cytosol to excitatory synapses [68].  The precise role for CaM kinase II in 
the induction and development of epilepsy is being actively pursued and several studies 
have discussed in great detail the paradoxical nature of its interactions with NMDA 
receptors versus the hyperexcitability observed in CaM kinase II knockdown studies [68]. 
In pentylenetetrazol or electroconvulsive shock studies it has been demonstrated that 
seizures cause CaM kinase II to translocate from the synapse to the cytosol [65,69].  
Therefore, in distancing the enzyme from its substrate, the translocation may serve to 
further reduce the effective enzymatic activity. 
 
Effects of Elevated [Ca2+]i on Cellular Function 
Cellular Ca2+ signaling is a complex process that is difficult to elucidate due to the 
interdependence of Ca2+ handling/regulatory systems.  However, clear links between Ca2+ 
levels and membrane excitability, protein phosphorylation, and gene regulation have been 
demonstrated [70].  Moreover, elevated [Ca2+]i also has a profound effect on the neuronal 
circuit, cell death, and glial function.  Several studies have demonstrated that this increase 
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in Ca2+ concentration triggers hypertrophy of glia and expression of proteins on glia that 
are not normally observed [71].  In addition, the elevations in [Ca2+]i have been shown to 
activate genes for growth factors, including brain-derived neurotrophic factor and 
fibroblast growth factor, induce changes in glutamate receptors, and cause altered 
expression of cytoskeletal proteins [71]. All of these alterations significantly affect the 
development or maintenance of the epileptic circuit [72].  Developing efficacious 
therapeutic strategies may be aided by a more thorough understanding of Ca2+ dynamics in 
neurons and how these alterations in Ca2+ can affect glia and the neuronal circuit. 
 
 Generally, the degree of Ca2+ influx contributes greatly to the level of injury sustained by 
the neurons and impacts the overall fate of the cell.  Severely injured cells exhibit an 
irreversible Ca2+ overload that leads to cell death through various means, some of which 
include: the disruption of cytoskeletal organization, formation of cell membrane blebs, 
activation of Ca2+-dependent endonuclease leading to chromatin cleavage, and 
mitochondrial impairment resulting in loss of ATP synthesis [73].  Notably, cell death is a 
prominent manifestation immediately after SE where [Ca2+]i  increases dramatically with a 
percentage cell death of approximately 10-15% in vivo [41] and 15% in vitro [24].  
Interestingly, epilepsy itself did not cause more cell death in vitro, in vivo, or in human 
studies [24,74-78].  Thus, although the elevated Ca2+ plateau is maintained, the levels are 
not high enough to induce significant cell death, but can cause permanent alterations in 
neuronal homeostasis. 
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The neurons that survive SE undergo altered Ca2+ homeostasis but not necessarily an 
irreversible Ca2+ overload; therefore, since dead neurons do not seize, it is these injured but 
surviving neurons that serve as the substrate for epileptogenesis.  These neurons sustain 
reversible elevations in [Ca2+]i that are maintained over days or weeks [32]—these 
increases mediate changes in synaptic plasticity, gene expression, and neuronal function.  
Therefore, the overall increased [Ca2+]i directly affects nuclear Ca2+  levels and leads to the 
induction of gene transcription of several pro-apoptotic or epileptogenic genes and alters 
neuronal functions including excitability, transmitter release, and neurotoxicity [79].  One 
effect is that increases in [Ca2+]i activate an enzyme, calcineurin, leading to a downstream 
cascade of events including an accelerated internalization of GABAA receptors, resulting in 
decreased inhibitory neurotransmission [18,80].  Thus, it is the injured neurons and these 
molecular changes that become potential targets for future therapies to prevent AE.  The 
ability to target these intracellular changes and reduce the Ca2+ load may prevent the 
development of the epileptic phenotype following SE or other neuronal injuries. 
 
Summary and Rationale 
Epilepsy is a common condition affecting 1-2% of the world’s population and can 
significantly impact an individual’s quality of life.  While much progress has been made in 
the development of treatments that can inhibit seizures, still approximately 30% of all 
people with epilepsy are resistant to anti-convulsant therapies [72,81].  Moreover, 40% of 
all cases of epilepsy are acquired following neuronal injury [81].  The development of AE 
can be divided into three phases: the injury itself (in this case, SE), followed by a latency 
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period during which the neurons are undergoing the changes that lead to the final phase, 
the chronic epileptic phase wherein an individual displays recurrent seizures. This 
transformation from healthy brain tissue to hyperexcitable neuronal networks responsible 
for seizure activity is called epileptogenesis.  Thus, studying the pathophysiological 
changes that occur during epileptogenesis could not only bolster our understanding of 
plasticity following brain injury but also aid in the development of anti-epileptogenic 
agents.  Currently, many anti-epileptic drugs (AEDs) exist that inhibit or dampen seizures 
in epileptic individuals; however, no therapeutics exist that can be given immediately after 
an injury to prevent the ultimate development of epilepsy.  Thus, the latency period 
between the injury and the development of AE represents a therapeutic window of 
opportunity in preventing epileptogenesis. 
 
Recently, several studies have demonstrated that Ca2+ dynamics are severely altered during 
SE and remain altered in those animals that develop AE following SE [4,32].  In the in 
vivo rat pilocarpine model of SE-induced AE, [Ca2+]i increases during SE and remains 
elevated for at least one year post-SE in those animals that later develop epilepsy [32].  
Moreover, hippocampal neurons from epileptic animals also demonstrate persistent 
alterations in homeostatic mechanisms, which may contribute to the altered phenotype 
[32].  Thus, the modulation of [Ca2+]i and Ca2+ regulatory systems by pharmacological 
agents immediately following neuronal injuries such as SE may help to prevent 
epileptogenesis. 
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The animal model utilized in many of the studies described above, while closely 
resembling the human condition, remains a challenging tool to study pharmacological 
effects or discern molecular mechanisms because of the difficulties in manipulating the 
system and controlling for variables.  Therefore, we were interested in testing whether 
similar changes as we observed in vivo also occurred in the in vitro low Mg2+ model of 
SE-induced AE.  If so, this well-characterized model would serve as an ideal tool to better 
elucidate molecular mechanisms as well as to perform high throughput screening tests on 
various pharmacological compounds.   
  
Central Hypothesis 
Studies utilizing the rat pilocarpine model of SE-induced AE have demonstrated that 
[Ca2+]i in hippocampal neurons increases during SE, and that these elevations are 
maintained only in those animals that go on to develop epilepsy.  Ca2+ is an important 
second messenger; therefore, changes in its concentration may be responsible for 
alterations in cellular function, neurotransmitter release, and, ultimately, neuronal 
plasticity.  Therefore, modulation of calcium post-injuries represents an interesting 
approach to understanding and potentially preventing epileptogenesis.  Our central 
hypothesis is that increases in [Ca2+]i that are triggered by neuronal injury play a role in 
mediating epileptogenesis and neuronal plasticity.  To test this hypothesis we have 
employed the in vitro low Mg2+ model, as hippocampal neuronal cultures provide an 
appropriate model to test both pharmacological and molecular modifications as external 
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variables are more easily controlled.  In order to address this hypothesis we will focus on 
the following aims: 
1) Evaluate whether changes in [Ca2+]i observed in the in vivo model of SE-induced AE 
are also present in the low Mg2+ hippocampal neuronal culture model 
2) Develop pharmacological means to lower [Ca2+]i post-injury (SE) 
3) Evaluate whether lowering [Ca2+]i can prevent the expression of spontaneous recurrent 
epileptiform discharges, the in vitro correlate to epilepsy 
The conclusions reached from this dissertation demonstrate that similar alterations in 
[Ca2+]i are observed in the low Mg2+ model as were demonstrated in vivo.  Various 
pharmacological agents have been tested to determine both which Ca2+ regulatory systems 
are contributing to the Ca2+ plateau and whether overall lowering Ca2+ can inhibit 
epileptogenesis in the in vitro model of SE-induced AE.  
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Table 1-1.  Models of SE-induced AE. 
 Inciting Agent Name of Model 
In Vitro Models   
Hippocampal 
Neuronal Culture 
3 hr treatment with 
low Mg2+ containing 
solution to mimic SE 
Low Mg2+ model 
In Vivo Models   
Rat/Mouse   
          Chemical: SE induced by 
treatment with 
pilocarpine 
 
Pilocarpine model 
 SE induced by 
treatment with kainic 
acid 
 
Kainic acid model 
          Electrical: SE induced by 
electrical stimulation 
Electrical stimulation 
model 
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Figure 1-1.  The progression to AE: Phases of epileptogenesis.
Injuries to the Central Nervous system such as SE (down arrow) can elicit 
permanent changes in neurons, resulting in the development of epilepsy. The 
period between the inciting injury (down arrow) and the manifestation of 
recurrent seizures or epilepsy (black) is called epileptogenesis (gray). This 
gray period may provide a therapeutic window of opportunity wherein the use 
of pharmacological agents or molecular tools can prevent the transition of 
healthy brain tissue to a hyperexcitable network manifesting spontaneous 
recurrent epileptiform discharges.
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Figure 1-2.  SE causes increased [Ca2+]i acutely in the in vivo pilocarpine model.   
A, representative EEG recording from control (vehicle) rats and rats in pilocarpine-
induced SE.  B, bar graph demonstrating that [Ca2+]i is higher in neurons from 
animals immediately following SE when compared to those from animals in the 
control group—850 ± 59 nM and 90 ± 22 nM, respectively (data expressed as mean 
± SEM). 
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Figure 1-3.  The Ca2+ plateau following SE.  At one day post-SE, [Ca2+]i are 
significantly elevated when compared to controls, 790 ± 43 nM and 98 ± 10 
nM, respectively (all data expressed as mean ± SEM).  Two days post-SE the 
[Ca2+]i is 684 ± 47 nM, which is significantly higher than the 96 ± 14 nM 
observed in the control.  At six days following SE, the [Ca2+]i is still markedly 
elevated when compared to controls yet has fallen slightly from earlier 
timepoints, 475 ± 36 nM and 100 ± 10 nM, respectively.  [Ca2+]i falls slightly 
at 10 days post-SE to 395 ± 56 nM but is still significantly elevated when 
compared to the controls with [Ca2+]i of 95 ± 14 nM.  Finally, at 30 days post-
SE the [Ca2+]i is 361 ± 28 nM versus 106 ± 16 nM in controls.  The persistent 
elevation in [Ca2+]i represents the Ca2+ plateau. 
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Figure 1-4.  AE is associated with alterations in [Ca2+]i and  Ca2+ 
homeostatic mechanisms one year post-in vivo SE.  A, representative 
EEG recording from control (vehicle) rats and epileptic rats (following 
pilocarpine-induced SE).  B, bar graph with neurons from epileptic 
animals at one year post-SE demonstrating [Ca2+]i  of 325 ± 35 nM (data 
represented as mean ± SEM), which is significantly higher than neurons 
from control group.  C, upon glutamate stimulation, the [Ca2+]i increases 
and then returns to baseline in neurons from the control group, unlike 
neurons from the epileptic group which also peak but then fail to return 
to baseline. 
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Figure 1-5.  Effect of elevated [Ca2+]i on neurons.  Normal stimuli cause 
transient elevations in [Ca2+]i that control synaptic activity and are 
responsible for learning and memory (top arrow). Mild to moderate injuries 
may cause prolonged elevations in [Ca2+]i that are ultimately reversible 
(middle arrow). Such elevations are not substantial enough to initiate cell 
death but are able to cause plasticity changes in neurons, leading to 
epileptogenesis. Finally, severe injury causes sustained, massive increases in 
[Ca2+]i that lead to cell death (bottom arrow). 
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Figure 1-6.  CNS injuries cause death or plasticity changes in 
neurons.  CNS injuries such as stroke, SE, and TBI can lead to one of 
two fates for affected neurons. First, all injuries cause increases in 
glutamate concentration, which leads to the over-stimulation of 
glutamatergic receptors, including NMDA receptors (NMDAR). The 
activation of these receptors trigger an influx of Ca2+ across the cell 
membrane and cause a Ca2+ overload. This elevation in [Ca2+]i can be 
irreversible and overwhelm cellular processes, resulting in cell death. In 
contrast, neurons that are less severely injured exhibit a sustained but 
reversible increase in [Ca2+]i that leads to alterations in gene 
expression, neuronal function, and synaptic plasticity through second 
messenger systems.  
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Table 1-2.  Effect of Ca2+ Inhibitors on SE and SREDs.  The first 
column shows the various conditions including control and low Mg2+ 
treated neurons as well low Mg2+ neurons that were then treated with Ca2+ 
channel inhibitors. The second column shows [Ca2+]i levels observed in 
each condition. The third and fourth columns show whether or not the 
neurons developed SREDs (epilepsy) or whether the frequency of SE was 
changed under each condition, respectively. Data is represented as mean ± 
SEM for [Ca2+]i and SE spike frequency and as all or none effects for the 
development of epilepsy. 
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Chapter 2: Characterization of the Calcium Plateau In Vitro 
 
 
Introduction 
It has been demonstrated in the in vivo pilocarpine model of SE-induced AE that Ca2+ 
dynamics are significantly altered during SE and that these alterations are maintained well 
past the duration of the injury itself [4,32].  As an important second messenger that is 
highly regulated so as to maintain low intracellular levels, such alterations could have 
tremendous implications in terms of plasticity and ultimately, in the development of 
epilepsy following SE.  One study published the novel finding that intracellular Ca2+ 
([Ca2+]i) is elevated almost 8-fold in hippocampal neurons acutely isolated from animals 
immediately following SE when compared to those isolated from controls [32].  
Interestingly, this elevation exists in hippocampal neurons, particularly those from the 
Cornu Ammonis area 1 (CA1) region, but not in frontal or occipital neurons.  This result 
corresponds to the well-recognized observation that the hippocampus is often most 
vulnerable to seizure activity [82] and likely to exhibit increased plasticity changes 
following injury.  Moreover, this same study evaluated [Ca2+]i at various time points post-
SE to determine whether the elevations observed acutely were more long-lasting or 
ephemeral.  It was demonstrated that [Ca2+]i falls gradually over the course of the week 
following SE.  However, at all latter time points (days 6, 10, 30, and 1 year) post-SE, the 
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[Ca2+]i remains significantly elevated when compared to levels recorded in neurons from 
either control animals or those animals that fail to develop AE following SE [32].  This 
study suggests that SE causes elevations in [Ca2+]i and these sustained elevations may be 
involved in the pathophysiology of epileptogenesis.  Therefore, it follows that modulation 
or inhibition of [Ca2+]i immediately after SE, may potentially prevent the development of 
AE.  However, since the precise mechanisms through which increased [Ca2+]i are 
maintained following SE remain unclear, it would be beneficial to study the 
pathophysiologic changes in an in vitro model wherein the system is more easily 
manipulated through molecular biological or pharmacological means. 
 
The purpose of this study is to evaluate [Ca2+]i in an in vitro model of SE-induced AE to 
determine if the changes observed in vivo also occur in this model.  If so, the model would 
be a tremendous tool in the evaluation of new therapeutic modalities aimed at restoring 
Ca2+ homeostasis post-injury.  The hippocampal neuronal culture model of SE-induced AE 
is a well-characterized model that utilizes a solution with no added Mg2+ (low-Mg2+) to 
simulate SE [23].  Once the Mg2+ is restored to these cultures and the cells are later 
evaluated by whole-cell current clamp electrophysiology, spontaneous, recurrent 
epileptiform discharges (SREDs) are observed for their life in culture.  These SREDs are 
the in vitro correlate to epilepsy.  The hippocampal neuronal culture model is an excellent 
in vitro model in that it closely corresponds to the human condition in several ways.  The 
spike frequency of epileptiform discharges during in vitro SE is greater than 3 Hz, which 
meets the clinical definition of SE [83].  Moreover, the in vitro SREDs manifested in this 
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culture model mimic the electrographic features observed in epilepsy.  Due to similarities 
between the human condition and this model, the model has been employed to characterize 
electrophysiological, cellular, and molecular mechanisms underlying SE and 
epileptogenesis [4,67,83].  Similarities in pharmacoresistance, changes in biochemical 
markers, and cell death have also been demonstrated between the clinical condition and 
both in vivo and in vitro models [24,84].  Thus, the hippocampal neuronal culture model 
provides a useful tool to evaluate changes in Ca2+ dynamics post-in vitro SE. 
 
Materials and Methods 
Hippocampal neuronal culture preparation 
Hippocampal tissue was harvested from 2-day postnatal Sprague-Dawley rats (Harlan, 
Indianapolis, IN) in phosphate buffered saline (PBS) with sucrose, N-[2-
Hydroethyl]piperazine-N’[2-ethanesulfonic acid] (HEPES), and penicillin (10,000 
units/mL) but  no added Ca2+ or Mg2+.  The dissection PBS was maintained at 4◦ and the 
dissection itself was performed at room temperature.  Hippocampal tissue was separated 
from vasculature and meninges under a dissection microscope and was subjected to 0.25% 
trypsin at 37°C for 30 minutes, followed by mechanical trituration using fire-polished 
Pasteur pipettes.  Cells were counted on a hemocytometer (Scientific Apparatus, 
Philadelphia, PA) using the trypan blue dye exclusion method to estimate the concentration 
of cells in suspension.  The single cell suspension was diluted to a concentration of 1x105 
cells/mL in either glial feed (minimal essential media (MEM) with Earle’s Salts 
(Invitrogen, Carlsbad, CA), 25 mM HEPES, 2 mM L-glutamine, 3 mM glucose, and 10% 
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fetal bovine serum (FBS)) or neuronal feed (MEM with Earle’s Salts, 25 mM HEPES, 2 
mM L-glutamine, 3 mM glucose, 100 µg/ml transferrin, 5 µg/mL insulin, 100 µM 
putrescine, 3 nM sodium selenite, 200 nM progesterone, 1 mM sodium pyruvate, 0.1% 
ovalbumin, 0.2 ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone) supplemented with 
5% horse serum (HS). 
 
To grow glial cultures, 1x105 or 5x104 cells in glial feed were plated onto 35 mm plastic 
culture dishes or Lab-Tek 2-well glass chambers (Nunc, Naperville, IL), respectively, that 
were previously coated with 0.05 mg/ml poly-L-lysine.  The cultures were maintained at 
37°C in a 5% CO2/95% O2 atmosphere and culture media was replaced three times per 
week with fresh glial feed.  The glia were grown until confluent and were then treated with 
5 µM cytosine arabinoside for two days to halt cell division.  On the 10th day in vitro 
(DIV), the culture media was replaced with glial feed supplemented with 5% HS instead of 
FBS.  Then, on the 13th DIV, the glial feed supplemented with HS was replaced with 
neuronal feed supplemented with 5% HS.   
 
On the 14th DIV, cells (8.75x104 for glass slides; 2x105 for 35 mm culture dishes) 
suspended in neuronal feed plus 5% HS were plated onto the confluent glial beds.  
Cultures were maintained under standard conditions at 37°C in a 5% CO2/95% air 
atmosphere and were fed twice weekly with neuronal feed containing 20% conditioned 
media.  Neurons were allowed to mature and all experiments were performed 14-18 days 
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following plating of neurons to allow formation of networks, adequate neuronal 
maturation, and development of NMDA receptors.  
 
Whole-cell current clamp electrophysiology 
Hippocampal neuronal cultures were transferred to the temperature-controlled stages of 
either a Nikon Diaphot inverted microscope (Garden City, NY) or Olympus IX-70 
(Olympus, Center Valley, PA) in order to perform electrophysiological recordings.  A 
Flaming-Brown P-80C electrode puller (Sutter Instruments, Sarasota, FL) was utilized to 
pull patch microelectrodes from thin borosilicate glass capillaries (World Precision 
Instruments, Inc., Sarasota, FL).  Only microelectrodes with a resistance of 3-7 MΩ were 
used to patch cells.  These microelectrodes were filled with an internal solution consisting 
of (in mM): 140 K+ gluconate, 1 MgCl2, 10 HEPES, 1.1 ethylene glycol tetraacetic acid 
(EGTA), adjusted to pH 7.2, 310 mOsm.   
 
An Axopatch 200A amplifier or an Axoclamp-2A amplifier (Axon Instruments, Foster 
City, CA) in current clamp mode was used to obtain recordings from phase-bright 
pyramidal-shaped neurons.  The filled microelectrode was secured to the amplifier 
headstage and moved using the course-manipulators until the tip is above the neuron to be 
patched.  Offset potentials were nulled and fine-adjustment manipulators were then used to 
position and lower the microelectrode so that it made contact with the surface of the 
neuron of interest.  Negative pressure was gently applied through the microelectrode to 
form a giga-ohm seal and rupture the membrane in the microelectrode tip.  Compensation 
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for capacitance was performed and recording was initiated.  Together, the Neuro-corder 
DR-890 (Neurodata Instruments Corp, New York, NY) and Sony Videocassette Recorder 
allowed for digitization and storage of data on videocassettes.  Acquired data were then 
analyzed by playing recordings back through a Dash IV chart recorder (Astro-Med Inc., 
Warwick, RI) or to a computer via a Digidata 1322A (Axon Instruments, Foster City, CA).  
Perfusions of drugs into the system were performed using a six-valve perfusion system 
(Warner Instrument Corp., Hamden, CT) at a rate of 1 mL/minute.   
 
Calcium microfluorometry 
To determine [Ca2+]i in hippocampal neuronal cultures, cells were loaded with Fura-2-
acetoxymethyl ester (AM) (Molecular Probes, Eugene, OR), a high affinity (Kd=145nM) 
Ca2+ indicator dye.  Fura-2AM is able to cross cell membranes and once inside the cell, the 
AM groups are cleaved by intracellular esterases leaving the cell-impermeant Fura-2 inside 
the cell.  Once the dye binds to Ca2+, Fura-2 exhibits an absorption shift that can be 
observed by exciting the dye at 340 nm instead of 380 nm, the excitation wavelength used 
to measure unbound Fura-2.  The emission generated by either of these wavelengths can be 
measured at 510 nm.  Therefore, alternating excitation wavelengths of 340 nm and 380 nm 
are utilized to quantify the relative concentration of Ca2+-bound Fura-2 and Ca2+-free Fura-
2.  Thus, the resulting 340/380 ratio recorded corresponds directly to the total 
concentration of Ca2+ inside the cell and can be used to determine changes in [Ca2+]i.  
Moreover, the utilization of the 340/380 ratio is important in that it accounts for potential 
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confounders such as unequal loading for Fura-2 or variable cell thickness from interfering 
with the measurements.     
 
Hippocampal neuronal cultures were loaded with 1µM Fura-2AM dissolved in 0.1% 
dimethyl sulfoxide (DMSO) and incubated at 37˚C in 5% CO2/95% air for 30 min.  The 
cultures were then washed so as to terminate dye-loading.  Following the wash, the cells 
incubated for another 15 minutes to maximize cleavage of the AM moiety by intracellular 
esterases.  The cultures were then transferred a heated stage (Harvard Apparatus, Holliston, 
MA) wherein the temperature of the cultures could be maintained at 37°C.  Pyramidal, 
phase-bright neurons were visualized through the 20X, 0.7 numerical aperture fluorite 
water immersion objective on an Olympus IX-70 inverted microscope.  The Fura-2 was 
excited by alternating excitation wavelengths of 340 nm and 380 nm, created through 
filtering light from a 75 W xenon arc lamp through optical filters on a Lambda 10-2 wheel 
(Sutter Instruments Co., Novato, CA).  Emissions were captured at 510 nm through a 400 
nm dichroic mirror in a Fura filter cube (Olympus, Center Valley, PA) by using a 
Hamamatsu ORCA-ER digital, charged-coupled device (CCD) camera (Hamamatsu, 
Bridgewater, NJ).  This system is connected to the fluorescent imaging software, 
MetaFluor (Olympus, Center Valley, PA), which allows for image acquisition and 
analysis.  Images were acquired from any given field at various time intervals depending 
on the specific experiment and background fluorescence was subtracted from all acquired 
data by imaging hippocampal neuronal cultures that were not loaded with Fura-2.  Ratio 
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values can be converted to [Ca2+]i using calibration curves described [85] or can be left as 
ratio values, which correlate directly with [Ca2+]i .  
 
In vitro SE and SREDs in hippocampal neuronal cultures  
In vitro SE was generated using the low Mg2+ model [18] that was developed in the 
DeLorenzo lab.  Maintenance media (neuronal feed plus conditioned media) was removed 
from the hippocampal neuronal cultures and replaced with physiological basal recording 
solution (pBRS) consisting of: 145 mM NaCl, 2.5 mM KCl, 10 mM HEPES, 10 mM 
glucose, 2 mM CaCl2, 1 mM MgCl2, 0.002 mM glycine, adjusted to pH 7.3, 325 mOsm or 
pBRS without the MgCl2 (hereafter referred to as, low Mg2+).  The cells then incubated at 
37 °C under 5% CO2/95% air atmosphere for 3 hours (hrs).  During this time, neurons 
were patched using whole-cell current clamp electrophysiology to determine whether cells 
in low Mg2+ demonstrated high frequency spiking of greater than 3 Hertz (Hz) in 
frequency, which is characterized as the in vitro correlate to SE.  The neurons treated with 
pBRS served as the controls for the low Mg2+-treated group.   
 
After 3 hrs of low Mg2+ or pBRS treatment, the cells were returned to normal, Mg2+-
containing maintenance media and were evaluated using whole-cell current clamp 
electrophysiology at least 12 hrs post-in vitro SE to determine expression of in vitro 
epilepsy, or SREDs.  SREDs are characterized by bursts of action potentials over-riding 
paroxysmal depolarization shifts.  The 3 hr treatment duration was determined after it was 
demonstrated that 1 and 2 hrs of low Mg2+ exposure did not produce consistent 
   
 39 
epileptogenecity [23]; whereas, following 3 hrs, greater than 95% of all neurons sampled 
expressed permanent alterations in excitability.  Interestingly, a 4 hr exposure produced 
more extensive cell death, leading to greater variability in the results, as network 
connectivity is important in the development of SREDs [23].  
 
Glutamate challenge: Assessing Ca2+ homeostatic mechanisms 
In order to assess Ca2+ homeostatic mechanisms, neurons were loaded with Fura-2AM and 
challenged with 50 µM glutamate for 2 minutes.  After this time, the cultures were washed 
with pBRS to remove the glutamate.  340/380 ratio images were captured every 30 seconds 
to record both the response to and recovery from glutamate exposure.     
 
Statistical analysis 
To determine statistical significance of Ca2+ imaging data, a one-way Analysis of Variance 
(ANOVA) test was employed, followed by Fisher’s post-hoc test when appropriate.  A p-
value<0.05 was considered statistically significant. Statistical analysis will be performed 
using SigmaStat 3.0 or SigmaPlot (Systat Software, San Jose, CA).     
 
Results 
In order to determine if the in vitro model of SE-induced AE resembles the in vivo 
pilocarpine model in terms of changes in [Ca2+]i, neurons were treated with low Mg2+ and 
then evaluated at various time points through both whole-cell current clamp 
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electrophysiology to determine activity as well as calcium imaging to quantify changes in 
Ca2+.   
 
Treatment of hippocampal neuronal cultures with low Mg2+ causes in vitro SE 
Similarly to previous results published by our laboratory [23], replacing neuronal 
maintenance media with low Mg2+ produced continuous, high frequency epileptiform 
activity consistent with SE (Figure 2-1 B).  This frequency of epileptiform discharges was 
recorded to be greater than 3 Hz, which is in accordance with the frequency of SE 
discharges observed in humans.  The high frequency discharges were observed 
immediately after replacing the maintenance media with the low Mg2+ solution and were 
quickly abolished (within ~1 min) upon restoration of MgCl2.  This activity observed in 
neurons treated with low Mg2+ was in contrast to control neurons that were treated with 
Mg2+-containing pBRS.  These control neurons showed only occasional action potentials 
(Figure 2-1 A), consistent with the activity observed in naïve neurons.     
  
In vitro SE causes a significant elevation in [Ca2+]i 
While the neurons were still in low Mg2+, the cultures were loaded with the Ca2+ indicator, 
Fura-2AM.  Fluorescent ratio values were obtained using alternating excitation 
wavelengths of 340 nm and 380 nm.  The resulting 340/380 ratios correspond directly to 
[Ca2+]i.  Moreover, pseudocolor images were generated wherein individual pixels from the 
captured image are assigned a color based on the associated grayscale values, which 
correspond to Ca2+ levels.  Red is associated with a higher grayscale value and thus, more 
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Ca2+; whereas, at the other end of the colorimetric spectrum, blue is associated with lower 
grayscale values and less Ca2+.  Pseudocolor allows for better visualization of changes in 
[Ca2+]i.  An increase from control, baseline [Ca2+]i was observed while the neurons were in 
the low Mg2+ solution (in vitro SE).  The Fura-2 340/380 ratios increased from 0.39±0.05 
in control neurons to 0.78±0.05 in neurons after 3 hrs of low Mg2+ (Figure 2-2 A).  
Pseudocolor images confirmed these changes in Fura-2 ratios with increased ratios in 
neurons post-low Mg2+ (Figure 2-2 B, right panel) but not in the sham controls (Figure 2-2 
B, left panel).  Previous studies have shown with high speed simultaneous 
electrophysiological and Ca2+ imaging that each epileptiform spike was associated with 
increases in [Ca2+]i. 
 
Three hours of low Mg2+ treatment leads to the development of in vitro epilepsy 
(SREDs) 
To evaluate Ca2+ dynamics following SE, cultured hippocampal neurons were patch-
clamped to study electrophysiological activity and also imaged for evidence of alterations 
in Fura-2 ratios 24 hrs post-low Mg2+ treatment [23,86].  When patched using whole-cell 
current clamp techniques, the low-Mg2+ treated cells consistently displayed SREDs (Figure 
2-3 B) unlike the sham-control neurons, which failed to show SREDs (Figure 2-3 A).  
Each event was spontaneous and on average, 8 events were observed per hour.  In 
accordance with previous studies in our lab, most SREDs lasted for ~30 sec with some 
extending for 1-2 min in duration [23].  These SREDs recorded in cultures that were 
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treated with low Mg2+ resembled what is generally observed in clinical epilepsy, with the 
in vitro seizure episodes consisting of paroxysmal depolarization shifts. 
 
Elevations in [Ca2+]i are maintained for at least 24 hours post-in vitro SE 
At the same time time-point upon which neurons were patched to look for SREDs, neurons 
were also loaded with Fura-2 to determine [Ca2+]i.  In brief, hippocampal neuronal cultures 
were treated with low Mg2+ for 3 hrs, returned to Mg2+-containing maintenance media, and 
then loaded with Fura-2 24 hrs post-in vitro SE.  340/380 ratios were recorded as a direct 
indicator of [Ca2+]i.  Ratio values in low Mg 2+ treated cells appeared significantly elevated 
when compared to control neurons even at 24 hrs post-in vitro SE.  This was indicated by 
an increase in Fura-2 340/380 ratios from 0.40±0.02 in control neurons to 0.46±0.02 in low 
Mg2+ neurons (Figure 2-4).    
 
Neurons displaying SREDs exhibit alterations in Ca2+ homeostatic mechanisms 
In addition, SE caused permanent changes in plasticity as demonstrated by alterations in 
Ca2+ homeostatic mechanisms.  Neurons were briefly stimulated with 50µM glutamate for 
2 minutes to test the ability of Ca2+ homeostatic mechanisms to compensate for brief 
excitatory challenges.  These cells demonstrated a markedly diminished ability to recover 
from the insult (Figure 2-5) suggesting that the homeostatic mechanisms, which under 
normal conditions maintain tight control of Ca2+ influx, efflux, and sequestration are 
altered or diminished following SE.  Stimulation with glutamate resulted in an increase in 
[Ca2+]i both in control and post-SE neurons; however, in neurons treated with low Mg2+, 
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Ca2+ never returned to basal levels and showed a decreased rate of recovery when 
compared to controls. 
 
Discussion 
These results demonstrate that the low Mg2+ hippocampal neuronal culture model of SE-
induced AE may prove to be a useful tool in studying epileptogenesis.  The in vitro SE that 
was produced resembled the human condition in spike frequency and the model 
reproducibly caused SREDs, the in vitro correlate to epilepsy.  Finally, and most 
interestingly, several pathophysiological features observed in the rat pilocarpine model of 
SE-induced AE also exist in this culture model, making it a useful tool to better understand 
molecular/cellular changes and develop new therapeutics before testing in the animal 
model.  We demonstrated in this study that, much like the in vivo model, increases in 
[Ca2+]i were observed during SE and that these elevations were maintained for at least 24 
hrs post-SE.  Moreover, as observed in hippocampal neurons acutely isolated from 
epileptic animals, cultured neurons that displayed SREDs also showed a decreased ability 
to recover from a glutamate challenge.  This suggests that epilepsy alters Ca2+ homeostatic 
mechanisms and that this may contribute either to the development or maintenance of the 
chronic epileptic phenotype.  
   
These studies demonstrated that well past the duration of in vitro SE, [Ca2+]i was elevated 
and Ca2+ homeostatic mechanisms were altered in the low Mg2+ culture model of SE-
induced AE.  In the in vivo model wherein approximately 2/3 of the animals develop 
   
 44 
epilepsy following SE, only the animals that have increased hippocampal [Ca2+]i develop 
epilepsy [32].  This finding suggests that the changes in Ca2+ appear to play a significant 
role in the maintenance of the epileptic phenotype.  Moreover, it has also been 
demonstrated in stroke-induced epileptogenesis that increases in [Ca2+]i are not simply 
triggered by the seizure activity itself, because in vitro treatment of neurons showing 
SREDs with tetradotoxin to block all action potentials does not completely inhibit the 
elevation in [Ca2+]i [87].  The elucidation of the specific mechanisms behind such long-
lasting alterations remains an important area of research; moreover, understanding how 
these changes lead to the development or maintenance of chronic epilepsy could provide 
new information for the design of efficacious treatments or new preventative measures to 
halt epileptogenesis.  
 
In the pilocarpine model of SE-induced AE, it is well established that the elevations in 
[Ca2+]i are maintained post-injury in animals that develop epilepsy.  However, other 
conditions including stroke and TBI can also lead to the development of epilepsy.  Finding 
common pathophysiologic mechanisms behind how excitotoxic injuries can lead to the 
epileptic condition will bolster efforts to design new therapeutics to prevent 
epileptogenesis.  Thus, the examination of Ca2+ dynamics in other models of injury-
induced epilepsy may be of great clinical importance and represent an important area to 
study in the future.  As a ubiquitous second messenger, alterations in [Ca2+]i and Ca2+ 
homeostatic mechanisms have significant repercussions on gene expression, 
neurotransmitter release, and hence, neuronal plasticity.  Therefore, the development and 
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use of myriad models of acquired epilepsy to better understand the relationship between 
Ca2+ and epileptogenesis may offer an important tool in the future.  
 
It should be noted that the modulation of [Ca2+]i is a challenging pursuit in that Ca2+ is a 
ubiquitous second messenger that affects everything from neurotransmission to gene 
expression and has important functions in most cells of the body.  This means that 
modulation of Ca2+ has the potential to cause many unwanted side effects until more 
specific methods of drug delivery/Ca2+ targeting are developed.  Despite these difficulties 
in the modulation of Ca2+, many studies have utilized Ca2+ channel antagonists or Ca2+-
chelating agents with varying degrees of success.  Perhaps the most promising study is a 
Phase II clinical trial that utilized DP-BAPTA, a Ca2+-chelating agent, to patients 
following stroke and found that this treatment did not cause vascular or neurological side 
effects, but did improve the National Institutes of Health stroke scores [88].  Moreover, 
patients with Alzheimer’s disease are being treated with the NMDA antagonist, 
Memantine, which affects Ca2+ influx into the cell [89].   
 
Despite these cases wherein Ca2+-modifying agents have been used to improve outcomes 
from various neurological pathologies without significant deleterious effects, there is both 
positive and negative data regarding whether or not Ca2+ channel antagonists can be used 
as anti-convulsants or to potentiate the effects of other AEDs [90,91].  However, a good 
AED does not necessarily exhibit anti-epileptogenic properties and very little work has 
explored whether Ca2+-modifying agents can affect epileptogenesis.  The few studies that 
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exist have predominately used the NMDA antagonist, MK-801.  One study demonstrated 
that this drug could effectively decrease the number of animals that developed epilepsy 
following electrically-stimulated SE [43], while another study showed that in the kainic 
acid model of SE-induced AE, MK-801 did not prevent the development of epilepsy [92].  
Such conflicting results between models have underscored the need for many different 
types of models to be utilized [93] and have demonstrated that common pathophysiologic 
features need to be understood so as to develop better targets for anti-epileptogenic agents.  
Thus, the in vitro hippocampal neuronal culture model provides a useful tool in 
preliminary tests to determine anti-epileptogenic effects prior to screening in more 
complex systems.  Moreover, the presence of these alterations in [Ca2+]i and Ca2+ 
homeostatic mechanisms in both the pilocarpine and low Mg2+ model suggest that these 
may be common pathophysiologic features of epileptogenesis; therefore, understanding 
these changes may aid in the development of anti-epileptogenic agents.   
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Figure 2-1. Treatment of hippocampal neuronal cultures with low 
Mg2+ causes in vitro SE.  A, representative whole-cell current-clamp 
electrophysiological recordings obtained from a control neuron and B, 
a neuron in low Mg2+, or in vitro SE.  The neuron in low Mg2+ shows 
epileptiform discharges at a frequency greater than 3 Hertz.  In contrast, 
the control neuron shows action potentials intermittently, consistent 
with baseline firing activity.  Resting membrane potential= -62 mV; 
duration of trace shown= 18 min. 
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Figure 2-2.  In vitro SE causes a significant elevation in [Ca2+]i.  A, bar 
graph comparing Fura-2 340/380 ratios in control neurons versus neurons 
immediately following 3 hrs of low Mg2+.  The low Mg2+-treated cells 
exhibit ratio values of 0.78±0.05 as compared to the control neurons with 
values of 0.39±0.01 (data expressed as mean ± SEM).  B, representative 
pseudocolor ratio images obtained from control (left panel) and low Mg2+-
treated (right panel) neurons.  Neurons from the low Mg2+ group show an 
increased 340/380 ratio immediately following treatment. 
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Figure 2-3. Low Mg2+ treatment leads to the development of in vitro 
epilepsy (SREDs).  A,  electrophysiological traces using current-clamp 
technique demonstrate baseline activity in control neurons and B, spontaneous, 
recurrent epileptiform discharges (SREDs) in neurons that had been treated in 
low Mg2+ for 3 hrs and then returned to normal maintenance media.  Resting 
membrane potential= -61.5 mV; duration of shown trace= 30 min. 
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Figure 2-4.  Elevations in [Ca2+]i are maintained for at least 
24 hours post-in vitro SE.  Bar graph comparing 340/380 ratio 
values in control versus SE groups 24 hrs after treatment with 
Mg2+-containing buffer solution or low Mg2+, respectively. 
Neurons in the SE group exhibit a 340/380 ratio of 0.46±0.02 
(mean ratio ± SEM). The ratio from control group neurons is 
significantly lower at 0.40±0.02. 
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Figure 2-5.  Neurons displaying SREDs exhibit alterations in Ca2+ 
homeostatic mechanisms.  Glutamate stimulation causes increased 
[Ca2+]i.  Peak ratios following glutamate are normalized to 1.0.  Recovery 
from this challenge is hindered in epileptic neurons when compared to 
controls. 
 
   
 53 
 
 
Chapter 3: Dantrolene Inhibits the SE-Induced Calcium Plateau and 
Prevents the Development of Spontaneous Recurrent Epileptiform 
Discharges in Hippocampal Neuronal Cultures 
 
 
Introduction 
Epilepsy is a common neurological condition that is characterized by spontaneous, 
recurrent seizures and affects 1-2% of the population worldwide [2,81].  Acquired epilepsy 
(AE) is one form of epilepsy that occurs following a brain injury such as status epilepticus 
(SE), traumatic brain injury (TBI), stroke, or infections of the central nervous system 
(CNS) [4,5].  AE represents approximately 40% of all cases of epilepsy [81]; thus, it 
remains an important public health concern.  The transformation of healthy brain tissue 
into hyperexcitable networks of neurons that manifest epileptiform discharges is called 
epileptogenesis.  Characterization of this process may help in elucidating particular targets 
to which potential anti-epileptogenic agents can be directed.  Currently, only anti-epileptic 
drugs (AEDs) exist, which limit the occurrence of seizures once an individual has epilepsy.  
However, there are no anti-epileptogenic agents to prevent the process of epileptogenesis.     
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In order to better understand the process of epileptogenesis, many divide the development 
of AE into three stages: the injury itself, a period of latency or epileptogenesis, and finally, 
the maintenance of chronic epilepsy [19,20].  The period between the injury and the 
development of epilepsy could provide a therapeutic window of opportunity wherein 
pharmacological agents could be administered to prevent epileptogenesis.  Thus, 
characterization of the pathophysiological changes that occur following neuronal injury is 
necessary in order to find new therapeutic targets.   
 
It was demonstrated in the pilocarpine model of SE-induced AE that SE causes significant 
changes in [Ca2+]i and Ca2+ homeostatic mechanisms in hippocampal neurons [32].  As far 
out as 1 year post-SE, animals that demonstrated epilepsy showed significant elevations in 
hippocampal neuronal Ca2+ levels (Ca2+ plateau), in contrast to those animals that failed to 
develop epilepsy post-SE [32].  As a ubiquitous second messenger, changes in [Ca2+]i can 
affect everything from neurotransmitter release to gene transcription.  Therefore, studying 
these alterations in Ca2+ and the underlying regulatory systems that control these changes 
is important not only in understanding plasticity but also in developing anti-epileptogenic 
strategies.        
 
It was also demonstrated in the rat pilocarpine model of SE-induced AE that the N-methyl-
D-aspartic acid (NMDA) antagonist, MK-801, when administered prior to SE, does not 
diminish SE but is able to prevent both the Ca2+ plateau as well as, the development of 
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epilepsy [32].  This study provided evidence that NMDA receptors (NMDAR) are 
involved in initiating the Ca2+ plateau during SE.  However, little is known regarding what 
systems contribute to the long-term maintenance of these elevations in intracellular Ca2+ 
([Ca2+]i) and whether inhibiting this elevation after the injury could prevent 
epileptogenesis.  We hypothesized that the calcium-induced calcium release (CICR) 
system was activated by the massive influx of Ca2+ into the cell through NMDAR.  
Ryanodine receptors (RyR), along with inositol triphosphate receptors (IP3R), are part of 
the CICR mechanisms and control [Ca2+]i inside of the cell by acting to either release or 
sequester Ca2+.  These receptors gauge cytoplasmic Ca2+ and mediate CICR from internal 
stores; therefore, these channels can either amplify or dampen the Ca2+ signal coming from 
outside the cell [45,46].  In these studies, dantrolene, a pharmacological inhibitor of RyR, 
was used to better elucidate the role of these receptors in the development of the Ca2+ 
plateau.       
 
While the rat pilocarpine model has provided a great deal of information regarding 
potential pathophysiologic changes that occur during epileptogenesis, the whole-animal 
model is far too complex to be useful in preliminary pharmacological screenings.  Thus, 
this study utilizes the hippocampal neuronal culture model wherein low Mg2+ is used to 
induce SE-like activity that leads to the development of spontaneous, recurrent 
epileptiform discharges (SREDs), the in vitro correlate to epilepsy.  We assessed whether 
the changes in [Ca2+]i observed in the rat pilocarpine model also existed in this model.  If 
such changes existed, this model could provide a useful tool in further characterizing these 
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pathophysiological mechanisms behind epileptogenesis in a less complex system.  
Furthermore, we examined whether giving the RyR inhibitor, dantrolene, post-in vitro SE 
could prevent the development of SREDs.  
 
Materials and Methods 
Reagents 
All the reagents were purchased from Sigma Chemical Co. (St Louis, MO) unless 
otherwise noted.  Cell culture media was purchased from Invitrogen (Carlsbad, CA). 
 
Hippocampal neuronal culture preparation 
All animal use procedures were in strict accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and approved by 
Virginia Commonwealth University's Institutional Animal Care and Use Committee.  As 
described previously [23],  hippocampal neurons were harvested from 2-day postnatal 
Sprague-Dawley rats (Harlan, Indianapolis, IN) and grown on a glial support layer that was 
previously plated onto poly-L-lysine (0.05 mg/mL) coated plates.  The cultures were 
maintained at 37°C in a 5% CO2/95% air atmosphere and neuronal cultures were fed twice 
a week with minimal essential media containing: Earle's Salts, 25 mM HEPES, 2 mM l-
Glutamine, 3 mM Glucose, 100 µg/mL transferrin, 5 µg/mL insulin, 100 µM putrescine, 3 
nM sodium selenite, 200 nM progesterone, 1 mM sodium pyruvate, 0.1% ovalbumin, 0.2 
ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone supplemented with 20% conditioned 
media.  Neurons were allowed to mature and all experiments were performed 14-18 days 
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following plating of neurons to allow formation of networks, adequate neuronal 
maturation, and development of NMDA receptors.  
 
Whole-cell current clamp electrophysiology 
Whole-cell current clamp electrophysiology was performed according to previously 
described procedures [23,84].  In short, hippocampal neuronal culture media was replaced 
with physiological basal recording solution (pBRS) containing (in mM): 145 NaCl, 
2.5 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, 10 glucose, and 0.002 glycine, pH 7.3, and 
osmolarity adjusted to 325 ± 5 mOsm with sucrose.  The plates were transferred to the 
temperature-controlled stages of either a Nikon Diaphot inverted microscope (Garden City, 
NY) or Olympus IX-70 (Olympus, Center Valley, PA) in order to perform 
electrophysiological recordings.  A Flaming-Brown P-80C electrode puller (Sutter 
Instruments, Sarasota, FL) was utilized to pull patch microelectrodes with resistances of 3-
7 MΩ from thin borosilicate glass capillaries (World Precision Instruments, Inc., Sarasota, 
FL).  These microelectrodes were filled with an internal solution consisting of (in mM): 
140 K+ gluconate, 1 MgCl2, 10 HEPES, and 1.1 ethylene glycol tetraacetic acid (EGTA), 
adjusted to pH 7.2, and osmolarity of 310 mOsm.   
 
An Axopatch 200A amplifier or an Axoclamp-2A amplifier (Axon Instruments, Foster 
City, CA) in current clamp mode was used to obtain recordings from phase-bright 
pyramidal-shaped neurons.  Together, the Neuro-corder DR-890 (Neurodata Instruments 
Corp, New York, NY) and Sony Videocassette Recorder allowed for digitization and 
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storage of data on videotapes.  Acquired data were then analyzed by playing recordings 
back through a DC-500 Hz chart recorder (Astro-Med Inc., Warwick, RI) or to a computer 
via a Digidata 1322A (Axon Instruments, Foster City, CA).  
 
Calcium microfluorometry 
To determine [Ca2+]i in hippocampal neuronal cultures, cells were loaded with 1µM Fura-
2-acetoxymethyl ester (AM) (Molecular Probes, Eugene, OR) for 30 min at 37˚C in 5% 
CO2/95% O2, as described previously [50].  The plates were then transferred a 
temperature-controlled stage (Harvard Apparatus, Holliston, MA) on an Olympus IX-70 
inverted microscope.  Ratio images were acquired using alternating excitation wavelengths 
(340 and 380 nm) with a filter wheel (Sutter Instruments, Novato, CA) and fura filter cube 
at 510/540 nm emissions with a dichroic mirror at 400 nm [94].  Thus, the resulting 
340/380 ratio recorded corresponds directly to the total concentration of Ca2+ inside the cell 
and can be used to determine changes in [Ca2+]i.  The utilization of the 340/380 ratio is 
important in that it accounts for potential confounders such as unequal loading for Fura-
2AM or variable cell thickness from interfering with the measurements.  This system is 
connected to the fluorescent imaging software, MetaFluor (Olympus, Center Valley, PA), 
which allows for image acquisition and analysis.  Images were acquired from any given 
field at various time intervals depending on the specific experiment and background 
fluorescence was subtracted from all acquired data by imaging hippocampal neuronal 
cultures that were not loaded with Fura-2AM. 
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In vitro SE and SREDs in hippocampal neuronal cultures  
In vitro SE was generated using a low Mg2+-containing solution [18].  Maintenance media 
was replaced with low Mg2+ (pBRS without any added MgCl2).  The cells then incubated 
at 37 °C under 5% CO2/95% O2 atmosphere for 3 hrs.  During this time, when the neurons 
were patch-clamped using whole-cell current clamp electrophysiology, they demonstrated 
high frequency spiking, characterized as in vitro SE.  Neurons treated with pBRS for 3 hrs 
served as the sham-controls. 
 
After 3 hrs of low Mg2+ or pBRS treatment, the cells were returned to normal, Mg2+-
containing maintenance media and were evaluated using whole-cell current clamp 
electrophysiology at least 12 hrs post-in vitro SE to determine expression of in vitro 
epilepsy, or SREDs.  Each episode of SREDs is characterized by paroxysmal 
depolarization shifts and generally, 5-9 SREDs are observed per hour. 
 
Cell death assay 
Neuronal death was assessed using the dye, Propidium Iodide (PI) as well as, Annexin V 
conjugated to fluorescein isothiocyanate (FITC).  PI binds DNA in membrane-
compromised neurons, whereas, Annexin V binds phosphotidylserines that translocate to 
the outer cell membrane in the early stages of apoptosis.  Several randomly selected fields 
from each plate were marked and both phase and fluorescent images were captured using 
MetaMorph (Olympus, Center Valley, PA).  Fraction of neuronal death was calculated as 
the number of neurons labeled with only Annexin V plus the number of neurons labeled 
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with Annexin V and PI, divided by the total number of neurons.  The data was subjected to 
an outlier test wherein all values outside of two standard deviations from the mean were 
considered outliers. 
 
Pilocarpine preparation 
All animal use procedures were in strict accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by Virginia 
Commonwealth University’s Animal Use Committee.  Sprague-Dawley rats, weighing 
between 185-235 g, were injected intra-peritoneally (i.p.) with the muscarinic agonist, 
pilocarpine (375 mg/kg).  20 minutes prior to this injection, the animals were given 
methyl-scopolamine nitrate (1mg/kg) i.p. to block the systemic effects of pilocarpine.  
Both of these drugs were dissolved in 0.9% saline and filter-sterilized.  Behavioral seizures 
generally began within 20 minutes of injection with pilocarpine. Animals were allowed to 
seize for 1 hr before SE was terminated by the i.p. administration of 4 mg/kg diazepam 
(DZP) at 1, 3, and 5 hrs post-SE.  Sham animals were injected with all of the drugs 
described above except pilocarpine, instead they received equal volumes of 0.9% saline i.p.  
When appropriate, animals received either dantrolene (10 mg/kg) or vehicle (DMSO) i.p. 
at the end of 1 hr of SE for studies related to epileptogenesis. 
 
Acute isolation of hippocampal neurons   
Animals were sacrificed 24 hrs post-SE to determine [Ca2+]i in hippocampal neurons from 
the sham, pilo-vehicle, and pilo-dantrolene treated groups.  Briefly, as described previously 
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[85], hippocampal slices were cut and incubated for 1 hr following dissection in 
oxygenated artificial cerebrospinal fluid (aCSF).  Slices were exposed to 8 mg/ml Type 
XXIII protease (Sigma Chemical Co, St. Louis, MO) for 6 minutes, and then washed to 
abolish protease activity. Mechanical dissociation of tissue was accomplished through 
trituration in N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer using a 
series of fire polished Pasteur pipettes. Dispersed neurons were plated in buffer containing 
Fura-2AM onto poly-L-lysine and Cell-Tak (BD Biosciences, Franklin Lakes, NJ) coated 
culture dishes allowing the appropriate adherence to conduct [Ca2+]i imaging. 
 
Racine score 
To evaluate severity of behavioral seizures during SE, the Racine scoring method was used 
[95].  The Racine scale scores various behavioral traits during SE and in doing so, serves 
as a quantitative tool to measure seizure severity.  The scale rates behaviors on a scale 
from 0-6, with 0=no SE to 6=severe tonic-clonic seizures resulting in death.    
 
Isolation and homogenization of hippocampal tissue 
At various time points either during or after SE, animals were anesthetized by inhalation of 
isoflurane until the righting reflex was lost and respiration rate slowed and were then 
rapidly decapitated.  The brain was quickly removed and dissected.  Hippocampal tissue 
was separated from the rest of the brain and flash-frozen in liquid nitrogen.  The frozen 
hippocampus was homogenized using a motorized homogenizer in 750 µL of modified, 
ice-cold RIPA buffer consisting of: 1% NP-40, 10 mM Tris-HCl (pH 7.4), 150 mM 
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NaCl, and 1% Triton- X100, as well as, phenylmethanesulphonylfluoride (PMSF), and 
Halt Phosphatase Inhibitor Cocktail (Pierce, Rockford, IL) to inhibit protease and 
phosphatase activity, respectively.  The homogenates were stored at -80°C and protein 
concentration was measured using the Bradford reagent (BioRad, Hercules, CA) and a 
spectrophotometer (595 nm). 
 
Western blotting 
Western blotting of hippocampal homogenates was performed as described previously 
[52].  In brief, protein (10 µg /lane) was resolved on SDS-PAGE and transferred to a 
polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA) at 100 V, 4°C.  
Membranes were blocked using 5% bovine serum albumin (BSA) made up in tris-buffered 
saline containing 0.1% Tween-20 (TBST) for 1 hr at room temperature (RT).  Primary 
antibodies were made up in this 5% BSA solution.  The membrane incubated in the RyR2 
primary antibody (1:200) (Alamone Labs #ARR-002, Jerusalem, Israel) overnight at 4°C 
or phospho-RyR2 (1:5,000, Serine-2809) (Badrilla #P010-30, Leeds, United Kingdom) for 
1 hr at RT.  To assess whether there was equal loading of protein, blots were cut and 
incubated in actin (1:8000) (Chemicon #MAB1501, Billerica, MA) or β-tubulin (1:4000) 
(AbCam #ab6046, Cambridge, MA) for 1 hr at RT.  The membranes were washed with 
TBST 5 times following incubation with primary antibody and incubated for 1 hr with goat 
anti-rabbit (1:10,000, for phospho-RyR2, RyR2, β-tubulin antibodies) (Chemicon 
#AP132P) or goat anti-mouse (1:10,000, for actin antibody) (Chemicon #AP124P) 
secondary antibodies conjugated to horseradish peroxidase.  The blots were washed 5 
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times with TBST and washed in enhanced chemiluminescence reagent (SuperSignal, 
Pierce, Rockford, IL) prior to exposing Kodak X-Omat Blue XB-1 X-ray film (Eastman 
Kodak, Rochester, NY) for detection of protein. 
 
Data analyses  
Data were expressed as mean ± SEM. To determine significance between treatment groups 
for Ca2+ imaging, SREDs, and neuronal death assays, one-way analysis of variance 
(ANOVA) tests were employed, followed by Fisher’s post-hoc test when appropriate. For 
the Ca2+ imaging and cell death experiments, at least 6 plates were used per treatment 
group.  For electrophysiology experiments, 2-3 neurons are patch-clamped from each plate 
with a minimum of 5 plates used for each treatment group.  All experiments were 
performed over the period of several weeks so that the results were representative of 
multiple cultures.  A p-value<0.05 was considered statistically significant. Statistical 
analysis was performed using StatView 5.0.1 and graphs were drawn using SigmaPlot 
(Systat Software, San Jose, CA).     
 
Results 
In the rat pilocarpine model of SE-induced AE, hippocampal neuronal [Ca2+]i increases 
during SE and significant elevations in [Ca2+]i are maintained for at least one year post-SE 
in those animals that go on to develop epilepsy.  Thus, our first aim was to evaluate 
whether similar long-term changes in [Ca2+]i are observed in the in vitro, low Mg2+ model. 
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In vitro SE causes significant, long-lasting elevations in [Ca2+]i (Ca2+ plateau) 
Neurons were treated for 3 hrs with either low Mg2+ to simulate in vitro SE or pBRS as a 
sham control, in accordance with previously described methodology [23].  The cells were 
loaded with the Ca2+ indicator, Fura-2AM to determine 340/380 ratios both at the end of 
this treatment and at various time points following the treatment (Figure 3-1).  These 
fluorescent ratio values were obtained using alternating excitation wavelengths of 340 nm 
and 380 nm, and the resulting 340/380 ratios correspond directly to [Ca2+]i.  There was no 
significant difference in 340/380 ratios between the sham control neurons that were treated 
with pBRS at any of the time points tested.  In contrast, neurons treated with low Mg2+ 
displayed ratio values of 0.78±0.05 acutely at the end of this 3 hr treatment, approximately 
double the ratio values observed in sham controls.   
 
In order to end in vitro SE, MgCl2 was restored to these cultures by washing them with 
pBRS.  The same neurons were imaged for the first hour post-restoration of MgCl2.  
Within 10 min of restoring the MgCl2 to the low Mg2+-treated plates, the 340/380 ratio 
dropped from 0.78±0.01 to 0.67±0.05.  At 30 min post-in vitro SE, the ratios fell slightly to 
0.66±0.06 and at 60 min post-SE to 0.60±0.07.  At the 3 hr and 6 hr time points, the 
340/380 ratios had dropped further to 0.46±0.01 and 0.43±0.01, respectively.  Finally, at 
24 hrs post-in vitro SE, the low Mg2+-treated cells exhibited 340/380 ratios of 0.46±0.02.  
n= 6 plates at each time point tested with 52-134 neurons imaged in total per treatment 
group.  The recorded ratios in the low Mg2+-treated group were significantly elevated when 
compared to the controls at each of the time points tested.  This suggests that low Mg2+-
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induced in vitro SE triggers long-lasting elevations in [Ca2+]i, as evidenced by maintenance 
of increased 340/380 ratios for at least 24 hrs. 
 
Dantrolene lowers [Ca2+]i to baseline levels following in vitro SE 
We next wanted to test whether these persistent elevations in [Ca2+]i following low Mg2+-
induced SE-like activity could be inhibited pharmacologically and whether doing so, 
would prevent the expression of SREDs.  Dantrolene, an inhibitor of RyR, was utilized 
immediately post-in vitro SE to determine whether inhibition of RyR-mediated CICR 
could lower the elevated [Ca2+]i. To test this, hippocampal neuronal cultures were treated 
for 3 hrs with low Mg2+ and were then loaded with Fura-2AM.  As shown in Figure 3-2, 
following 3 hrs of in vitro SE (time 0 on x-axis), neurons showed elevations in 340/380 
ratios that were normalized to the peak ratio.  These neurons were then treated with either 
dantrolene (50 µM) or vehicle (0.1% DMSO).  At 5 min post-treatment, vehicle-treated 
cells showed a slight decrease in 340/380 ratio; in contrast, dantrolene-treated cells 
exhibited 340/380 ratios that were 47% of the peak observed at the end of in vitro SE.  At 
10 min post-treatment, the 340/380 ratio values were 83% and 43% of the post-SE peak in 
vehicle- and dantrolene-treated groups, respectively.  At 15 min post-treatment, the 
340/380 ratio values were 82% and 40% of the post-SE peak in vehicle- and dantrolene-
treated groups, respectively.  In the cells that were exposed to dantrolene after the low 
Mg2+ treatment, [Ca2+]i returned to the baseline levels observed in the naïve controls (data 
not shown) within 20 minutes.  In contrast, the vehicle controls showed elevated [Ca2+]i at 
all time points tested—the 340/380 ratios fell by only 18% over the first 20 minutes 
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following in vitro SE, consistent with the data reported in Figure 3-1.  There was a 
significant difference in the 340/380 ratios between the dantrolene and vehicle treated 
groups at each time point after 1 min of treatment, with the dantrolene-treated group 
showing marked enhancement in the ability to rapidly lower the [Ca2+]i.  n=6 plates were 
used per treatment group with ~60 neurons imaged in total per condition. These 
experiments demonstrated that dantrolene was able to lower [Ca2+]i when administered 
acutely after in vitro SE; thus, suggesting that RyR may play a role in mediating the post-
SE elevations in [Ca2+]i. 
 
In vitro SE is not inhibited by dantrolene 
This in vitro hippocampal neuronal culture model of SE is, much like the clinical 
condition, difficult to treat because it is highly refractory to anticonvulsant treatment.  
Thus, we sought to determine if dantrolene could act to block this low Mg2+-induced, high 
frequency spiking.  Using whole-cell current clamp electrophysiology, we observed that 
naïve cultured hippocampal neurons exhibited infrequent spontaneous action potentials 
while in normal pBRS (Figure 3-3 A).  Upon replacing the culture media with low Mg2+, 
the neurons demonstrated continuous, high frequency epileptiform discharges (Figure 3-3 
B).  The spike frequency observed in cultures treated with low Mg2+ was greater than 3 Hz.  
This frequency is consistent with the criteria for clinical SE.  We demonstrated that 
treatment with dantrolene (50 µM) failed to slow down the low Mg2+-induced high 
frequency spiking (Figure 3-3 C).  No change in mean membrane potential or mean input 
resistance was observed between groups.  There was no significant difference in spike 
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frequency between neurons treated with low Mg2+ plus dantrolene versus low Mg2+ 
alone—this suggests that dantrolene is unable to inhibit low Mg2+-induced in vitro SE.   
 
Dantrolene maintaines baseline Ca2+ levels 24 and 48 hours post-SE 
In order to evaluate whether the dantrolene-mediated changes in [Ca2+]i that were observed 
acutely were more long-lasting, we treated neurons with low Mg2+ followed by dantrolene 
or vehicle and imaged the cells 24 (Figure 3-4 A) and 48 hrs (Figure 3-4 B) post-treatment.  
Neurons treated with low Mg2+ and then vehicle exhibited significantly elevated 340/380 
ratios when compared to the control, these numbers were consistent with data collected in 
Figure 3-1.  Interestingly, in neurons treated with low Mg2+ and then dantrolene, 340/380 
ratios were not significantly different from those observed in the control.  Thus, 24 hrs 
post-SE, dantrolene was able to maintain [Ca2+]i at baseline levels (96.25 ± 5.13% of the 
control).  Whereas, hippocampal neuronal cultures treated with low Mg2+ and then vehicle 
demonstrated significant elevations in [Ca2+]i (120.47 ± 6.95% of the control).  n=10 or 
more plates with ~100 cells imaged per treatment group at this time point.  
 
At 48 hrs post-treatment, [Ca2+]i in the dantrolene-treated neurons was comparable to 
concentrations observed in controls (96.23 ± 3.45% of the control).  In contrast, neurons 
treated with low Mg2+ and then vehicle, showed significant elevations in 340/380 ratios 
compared to both the drug-treated and the control neurons (120.74 ± 3.58% of the control).  
n=5 plates with ~60 cells imaged per treatment group at 48 hr time point.  Therefore, 
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dantrolene appears to be able to maintain [Ca2+]i for at least 48 hrs post-in vitro SE at the 
baseline concentrations observed in control neurons.    
 
Dantrolene prevents the development of SREDs 24 and 48 hours post-SE but does not 
inhibit SREDs acutely 
Also at 24 and 48 hrs post-in vitro SE, neurons were patched using current-clamp 
electrophysiology to evaluate for the expression of SREDs.  Control neurons demonstrated 
“normal” activity consisting of sporadic firing of action potentials (Figure 3-5 A).  In 
contrast, 84% and 100% of neurons treated with low Mg2+ showed SREDs at 24 and 48 hrs 
post-in vitro SE, respectively.  A representative trace is shown that highlights the 
characteristics of the observed SREDs (Figure 3-5 B).  These episodes consisted of 
paroxysmal depolarization shifts and occurred at a frequency of 5-8 episodes per hour with 
each SRED lasting 1-3 minutes.    Neurons from the plates that were treated with low Mg2+ 
followed by dantrolene showed a marked inhibition in the expression of SREDs 24 hrs 
(Figure 3-5 C) and 48 hrs (Figure 3-5 D) post-treatment.  Only 10% and 20% showed 
SREDs at 24 and 48 hrs post-SE, respectively.  Of this small percentage, the SRED 
frequency was 1.7/hr at the 24 hr time point and 1.9/hr at the 48 hr time point, a marked 
reduction when compared to the SRED frequency observed in cells treated with low Mg2+ 
but no drug.      
 
To test for potential anti-convulsant properties, we studied whether acutely adding 
dantrolene (50µM) to neurons already demonstrating SREDs could inhibit these episodes.  
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Dantrolene did not inhibit SREDs when administered acutely (line over Figure 3-5 B 
represents treatment with dantrolene); in fact, there was no change in the frequency or 
duration of the SREDs.  No change in mean resting membrane potential or mean input 
resistance was observed between groups.   
 
Dantrolene is neuroprotective  
While several studies have demonstrated in other models of epilepsy that dantrolene 
exhibits some neuroprotective properties [96-98], we wanted to evaluate whether it could 
be neuroprotective when given after the SE-related injury in the hippocampal culture 
model.  We treated cells with low Mg2+ for 3 hrs followed by drug or vehicle and 
determined cell viability 24 and 48 hrs later (Figure 3-6).  Cell viability was ascertained 
using PI and Annexin V-FITC.  At the 24 hr time point, sham control cultures that had 
been subjected to 3 hrs of pBRS instead of low Mg2+ had a fraction cell death of 0.141 ± 
0.013.  Neurons treated with low Mg2+ and then dantrolene (50 µM) had an average 
fraction cell death of 0.138 ± 0.012, consistent with levels observed in the sham control.  
Lastly, cultures exposed to 3 hrs of low Mg2+ and then vehicle had an average cell death 
fraction of 0.180 ± 0.013, which was significantly higher than the cell death observed in 
both drug and control groups.  This demonstrated that at 24 hrs post-treatment with low 
Mg2+ or pBRS, dantrolene was able to reduce cell death to levels observed in the sham 
controls.  
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Data was also collected at 48 hrs post-SE.  There was no significant difference in fraction 
cell death between sham and low Mg2+ plus dantrolene groups; however, low Mg2+ plus 
vehicle neurons showed a significant increase from the other two groups.  Fraction cell 
death was 0.139 ± 0.019, 0.208 ± 0.022, and 0.128 ± 0.028 in sham, low Mg2+ plus 
vehicle, and low Mg2+ plus dantrolene treated neurons, respectively.  n=7 or more plates 
per treatment group and time point.  Thus, these results showed that dantrolene-treated 
neurons exhibited decreased fraction cell death, which suggests that dantrolene may be 
neuroprotective when administered after in vitro SE.   
  
In the rat pilocarpine model of SE-induced AE, dantrolene is able to lower 
hippocampal neuronal Ca2+ post-SE 
In order to test whether our in vitro observations were valid in a whole animal model, we 
utilized the rat pilocarpine model of SE-induced AE.  Long-lasting elevations in [Ca2+]i 
following SE were first demonstrated in this model [32].  We tested whether dantrolene 
was able to lower hippocampal neuronal [Ca2+]i when administered following 1 hr of 
pilocarpine-induced SE.  Animals were given pilocarpine and allowed to seize for 1 hr, 
upon which time they were administered diazepam to terminate the SE and then either 
dantrolene (10 mg/kg) or vehicle (DMSO).  Then, 24 hrs post-SE, the animals were 
sacrificed and hippocampal neurons were acutely isolated and imaged to determine [Ca2+]i.  
As demonstrated in Figure 3-7, in the neurons isolated from the naïve control animals, an 
average 340/380 ratio of 0.615 ± 0.019 was observed.  Neurons from animals in the SE 
group had an average 340/380 ratio of 0.763 ± 0.047, which was significantly higher than 
   
 71 
the ratios observed in the naïve control.  In contrast, neurons from animals that were in SE 
and then treated with dantrolene had an average 340/380 ratio of 0.571 ± 0.014, which was 
consistent with that observed in the control but significantly lower than the SE alone 
neurons.  n=2 or more animals in each group with approximately 30 cells imaged per 
animal.  This suggests that dantrolene, when administered immediately following SE, may 
lower [Ca2+]i in hippocampal neurons in vivo.   
 
Dantrolene does not affect the severity of pilocarpine-induced SE 
To ensure that dantrolene was decreasing the [Ca2+]i by directly inhibiting Ca2+ rather than 
simply abolishing SE more efficiently and thus, decreasing the severity of the insult, we 
quantified the robustness of pilocarpine-induced seizures in animals pre-treated with either 
vehicle (DMSO) or dantrolene (10 mg/kg).  A modified Racine scale was used that ranged 
from 0-6, with no response scored as a 0 and death scored as a 6.  Two trained observers 
independently scored the SE and scores were averaged for each animal.  The severity of 
the seizures in pilocarpine plus vehicle scored a 3.5 ± 0.20 and in pilocarpine plus 
dantrolene a 3.75 ± 0.25; thus, no significant difference was observed between the two 
groups (Figure 3-8).  n=4 animals per group.  The results from this experiment 
demonstrated that dantrolene does not affect the severity of seizures induced by 
pilocarpine. 
 
The Ca2+ plateau may be maintained in vivo by “leaky” ryanodine receptors 
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It has been demonstrated in a cardiac model of ventricular arrhythmias, phosphorylation of 
the RyR leads to increased dissociation of a protein, calstabin [99,100].  Dissociation of 
this protein is associated with increased Ca2+ leak from the receptor, leading to ventricular 
arrhythmias [99,100].  It can be hypothesized that if RyR are contributing to the Ca2+ 
plateau post-SE, they are either upregulated or simply more active, allowing for increases 
in [Ca2+]i.  Western blot analysis was carried out at several time points both during and 
after SE.  The most interesting change in expression noted was at 1 wk post-SE.  At this 
time point, no significant difference was observed in quantity of RyR2; however, the 
phosphorylated (at serine-2809) form of the receptor was significantly upregulated in the 
SE animals when compared to both the naïve and sham controls (Figure 3-9).  At 1 hr and 
1 day post-SE there does not appear to be an upregulation in either RyR or the 
phosphorylated form of this receptor (data not shown).  This suggests that ‘leaky’ RyR, 
which increase in expression only during the period of epileptogenesis, may contribute to 
the ultimate phenotype.   
 
Discussion 
This study demonstrated that neuronal injuries such as SE can cause an increase in [Ca2+]i 
that is sustained well past the duration of the injury itself in the hippocampal neuronal 
culture model of SE-induced AE.  Moreover, dantrolene, a RyR inhibitor, is able to both 
lower [Ca2+]i to levels observed in control neurons and prevent the development of SREDs 
when used after in vitro SE.  The observation that an injury-triggered, sustained elevation 
in [Ca2+]i (the calcium plateau) exists in vitro correlates closely to findings reported in 
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Raza et al [32].  This group demonstrated in the rat pilocarpine model of SE-induced AE 
that hippocampal neuronal [Ca2+]i increases during injury and remains elevated only in 
those animals that later develop epilepsy [32].  This study suggests that changes in [Ca2+]i 
and Ca2+ homeostatic mechanisms lead to a Ca2+ plateau, which may be a 
pathophysiological characteristic of neuronal injury and epileptogenesis.  Understanding 
various cellular and molecular changes that occur either during or following neuronal 
injuries is important in developing new therapeutics to prevent the ultimate development of 
AE.  Therefore, the finding that the changes in [Ca2+]i that were observed in vivo are also 
seen in vitro suggests that this culture model may provide a useful tool in screening various 
pharmacological agents and performing new molecular modulations in order to prevent 
epileptogenesis. 
 
The in vitro model utilizing low Mg2+ to elicit SE-like activity and ultimately, SREDs is a 
commonly used model to study various characteristics of both SE and epilepsy such as 
pharmacoresistance, plasticity changes, mechanisms of epileptogenesis, and cell death 
[18,24,84].  The model exhibits several features consistent with the development of AE in 
both animal models and the clinical condition, which make it a useful tool in elucidating 
the underlying mechanisms of epileptogenesis and seizures [23,24].  Moreover, the cell 
injury observed in the in vitro and in vivo models correspond to that seen in clinical studies 
documenting the relationship between SE and neuronal injury [25-27].  It should be noted 
that the hippocampal neuronal cultures do not have the true anatomical connections 
maintained in slice preparations or the intact brain.  However, the cultures are an essential 
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tool in the development of new drugs and the study of molecular mechanisms because they 
provide a controlled environment to do high-throughput screenings and are more easily 
manipulated for molecular studies.   
 
While currently there are several anti-epileptic drugs, there are no anti-epileptogenic drugs.  
Such therapeutic agents that can be administered immediately following injury so as to 
prevent long-term sequelae, namely the development of AE, would be extremely important 
clinically.  In this study, we demonstrated that dantrolene, when given post-SE inhibited 
the Ca2+ plateau and prevented the development of SREDs in the in vitro low Mg2+ model.  
Our results also highlighted that dantrolene did not stop SE or serve as an anti-convulsant 
but is neuroprotective in the low Mg2+ model even when used following the neuronal 
injury.  The ability to offer neuroprotection following a neuronal injury is an important 
strategy to prevent the development of injury-related chronic neurological conditions 
[101,102].  In this study, many of the in vitro experiments were also replicated in the rat 
pilocarpine model and the novel finding that dantrolene was able to lower [Ca2+]i when 
administered following SE without diminishing the SE itself was demonstrated.  This 
finding affirms that the in vitro model may prove to be an effective tool in preliminary 
pharmacological studies.  Studies have been initiated to determine whether this drug has 
anti-epileptogenic properties in vivo, as this would have tremendous clinical implications.   
 
It should be noted that the pharmacological modulation of Ca2+ in vivo is a challenge in 
that the ubiquitous nature of this ion suggests that systemic inhibition would potentially 
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have numerous side effects [103].  However, a recent clinical trial has utilized a Ca2+-
chelating agent in patients following stroke and the unpublished results have indicated that 
not only are stroke outcome scores improved, but the patients experienced no significant 
negative cardiovascular or neurological side effects [88].   
 
The data also suggest that the RyR, a regulator of CICR, may contribute to the 
maintenance of the calcium plateau.  Much of what is currently known regarding the role 
of RyR in epilepsy is based on studies using dantrolene either as a prophylactic 
neuroprotective agent before injury so as to prevent the development of AE or as an anti-
convulsant after the full development of AE. It has been demonstrated that pre-treatment 
with dantrolene blocks the induction phase in hippocampal slice preparation [104]. 
Another study confirmed these results in the kindling model of epilepsy, showing that 
animals pre-treated with dantrolene require significantly greater stimuli to generate 
seizures [105]. Moreover, after the animals are kindled, during the chronic phase of 
epilepsy, dantrolene has no anti-convulsant effects [91,105].  Thus, while such studies 
have suggested that treatment with dantrolene could provide tremendous benefits when 
administered before the inciting injury, there is still a need for studies to examine its 
effects when administered after the injury, as this would be more clinically relevant.  It 
remains plausible that during an excitotoxic neuronal injury, the massive release of 
glutamate activates NMDAR leading to increased [Ca2+]i.  However, following the injury, 
CICR mechanisms controlled by the RyR may play a role in maintaining the long-lasting 
elevations observed both in the rat pilocarpine model and in the in vitro model used in this 
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study.  This hypothesis is supported by western blot experiments performed in this study 
demonstrating that at 1 week post-SE, during the period of epileptogenesis, there is an 
increase in phospho-RyR2 and no change in RyR2 expression in the hippocampus.  
Phospho-RyR2 has been associated with increased Ca2+ leak from the RyR, therefore, this 
may contribute to the maintenance of a Ca2+ plateau [99,100]. 
 
Thus, this study is the first to demonstrate the novel finding that in vitro SE causes long-
lasting elevations in [Ca2+]i, which can lowered post-injury by treatment with dantrolene in 
both in vitro and in vivo models of SE-induced AE.  More studies are needed to better 
understand and characterize the post-SE Ca2+ plateau, as this may be a useful tool in the 
development of anti-epileptogenic targets. Lowering the post-SE Ca2+ plateau may prevent 
the second messenger effects that lead to epileptogenesis and the development of chronic 
epilepsy.   
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Figure 3-1.  In vitro SE causes significant, long-lasting elevations in [Ca2+]i 
(Ca2+ plateau).  Time course comparing sham controls treated with pBRS (solid 
black circles) versus neurons treated with low Mg2+ (clear circles) at the end of 
in vitro SE (acute) and at various time points following in vitro SE (10 min, 30 
min, 60 min, 3 hrs, 6 hrs, 24 hrs).  All data represented as average 340/380 ratio 
± standard error of the mean (SEM). *p<0.05, n= 6 or more plates with 52-134 
neurons imaged per condition at each time point studied. 
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Figure 3-2.  Dantrolene lowers [Ca2+]i to baseline levels following 
in vitro SE.  Following 3 hours of in vitro SE (time=0), cells were 
treated with either dantrolene (50 µM, clear circles) or vehicle (solid 
black circles). 340/380 ratios were recorded every 30 seconds for 20 
minutes and normalized to percent of the peak ratio observed at 
time=0.  *p<0.05, n=6 plates per treatment group with ~60 neurons 
imaged per condition. 
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Figure 3-3.  In vitro SE is not inhibited by dantrolene.  A, representative current-
clamp trace from control neuron B, neuron in low Mg2+ or in vitro SE and C, neuron 
in low Mg2+ plus dantrolene (50 µM). 
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Figure 3-4. Dantrolene maintains baseline Ca2+ levels 24 and 48 hrs post-SE.  
A, effect of dantrolene (50µM) (light gray bar) versus vehicle (black bar) on 
340/380 ratios 24 hrs post-in vitro SE and B, 48 hrs post-in vitro SE.  Data 
represented as average percent of naïve control ± SEM.  *p<0.05, n=10 or more 
plates with ~100 cells imaged per treatment group for 24 hr time point; n=5 plates 
with ~60 cells imaged per treatment group at 48 hr time point. 
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Figure 3-5.  Dantrolene prevents the development of SREDs 24 and 48 hours 
post-SE but does not inhibit SREDs acutely.  A, representative current-clamp trace 
from control neuron, B, low Mg2+-treated neuron displaying characteristic SREDs, and 
C, neurons treated with low Mg2+ then dantrolene at both 24 hrs and D, 48 hrs post-
treatment.  Dantrolene did not inhibit SRED activity when added acutely to neurons 
displaying SREDs (line over B). 
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Figure 3-6.  Dantrolene is neuroprotective.  A, Cell death was assessed 
at 24 hrs and B, 48 hrs post-treatment with pBRS (sham, black bars), low 
Mg2+ then vehicle (light gray bars), and low Mg2+ then dantrolene 
(50µM) (dark gray bars).  No significant difference observed between 
sham and drug-treated group at either of the time points.  Low Mg2+ 
neurons demonstrated significantly more cell death than the other two 
groups at both 24 and 48 hrs post-treatment.  Data represented as mean 
fraction cell death ± SEM. *p<0.05, n=7 or more plates per treatment and 
time point.   
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Figure 3-7.  In the rat pilocarpine model of SE-induced AE, dantrolene 
is able to lower hippocampal neuronal Ca2+ post-SE.  Animals were 
treated with vehicle (DMSO) or dantrolene (10 mg/kg) following 
pilocarpine-induced SE.  24 hrs later hippocampal neurons were isolated and 
imaged for Ca2+ levels.  Bar graph compares naïve control animals (black 
bar), SE-vehicle animals (light gray bar), and SE-dantrolene animals (dark 
gray bar).  Data is represented as mean 340/380 ratio ± SEM.  *p<0.05, n=2 
or more animals in each group with approximately 30 cells imaged per 
animal. 
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Figure 3-8.  Dantrolene does not affect the severity of pilocarpine-
induced SE.  The severity of pilocarpine-induced seizures was quantified 
using a modified Racine scale (0-6, with 0= no response to 6= death) by 
averaging scores from 2 independent observers.  Data is represented as 
mean ± SEM.  n=4 animals per group 
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Figure 3-9.  The Ca2+ plateau may be maintained in vivo by “leaky” RyR2.  
A, western blot analysis of hippocampal RyR2 and B, phospho-RyR2 expression 
1wk after pilocarpine-induced SE.  The data demonstrated no change in the 
expression of the 5x102 kD RyR between the naïve, sham, and pilocarpine 
groups.  However, the expression of the 5x102 kD phospho-RyR is significantly 
increased in the pilocarpine-treated group. 
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Chapter 4: Levetiracetam Inhibits Both Ryanodine and IP3 Receptor 
Activated Calcium Induced Calcium Release in Hippocampal Neurons in 
Culture 
 
Introduction 
Epilepsy is a major neurological condition that affects approximately 1-2% of the 
population worldwide and over 40% of all epilepsy cases arise following a previous brain 
insult [106], [107].  Progress has been made in the treatment of epilepsy during the past 
decade with the discovery of newer antiepileptic drugs (AEDs) and surgical treatments.  
Understanding the mechanisms of action of AEDs has helped in better characterizing 
neuronal excitability and may also aid in the development of more effective strategies to 
treat epilepsy.  Levetiracetam (LEV) is a new AED that is currently in widespread clinical 
use. However, LEV appears to have different anticonvulsant properties from other AEDs 
[108] and little is known of its mechanism of action except that it acts in a manner and at 
sites distinct from other commonly used AEDs [109].  Understanding how this drug works 
as an AED and an examination of its ability to block certain cellular changes could provide 
insights into its powerful anticonvulsant effect and into the development of more effective 
AEDs that act in a similar manner.   
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LEV, the S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide, is used to treat a variety 
of forms of epilepsy [110].  Unlike many AEDs, LEV does not appear to exhibit direct 
effects on GABAergic neurotransmission, fails to interact with the benzodiazepine binding 
site, and lacks a significant affinity for GABAergic or glutamatergic receptors 
[111],[112],[113].  In addition, compared to other AEDs, LEV is not effective in a use 
dependent fashion on sodium channel inhibition, maximal electric shock or 
pentylenetetrazole tests for anticonvulsant agents [114]. Most recently, it has been 
demonstrated that LEV inhibits GABA-A current run-down [115] and that it binds to the 
synaptic vesicle protein 2A (SV2A) [109].  While studies have demonstrated that SV2A 
modulates exocytosis of neurotransmitter-containing vesicles [116],[117], the specific 
mechanistic relationship between LEV and SV2A remains to be elucidated.  Thus, LEV 
represents a distinct class of AEDs.  
 
Both changes in Ca2+ homeostatic mechanisms and persistent elevations in baseline 
intracellular calcium ([Ca2+]i) have been implicated in playing a key role in the induction 
and maintenance of post-injury spontaneous recurrent seizures, or acquired epilepsy (AE) 
[4].  Studies have demonstrated that inositol 1,4,5-triphosphate (IP3) and ryanodine 
receptor (RyR) mediated calcium-induced calcium release (CICR) play key roles in the 
changes in [Ca2+]i observed in epileptic conditions [48],[97].  The effect of LEV on Ca2+ 
remains to be fully elucidated.  However, it is known that LEV does not affect T-type 
voltage-gated Ca2+ and exhibits only a mild inhibition of high voltage activated Ca2+ 
channels [118].  LEV has been shown to inhibit caffeine-induced calcium transients in 
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studies in rat pheochromocytoma PC12 cells [51], and bradykinin-induced calcium 
transients in hippocampal slices [119].  Since it has been shown that [Ca2+]i regulation in 
hippocampal neurons plays an important role in modulating anticonvulsant and 
epileptogenic effects and in mediating injury during seizures [32],[120],[121] it is 
important to evaluate the effects of LEV on [Ca2+]i in hippocampal neurons by regulating 
IP3R or RyR induced CICR.   
 
This study was initiated to evaluate whether LEV was able to inhibit both IP3R- and RyR-
induced CICR in primary hippocampal neurons in culture.  The results demonstrate that 
LEV affects CICR from IP3 and Ry-sensitive stores, employing the use of single-cell Fura-
2 imaging to record the response to caffeine and bradykinin, two agents that induce 
prototypic IP3 and Ry-mediated calcium release respectively [122],[123]. The exploration 
of whether LEV modulates CICR could prove a valuable addition to what is currently 
understood on the effects of LEV on hippocampal neurons. Moreover, the ability of a drug 
to reduce [Ca2+]i may make it an ideal therapeutic candidate in neuroprotection following 
injury and the prevention of long-term plasticity changes leading to epilepsy.  
 
Materials and Methods 
Reagents 
UCB Pharma supplied Levetiracetam.  Caffeine and bradykinin were obtained from 
Sigma-Aldrich (St. Louis, MO).  All agents were solubilized in physiologic bath-recording 
solution. 
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Hippocampal neuronal culture preparation 
Preparation of primary mixed hippocampal neuronal culture was performed as previously 
described [23].  In summary, hippocampal cells were isolated from 2-day post-natal 
Sprague-Dawley rats (Harlan, Frederick, MD).  Cells (7.5x104) were plated onto a glial 
support layer that was previously plated onto poly-L-lysine (0.05 mg/ml) coated Lab-Tex 
glass chambers (Nalge-Nunc International, Naperville, IL).  Cultures were maintained at 
37°C in 5% CO2/95% O2 incubator and fed twice weekly with Neurobasal A medium 
(Invitrogen, Carlsbad, CA) with B-27 serum-free supplement (Invitrogen) and 0.5mM L-
glutamine.  All experiments were performed on neurons maintained for 14-17 days in vitro 
to ensure proper development.  All procedures adhered strictly to the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals and were approved by Virginia 
Commonwealth University’s Institutional Animal Care and Use Committee. 
 
Ca2+ Microfluorometry  
Primary hippocampal cultures were loaded with Fura-2 acetoxymethyl ester and then 
placed on the 37°C stage of an Olympus IX-70 inverted microscope (Olympus, Center 
Valley, PA) coupled to an ultra-high-speed fluorescence imaging system (Perkin-Elmer 
Life and Analytical Sciences, Boston, MA) as described previously [94].  Data were 
collected using the UltraVIEW Imaging System.  Ratio images were acquired every 5 s 
using alternating excitation wavelengths (340/380 nm) with a filter wheel (Sutter 
Instruments, Novato, CA) and fura filter cube at 510/540 nm emissions with a dichroic 
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mirror at 400 nm [94].  Image pairs were captured for 50 s before and 100 s post-addition 
of bradykinin or caffeine, and were corrected for background fluorescence by imaging a 
non-indicator loaded field [94].  
 
Data Analysis 
Data were statistically analyzed using StatView (Version 5.0.1).  Experiments were 
repeated at least three times from different culture batches.  The significance of the data 
was tested by one-way analysis of variance (ANOVA), or one-way repeated measures 
(RM) ANOVA followed by Fisher’s post-hoc test when appropriate.  P < 0.05 was 
considered significant for all data analysis. 
 
Results  
LEV does not affect baseline [Ca2+]i in cultured hippocampal neurons  
To determine the effect of LEV on basal [Ca2+]j, Fura-2 340/380 ratios were measured in 
the presence and absence of clinically relevant concentrations [119] of LEV (1, 10, 33, and 
100 µM).  Cells were pre-treated for 20 minutes with either vehicle (control) or LEV and 
Fura-2 ratios were recorded.  As shown in Figure 4-1, no significant changes in 340/380 
ratios were observed between control and LEV-treated cells during the 20-minute period 
following the addition of LEV to the hippocampal culture. These results demonstrate that 
at all concentrations tested, LEV does not affect baseline [Ca2+]i.   
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LEV inhibits caffeine induced CICR in hippocampal neurons 
Caffeine-induced Ca2+ transients are mediated by stimulation of RyR [119],[124].  Thus, in 
order to investigate the effects of LEV on ryanodine induced Ca2+ release, caffeine-
induced Ca2+ transients were studied following pre-treatment with 33 µM LEV in 
accordance with other studies [119].  Before the addition of caffeine, both control and LEV 
pre-treated cells exhibited similar baseline ratios of 0.294±0.018 and 0.319±0.120 
respectively, consistent with ratios observed in Figure 4-1.  Stimulation with caffeine 
elicited a marked increase in [Ca2+]i in control neurons as evidenced by increased 340/380 
Fura-2 ratios from the baseline value of 0.294±0.018 to 0.653±0.026, as shown in 
representative trace (Figure 4-2 A).  Pseudocolor ratio images prior and subsequent to 
caffeine stimulation demonstrate this change in calcium following caffeine challenge 
(Figure 4-2 B).  Thus, the overall change from baseline 340/380 ratio following treatment 
with 10mM caffeine was 0.328±0.018 (Figure 4-2 C).   
 
In contrast, cells pre-treated with LEV displayed a significantly diminished response to 
caffeine-induced stimulation.  In LEV-treated cells, the baseline 340/380 ratio of 
0.319±0.120 increased to a maximum value of 0.445±0.045 following the caffeine 
challenge (Figure 4-2 A).  Pseudocolor ratio images demonstrate the contrast in the ability 
of caffeine to mediate changes in calcium in LEV pre-treated cells when compared to 
control (Figure 4-2 B).  Thus, as shown in Figure 4-2 C, following treatment with 10mM 
caffeine, the overall change from baseline 340/380 ratio was 0.126±0.022 in cells pre-
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treated with 33µM LEV.  Therefore, LEV pre-treatment inhibits the height of caffeine-
induced Ca2+ transients by 61.50%.    
 
LEV inhibits bradykinin induced Ca2+ transients in hippocampal neurons 
To investigate how LEV affects IP3R activated Ca2+ release, the effect of LEV (100µM) 
pre-treatment on the inhibition of bradykinin-induced Ca2+ release was evaluated.  
Bradykinin-induced Ca2+ transients are mediated by activation of IP3R [125].  Before the 
addition of bradykinin, similar baseline ratio values of 0.304±0.020 in control and 
0.263±0.015 in LEV (100µM) pre-treated cells were observed, as shown in Figure 4-1.  
Control neurons demonstrated a marked increase in [Ca2+]i  when stimulated with 
bradykinin (1µM) from baseline to 0.574±0.055 (Figure 4-3 A).  This change in Fura-2 
ratio in control neurons is shown in the pseudocolor ratio image (Figure 4-3 B).  Thus, 
treatment with 1 µM bradykinin caused a change in 340/380 ratio of 0.269±0.063 from the 
baseline.   
 
LEV-treated neurons showed a markedly diminished response to bradykinin when 
compared to control neurons.  Stimulation with bradykinin caused a small increase from 
baseline to 0.332±0.037 (Figure 4-3 A), as shown also in the pseudocolor ratio image 
(Figure 4-3 B).  Therefore, neurons pre-treated with 100 µM LEV, bradykinin elicited a 
change from baseline of only 0.069±0.032 (Figure 4-3 C).  Thus, LEV pre-treatment 
inhibited the height of bradykinin-induced Ca2+ transients by 74.35%.  We found at 
   
 94 
concentrations lower than 100µM LEV, there was no significant inhibition in bradykinin-
induced Ca2+ transients.   
 
Discussion 
The results from this study provide direct evidence that LEV inhibits RyR and IP3R 
induced CICR in hippocampal neurons in culture.  LEV was effective in decreasing both 
caffeine-mediated activation of RyR induced CICR and bradykinin activation of IP3R 
stimulated CICR.  These results indicate that LEV is an effective inhibitor of [Ca2+]i 
release mediated by two of the major CICR receptor activated systems.  While the effect of 
LEV on Ca2+ dynamics in an in vitro model of acquired epilepsy remains to be determined, 
Ca2+ is a major second messenger and has been implicated in neurotoxicity, neuronal 
plasticity and the maintenance of epilepsy [34], [32]; thus, the ability of LEV to inhibit 
CICR may prove to be an important property of this drug. 
 
The experiments performed in this study were designed to test whether LEV was able to 
inhibit CICR and to evaluate the mechanisms mediating its effects on these systems, as 
dysregulation of RyR and IP3R has been associated with neurotoxicity, neuronal plasticity 
and epilepsy [34].  To study the ryanodine system, caffeine was employed because it has 
been demonstrated that it functions similarly on RyR as nanomolar concentrations of 
ryanodine with the added benefit of faster kinetics and the ability to quickly reverse its 
effects by washing [124].  Non-physiologic concentrations of caffeine (in the millimolar 
range) are utilized in studies evaluating RyR-mediated Ca2+ release and the Ca2+ response 
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elicited has been well-characterized [126],[127],[119].  At sub-millimolar doses, the 
actions of caffeine are dependent on cytosolic concentrations of Ca2+, whereas, at 
concentrations greater than 5 mM, caffeine causes a Ca2+ independent activation of the 
ryanodine receptor [128].  Thus, using caffeine is an established method to activate RyR-
mediated Ca2+ release [126],[127],[119]. One study employed caffeine in a hippocampal 
slice model to suggest that LEV reduces caffeine-mediated Ca2+ transients [119].  In 
studying IP3R-mediated CICR, lack of commercially available membrane-permeable IP3 
makes bradykinin an ideal choice to study this system because it has been demonstrated 
that it stimulates Ca2+ release through IP3 stores [125]. One study in PC12 cells 
demonstrated that LEV was able to reduce bradykinin-induced Ca2+ transients [51].  
However, no studies have investigated the effect of LEV on both IP3 and RyR in the 
highly relevant hippocampal culture model.  Conducting these studies in hippocampal 
cultures is of utility because networks of hippocampal neurons have been used as models 
to study AE [23],[4].  
 
Our results supplement the current literature aimed at elucidating the mechanism of action 
of LEV [115],[118],[129].  Currently, little is known regarding the mechanism behind the 
anti-epileptic properties of LEV.  Studies have demonstrated that while LEV does not 
exhibit any direct action on GABAergic transmission and does not show affinity for 
GABAergic or glutamatergic receptors, it does induce a change in GABA turnover in the 
striatum [111],[112],[113],[108].  Other studies have focused on biochemical alterations 
induced by LEV and have found that it decreases levels of the amino acid taurine, a low 
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affinity agonist for GABAA receptors, in the hippocampus but does not elicit changes in 
other amino acids [129].   
 
The most promising mechanistic hypothesis explaining the actions of LEV has come from 
experiments that suggest that the action of LEV is presynaptic, as it binds to the 
presynaptic membrane protein, SV2A [130],[109].  SV2A is ubiquitously expressed in the 
brain [131], yet little is known regarding the effects of the interaction between SV2A and 
LEV.  It appears that SV2A is involved in controlling exocytosis of neurotransmitter-
containing vesicles [116],[132].  More recently, it has been demonstrated that LEV 
prevents GABA-A current run-down [115]; thus, increasing inhibitory tone.  Interestingly, 
it has been observed that increases in cytoplasmic Ca2+ triggered by caffeine-induced Ca2+ 
release from intracellular pools depress the GABA-A response [133].  In light of our 
studies, it will be interesting to study whether the ability of LEV to inhibit RyR-mediated 
CICR contributes to the inhibition of GABA-A current run-down following treatment with 
LEV.   
 
Studying the effect of LEV on CICR mechanisms is also important, since alterations in 
[Ca2+]i have been associated with many of the second messenger effects of Ca2+ [134] and 
have been shown to play an important role in underlying neurotoxicity, neuronal plasticity, 
and the development of AE [34], [32].  Moreover, the neuroprotective properties of LEV 
have been observed in several different models [135],[136],[137].  Following neuronal 
injury, excitotoxic glutamate release has been associated with increased stimulation of 
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NMDA receptors and the massive influx of Ca2+ into the cell [138],[4],[139].  This influx 
of Ca2+ triggers CICR and this irreversible Ca2+ overload has been linked to cell death 
[140],[97],[134].  Agents that can reduce these elevations in [Ca2+]i have the potential to be 
neuroprotective [34] and thus, the findings in this study may shed light on a new 
application for LEV.   
 
This study demonstrates that LEV is able to significantly inhibit Ca2+ release through both 
the RyR and IP3R systems.  The ability of LEV to modulate the two major CICR systems 
demonstrates an important molecular effect of this agent on a major second messenger 
system in neurons. Further studies on the effects of LEV may offer insight into novel 
therapeutic uses for this agent and may offer further opportunities to study Ca2+-mediated 
epileptogenesis, neuronal plasticity and neurotoxicity. 
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Figure 4-1. LEV has no effect on baseline [Ca2+]i in cultured 
hippocampal neurons.  Hippocampal neurons loaded with Ca2+ indicator, 
Fura-2, were treated for 20 minutes with vehicle (control) or LEV (1, 10, 
33, and 100 µM).  No significant difference in 340/380 ratio was observed 
between vehicle and drug treated cells at all concentrations tested.  n=9, 3, 
3, 7, 5 (Vehicle, 1, 10, 33, 100 µM LEV, respectively) plates with ~15-20 
cells imaged per plate. 
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Figure 4-2. LEV inhibits caffeine induced CICR in cultured 
hippocampal neurons.  A, representative time course of Ca2+ 340/380 
ratios with baseline normalized to zero before and after 10 mM caffeine 
challenge in control (n=74) and LEV pre-treated (n=88) cells.  5 s intervals 
showing ratios 25 s before and 55 s following the addition of caffeine are 
displayed.  Caffeine elicits an increase in basal Ca2+, this increase is 
diminished in cells pre-treated with LEV (33 µM).  B, 340/380 ratio 
images of representative cell before and after caffeine in both control and 
LEV-treated group.  C, LEV inhibits height of caffeine-induced Ca2+ 
transients by 61.50%.  An increase of 0.328±0.0183 from the baseline was 
observed in control neurons post-caffeine; whereas, upon caffeine 
stimulation cells pre-treated with LEV showed a change from baseline of 
0.126±0.0229.  n=5, control and n=6, LEV group, with ~15 cells imaged 
per plate (p=0.0002). 
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Figure 4-3. LEV inhibits bradykinin induced Ca2+ transients in 
hippocampal neuronal cultures.  A, representative time course of Ca2+ 
340/380 ratios with baseline normalized to zero before and after 1µM 
bradykinin challenge in control (n=119) and LEV-treated (n=82) cells.  5 s 
intervals showing ratios 20 s before and 50 s following the addition of 
bradykinin are displayed.  Bradykinin elicits an increase in basal Ca2+, this 
increase is diminished in cells pre-treated with LEV (100 µM).  B, 340/380 
ratio images of representative cell before and after bradykinin in both control 
and LEV-treated group.  C, LEV inhibits height of bradykinin-induced Ca2+ 
transients by 74.35%.  An increase of 0.269±0.063 from the baseline was 
observed in control neurons post-bradykinin; whereas, upon bradykinin 
stimulation cells pre-treated with LEV showed a change from baseline of 
0.069±0.032.  n=7 (control), n=5 (LEV group) with ~15 cells imaged per 
plate (p<0.05). 
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Chapter 5: The Novel Antiepileptic Drug Carisbamate (RWJ 333369) Is 
Effective in Inhibiting Spontaneous Recurrent Seizure Discharges and 
Blocking Sustained Repetitive Firing in Cultured Hippocampal Neuron 
 
 
Introduction 
Epilepsy is one of the most common neurological disorders affecting approximately 1-2% 
of population worldwide [141,142]. It is characterized by the occurrence of spontaneous, 
recurrent unprovoked seizure discharges [143]. A seizure is the symptomatic, behavioral 
manifestation of abnormal, disordered, spontaneous, and synchronized high frequency 
firing of populations of neurons in the CNS [4,142,143]. Epilepsy also has severe socio-
economic implications [144]. Although great advances have been made in the development 
of newer antiepileptic drugs (AEDs) and surgical interventions for the treatment of 
epilepsy, approximately 40% of the patients are still refractory to treatment with 
conventional AED’s [141,145]. A sizeable population of epileptic patients deals with the 
issue of daily management of epilepsy that ultimately affects their quality of life [146]. 
Thus, there is a growing demand for developing newer medications to treat epilepsy. 
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Carisbamate, or RWJ-333369 (S-2-O-carbamoyl-1-o-chlorophenyl-ethanol), is a novel 
neuromodulator initially developed by SK-Biopharmaceuticals and now under 
development by Johnson & Johnson, Pharmaceutical Research & Development L.L.C.  It 
has completed phase 2 clinical trials for the treatment of epilepsy [147]. Carisbamate is a 
monocarbamate derivate of the broad spectrum AED felbamate, that is no longer used 
clinically due to its hematological and hepatic toxicities [148]. Unlike felbamate, 
carisbamate has only two carbons in its side chain and only one carbamate group that 
prevents the formation of the toxic aldehyde causing the toxicity of felbamate [147]. 
Because of its potential safety, carisbamate has been evaluated as a novel AED and has 
been demonstrated to possess anticonvulsant activity in a variety of in vivo seizure models 
including hippocampal and corneal kindling [147,149] and the GAERS model of absence 
epilepsy [150]. It also inhibits spontaneous recurrent seizures after kainite [151] or Li-
Pilocarpine [152] induced epilepsy. Carisbamate is also anticonvulsant against bicuculline 
and picrotoxin induced seizures and in pentylenetetrazole and maximal electroshock 
induced seizure models [147,149,153]. However, the exact mechanism of action of 
carisbamate is still unknown. The dicarbamate, felbamate, has been reported to affect a 
variety of ionic currents including the sodium (Na+) [154], calcium (Ca2+) [155], and N-
methyl d-aspartate (NMDA) currents [156]. However, significance of this action for 
seizure protection is uncertain. Thus, it is important to determine mechanisms underlying 
the antiepileptic effects of carisbamate. 
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This study was initiated to investigate mechanisms underlying the antiepileptic effects of 
carisbamate using the hippocampal neuronal culture model of status epilepticus (SE)-
induced acquired epilepsy (AE) [4,23,157]. The low Mg2+ model of AE utilizes an episode 
of continuous seizure activity (in vitro SE) for 3 hrs to induce epileptogenesis. Upon return 
to solutions containing MgCl2, networks of neurons manifest synchronized spontaneous 
recurrent epileptiform discharges (SREDs) for the life of the neurons in culture (in vitro 
AE). The low Mg2+ model of SREDs in hippocampal neuronal cultures has been routinely 
used to characterize biochemical, electrophysiological, and molecular mechanisms 
underlying epilepsy in an in vitro setting [4,48,157,158]. This in vitro model allows for 
careful control of the neuronal environment and is thus, ideally suited to evaluate the 
effects of various investigational compounds on electrographic seizure activity.  
 
Materials and Methods 
Reagents 
All reagents were purchased from Sigma Chemical Co (St. Louis, MO) unless otherwise 
noted. Sodium pyruvate, minimum essential media containing Earle’s salts, fetal bovine 
serum and horse serum were obtained from Gibco-BRL (Invitrogen Corp., Carlsbad, CA). 
Carisbamate was provided by Johnson & Johnson, Pharmaceutical Research & 
Development L.L.C., Titusville, NJ, USA and was dissolved in sterile water made slightly 
basic with sodium hydroxide and diluted to a final concentration in buffer. 
 
Hippocampal neuronal culture preparation 
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All animal use procedures were in strict accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and approved by Virginia 
Commonwealth University’s Institutional Animal Care and Use Committee. Studies were 
conducted on primary mixed hippocampal neuronal cultures prepared as described 
previously with slight modifications [23,159,160]. In brief, hippocampal cells were 
obtained from 2-day postnatal Sprague-Dawley rats (Harlan, Frederick, MD) and plated at 
a density of 1 x 105 cells/cm2 onto 35-mm Falcon cell culture dishes (Becton Dickinson and 
Co., Franklin Lakes, NJ) previously coated with poly-L-lysine (0.05 mg/ml). Glial cultures 
were maintained at 37°C in a 5% CO2/95% air atmosphere and fed thrice weekly with glial 
feed (minimal essential media with Earle’s Salts, 25 mM HEPES, 2 mM L-Glutamine, 3 
mM Glucose, and 10% fetal bovine serum). When confluent, glial beds were treated with 5 
µM cytosine arabinoside for 2 days to curtail cell division.  On the 13th day in vitro, the 
media was fully replaced with a 5% horse serum supplemented neuronal feed (composition 
given below) in preparation for neuronal plating on the following day.  At this time, these 
cultures predominantly consisted of glial cells with few, if any, neurons. On the 14th day in 
vitro, hippocampal cell suspension was plated on these confluent glial beds at a density of 
2 x 105 cells/cm2.  24 hrs after plating, cultures were treated with 5 µM cytosine 
arabinoside to inhibit non-neuronal growth. Cultures were maintained at 37°C in a 5% 
CO2/95% air atmosphere and fed twice weekly with neuronal feed (minimal essential media 
with Earle’s Salts, 25 mM HEPES, 2 mM L-Glutamine, 3 mM Glucose, 100 µg/ml 
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transferrin, 5 µg/ml insulin, 100 µM putrescine, 3 nM sodium selenite, 200 nM 
progesterone, 1 mM sodium pyruvate, 0.1% ovalbumin, 0.2 ng/ml triiodothyroxine and 0.4 
ng/ml corticosterone supplemented with 20% conditioned media). These mixed cultures 
were used for experiments from 13 days in vitro following neuronal plating through the life 
of the cultures. 
 
Whole-cell current clamp recordings 
Whole-cell current clamp recordings were performed using previously established 
procedures [23,159,160].  Briefly, a cell culture dish was mounted on the stage of an 
inverted microscope (Nikon Diaphot, Tokyo, Japan) continuously perfused with 
physiological basal recording solution (pBRS) containing (in mM): 145 NaCl, 2.5 KCl, 10 
HEPES, 2 CaCl2, 1 MgCl2, 10 glucose, and 0.002 glycine, pH 7.3, and osmolarity adjusted 
to 325 ± 5 mOsm with sucrose. Patch electrodes with a resistance of 2 to 4 mΩ were pulled 
on a Brown-Flaming P-80C electrode puller (Sutter Instruments, Novato, CA), fire-
polished and filled with a solution containing (in mM): 140 K+ gluconate, 1.1 EGTA, 1 
MgCl2, and 10 Na-HEPES, pH 7.2, osmolarity adjusted to 290 ± 10 mOsm with sucrose. 
Whole-cell recordings were carried out using an Axopatch 200B amplifier (Molecular 
Devices, Foster City, CA) in a current-clamp mode. Data were digitized via Digidata 
1322A (Molecular Devices, Foster City, CA) and transferred to VHS tape using a PCM 
device (Neurocorder, New York, NY) and then played back on a DC-500 Hz chart recorder 
(Astro-Med Dash II, Warwick, RI). Carisbamate was included in the recording solution 
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and applied to the whole-cell dish by using a multi-channel gravity-feed perfusion system 
(Warner Instruments, Hamden, CT).  
 
Hippocampal neuronal culture model of SREDs  
SREDs were induced into neuronal cultures by exposing them for 3 hrs to a solution 
containing no added MgCl2 (low Mg2+) using procedures described previously 
[23,159,160]. Briefly, after the removal of maintenance media, neurons were gently 
washed with pBRS or low Mg2+ and then allowed to incubate in this solution at 37oC under 
5% CO2/95% air atmosphere. At the end of the 3-h period, cultures were restored to the 
physiological concentration (1 mM) of MgCl2, returned to maintenance media, and 
incubated at 37oC under 5% CO2/95% air atmosphere. 
 
Sustained repetitive firing in cultured hippocampal neurons  
Sustained repetitive firing (SRF) was induced by S-90 Tri-level Stimulator (Medical 
Systems Corp., Greenvale, NY) by depolarizing pulses of 500 ms duration, 0.3 Hz and 
increasing current strength from 0.1 to 0.5 nA through the micropipette. The duration and 
frequency of depolarizing pulses were kept constant for all experiments. Current strength 
was increased until the cell under study exhibited a suitable number of action potentials 
throughout the duration of the depolarizing pulse. 
 
Hippocampal neuronal culture model of SE  
After 2 weeks in cultures, neurons were utilized for experimentation. SE-like activity was 
induced in vitro as described previously [23]. Maintenance media was replaced with pBRS 
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with or without MgCl2. Continuous high frequency epileptiform bursts (in vitro SE) were 
induced by exposing neuronal cultures to pBRS without added MgCl2 (low Mg2+). The 
high frequency spiking continued until pBRS containing 1 mM MgCl2 was added back to 
the cultures. Unless indicated as low Mg2+ treatment, experimental protocols utilized pBRS 
containing 1 mM MgCl2. 
 
Data analyses 
Data are reported as mean ± SEM. For concentration-response analysis, suppression of SE 
or SREDs was determined as a percentage decrease in frequency over increasing 
concentrations of carisbamate. Status epilepticus frequency was determined by counting 
individual epileptiform bursts over a recording duration of 5 min for each neuron analyzed 
before and after application of the drug. SRED frequency was determined by counting 
individual SREDs over a recording duration of 30 min for each neuron analyzed before and 
after application of the drug. Frequency analysis was carried out on multiple neurons at 
each concentration of carisbamate. SRF data were examined using one-way analysis of 
variance (ANOVA) followed by a post-hoc Tukey test. Data were analyzed using 
SigmaStat 2.0 and graphs were generated using SigmaPlot analysis software 8.02 (SPSS 
Inc., Chicago, IL).  
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Results 
Effects of carisbamate on SREDs 
Whole-cell current clamp recordings from neurons in cultures 1 day after a 3 hr low-Mg2+ 
treatment demonstrated SREDs or in vitro seizure events. Figure 5-1 B shows recording 
from a neuron that exhibited 3 SREDs that lasted between 1-2 min in duration. These 
SREDs occurred for the life of the neurons in culture and manifested paroxysmal 
depolarization shifts, pathophysiological characteristic of AE. SREDs started in an 
unprovoked manner and stopped spontaneously. Multiple recordings from adjacent 
neurons demonstrate that these SREDs were synchronous events occurring throughout the 
neuronal network in populations of neurons (data not shown, [23]).  Thus, SREDs are the 
in vitro equivalent of spontaneous electographic seizure discharges. Age-matched control 
neurons revealed "normal" baseline activity consisting of intermittent action potentials 
(Figure 5-1 A). There were no significant differences in membrane potential and input 
resistance between control and epileptic neurons. 
 
To evaluate the antiepileptic effects of carisbamate we used the in vitro hippocampal 
neuronal culture model of SREDs. As shown in Figure 5-1 C, application of carisbamate 
(100 µM) fully inhibited the expression and reoccurrence of SREDs. The effects of 
carisbamate were dose dependent and concentrations of 10-100 µM caused a progressive 
decrease in the occurrence of SREDs. The graph in Figure 5-2 demonstrates the effects of 
increasing carisbamate concentration on the frequency of SREDs. Carisbamate displayed a 
steep dose-response curve. The lower doses were less effective in stopping SREDs while 
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higher doses produced almost complete inhibition of SREDs. The ED50 value was 
computed to be 58.75 ± 2.43 µM. Carisbamate was applied to neurons during SREDs and 
it took approximately 10-15 min for its antiepileptic effect to be fully manifested. Upon 
washout of carisbamate, SREDs returned and seizures recurred after approximately 15-20 
min (Figure 5-1 C). 
 
Carisbamate produced identical effects to well-known anticonvulsants in this in vitro 
model of AE (Sombati and DeLorenzo, 1995). Phenytoin, a clinically used AED, is a use-
dependent Na+ channel blocker that is utilized for the treatment of generalized tonic-clonic 
and partial complex seizures [161,162]. As shown in Figure 5-1 D, Phenytoin (10 µM) at 
therapeutically relevant concentrations reversibly blocked SREDs. Phenobarbital, a 
GABAergic agonist, is another anticonvulsant that effectively blocked SREDs in our 
model (data not shown). Ethosuximide, a T-type Ca2+ channel blocker used to treat 
absence seizures, failed to block SREDs at concentrations up to 1 mM in this model 
(Figure 5-1 E). These results are consistent with clinical effects of these drugs for the 
treatment of temporal lobe epilepsy.  
 
Effect of carisbamate on SRF 
Several AEDs including phenytoin, carbamazepine, phenobarbital, and lamotrigine are 
known to block SRF in neurons [161,162]. This effect of AEDs is believed to be due to 
their ability to block voltage-gated Na+ channels. We investigated if carisbamate shares 
this property with other AEDs. Cultured hippocampal neurons respond to a sustained 
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depolarizing current by generating a series of action potentials. Under control conditions, a 
depolarizing current (0.5 nA, 0.3 Hz) elicited between 4-10 action potentials (spikes) 
(Figure 5-3 A). Carisbamate (100 µM) caused a significant (p < 0.001) decrease in the 
frequency of spikes elicited by the depolarizing current and abolished the late sustained 
phase of firing without blocking the initial spike (Figure 5-3 B,D). These results suggest 
that carisbamate blocks Na+ channels in a state- or use-dependent manner. While the 
effects of carisbamate were reversible, it took between 10-15 min for the restoration of 
SRF following washout (Figure 5-3 C). Spike frequency following carisbamate washout 
was not significantly different from pre-carisbamate spike frequency (Figure 5-3 D).  
 
Effects of carisbamate on low Mg2+ induced high frequency spiking 
In normal conditioned media, cultured hippocampal neurons exhibited spontaneous action 
potentials that were comparatively infrequent and irregular (Figure 5-4 A). However, upon 
removal of Mg2+ from extracellular environment, neurons generated bursts of action 
potentials resulting in the development of continuous high frequency epileptiform 
discharges (Figure 5-4 B). This epileptiform activity consisted of repetitive burst 
discharges with each burst comprised of multiple spikes overlaying a depolarization shift. 
Spike frequency upon removal of Mg2+ was greater than 3 Hz, meeting the criteria of 
clinical electrographic in vitro SE [23]. This technique has been widely used to model the 
electrographic SE-like condition in vitro.  
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As shown in Figure 5-4, clinically used AEDs including phenytoin (50 µM) and 
ethosuximide (1 mM) at therapeutic concentrations or higher failed to stop low Mg2+ 
induced in vitro SE activity in this model [23]. This type of in vitro continuous seizure 
discharge has been extremely refractory to anticonvulsant treatment [23,159,160]. We 
investigated if carisbamate could act differently and block this high frequency spike 
activity. Treatment with carisbamate (100 µM) appeared to marginally slow down the low 
Mg2+-induced high frequency spiking (Figure 5-4 E). However, this effect was not 
significantly different from low Mg2+ treated neurons alone. The graph in Figure 5-5 shows 
the effects of increasing concentrations of carisbamate on the inhibition of low Mg2+-
induced high frequency spike activity. Even at concentrations of up to 200 µM, 
carisbamate inhibited spike frequency only by 10-15%. The ED50 value for effects of 
carisbamate on inhibition of SE-like activity could not be calculated since the effects never 
reached 50% inhibition. High frequency firing was restored within 10-15 min following 
washout of carisbamate with low Mg2+ solution. 
 
Discussion 
This study demonstrates that carisbamate blocks the expression of SREDs in the 
hippocampal neuronal culture model of in vitro AE.  In addition, carisbamate reduced the 
frequency of action potentials generated during depolarization-induced SRF.  Our results 
are consistent with other studies that have demonstrated antiepileptic properties of 
carisbamate in various in vivo models of seizures [147,149-153].  While the exact 
mechanism of action of carisbamate is actively pursued, the ability of carisbamate to 
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inhibit depolarization-induced SRF suggests that it may block Na+ channels in a state- or 
use-dependent manner and that this effect may account in part for some of the 
anticonvulsant effects of carisbamate.  
 
The majority of patients with epilepsy have their seizures well controlled with 
conventional AEDs; however, approximately 40% of patients manifest refractory epilepsy 
[163,164]. Thus, there is a significant need to develop new AEDs to attempt to treat 
refractory patients. Novel AEDs are being designed to treat drug resistant epilepsy 
[147,149]. In fact, out of the currently available 20 AEDs, 8 were introduced in past 
decade [165]. However, despite the introduction of newer AEDs, the prognosis still 
remains poor [163,166]. Thus, there are continual efforts to develop more efficacious drugs 
that have fewer side effects and a wider margin of safety [147,149].  
 
The novel neuromodulator, carisbamate, displays high potency in a variety of in vivo and 
in vitro seizure models at doses well below those that produce CNS toxicity [167]. 
However, its mechanism of action remains to be elucidated.  Chemically, carisbamate is a 
monocarbamate that is a derivative of the dicarbamate, felbamate.  Felbamate has been 
shown to affect Na+, Ca2+, and NMDA currents [154] [155,156].  All of these effects could 
contribute to the antiepileptic properties of dicarbamates.  While the effects of carisbamate 
on various ionic currents and the contribution of these effects towards its antiepileptic 
profile remain to be investigated, our studies indicate that a use- or state-dependent block 
of Na+ channels could account for such properties. Alterations in intracellular Ca2+ 
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dynamics have been shown to affect the expression of SREDs in this in vitro model of 
acquired epilepsy. The ability of carisbamate to inhibit SREDs could also be due to its 
ability to restore altered Ca2+ homeostasic mechanisms in epileptic neurons. It will be 
interesting to investigate this possibility in future studies  
 
The model of recurrent epileptiform discharges after low Mg2+-induced in vitro SE is a 
commonly used system to study the mechanisms underlying seizures, seizure-induced 
plasticity, and the development of pharmacoresistant seizures [4,168-170]. The 
hippocampal neuronal culture model of SREDs mimics the electrophysiological and 
molecular changes observed during the induction, maintenance, and expression phases of 
epilepsy [4]. Moreover the SREDs exhibited in cultured neurons manifest identical 
electrographic properties, neuronal population synchronicity, and anticonvulsant sensitivity 
as observed in epileptic seizures recorded in in vivo models [4,23,83]. While the neuronal 
cultures do not have true anatomical connections and do not display clinical seizures, the 
hippocampal neuronal culture models offer the ability to utilize various in vitro techniques 
to study molecular mechanisms underlying epilepsy and mechanisms of actions of 
investigational drugs in a more controlled environment.  
   
 114 
   
 115 
Figure 5-1. Effects of carisbamate on SREDs in cultured hippocampal 
neurons. A, Current-clamp recording from a representative control neuron 
displaying baseline activity consisting of intermittent action potentials. B, 
Recording from an “epileptic” neuron 1-day following a 3-h exposure to low Mg2+ 
solution demonstrates occurrence of characteristic SREDs. Three SREDs or 
spontaneous seizure episodes lasting ~60-90s can be seen in this recording frame. 
These SREDs occurred throughout the life of the cultures and are indicative of the 
pathophysiological “epileptic” phenotype. Effects of various AEDs on SREDs in 
cultured hippocampal neurons. Application of C, carisbamate (100 µM) or D, 
phenytoin (10 µM) to the epileptic neurons abolished the expression of SRED 
activity. However application of E, ethosuximide (1 mM) failed to stop SRED 
activity. The effects of AEDs on SREDs were reversible and seizures reappeared 
following drug washout. 
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Figure 5-2. Carisbamate inhibits low Mg2+-induced SRED activity 
in a concentration dependent manner. Frequency of SREDs in the 
presence of varying concentrations of carisbamate was measured over a 
30-min period and then plotted as a percentage change (inhibition) 
from control (absence of carisbamate) SRED frequencies. Carisbamate 
blocked low Mg2+-induced SREDs with an EC50 = 58.75 ± 2.43 µM. 
Each data point represents percentage change from control ± S.E.M. (n 
= 5-7 neurons/ concentration). 
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Figure 5-3.  Carisbamate inhibition of sustained repetitive firing (SRF) 
in cultured hippocampal neurons. Depolarizing pulses (0.5 nA, 1 s) were 
applied during each set of recordings obtained as follows: A, control period 
before application of carisbamate, B, during the application of carisbamate 
(100 µM) and C, following carisbamate washout. D, A bar graph 
representation of average inhibitory effect of carisbamate on SRF in 
hippocampal neurons. Data represented as mean spike frequency ± S.E.M. (n 
= 6, * p < 0.001). 
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Figure 5-4. Effect of carisbamate and other AEDs on low Mg2+-
induced SE in cultured hippocampal neurons. A, Representative 
control neuron displaying intrinsic baseline activity consisting of 
spontaneous action potentials. B, Induction of continuous epileptiform 
status epilepticus activity in a neuron upon low Mg2+ treatment. Effects 
of clinically used AEDs on low Mg2+ induced high frequency spiking. C, 
phenytoin (50 µM) or D, ethosuximide (1 mM) failed to block high 
frequency spiking. E, carisbamate (100 µM) appeared to slow down 
spike frequency compared to phenytoin or ethosuximide but this effect 
was not different from neurons exposed to low Mg2+ alone. 
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Figure 5-5. Concentration-response analysis of effects of 
carisbamate on low Mg2+ induced high frequency spiking in 
cultured hippocampal neurons. Increasing concentrations of 
carisbamate had little effect on low Mg2+ induced high frequency 
spiking. Even at concentrations of up to 200 µM only a 10-12% 
inhibition was achieved. Spike frequencies in the presence of 
varying concentrations of carisbamate were measured over a 15-
min period and then plotted as a percentage change (inhibition) 
from control (absence of carisbamate) spike frequencies. An EC50 
value could not computed since 50% inhibition was not achieved. 
Each data point represents percentage change from control ± 
S.E.M. (n = 5-7 neurons/ concentration). 
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Chapter 6: Carisbamate Prevents the Development and Expression of 
Spontaneous Recurrent Epileptiform Discharges and is Neuroprotective 
in Cultured Hippocampal Neurons 
 
 
Introduction 
Epilepsy is a common neurological disorder affecting approximately 1–2% of the 
population worldwide and is characterized by the occurrence of recurrent, unprovoked 
seizures[81,171].  It is estimated that 50% of epilepsy cases are of idiopathic (genetic) 
etiology, but the other 50% develop after a presumed brain injury, such as status 
epilepticus (SE), stroke, traumatic brain injury, or CNS infections, and are classified as 
acquired epilepsy (AE), resulting in permanent plasticity changes in the brain that cause 
the development of spontaneous recurrent seizures [4,81]. This process of transformation 
of healthy CNS tissue with a functional balance between excitation and inhibition to a 
brain manifesting hyperexcitable neuronal epileptiform discharges is called epileptogenesis 
[4,18,172].  Despite important advances in our understanding of the regulation of neuronal 
excitability and antiepileptic drug (AED) action [173,174], approximately 40% of patients 
remain refractory to treatment with conventional AEDs [81,175]. Thus, it is important to 
develop novel AEDs [176].  Compounds that prevent the process of epileptogenesis have 
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important clinical ramifications, because administering such agents following a brain 
injury could potentially prevent acquired epilepsy [4,172,177]. 
 
Carisbamate (RWJ 333369) is a novel AED with a wide margin of safety in humans based 
on a completed phase 2 clinical trial for the treatment of epilepsy [178,179].  Carisbamate 
has been reported to possess anticonvulsant effects in a variety of seizure models [180]. 
Although there are no peer-reviewed studies demonstrating that carisbamate can prevent 
epileptogenesis, a recent abstract presented at the American Epilepsy Society's annual 
meeting did show that carisbamate might delay or prevent the occurrence of spontaneous 
seizures in the lithium-pilocarpine model of epilepsy [181].  The mechanism of action of 
carisbamate is still unknown and is being investigated by several research groups including 
our own.  However, there are no studies evaluating the ability of carisbamate to inhibit the 
development and expression of epileptiform discharges in vitro and comparing it to other 
conventional AEDs. 
 
This study was initiated to investigate the ability of carisbamate to inhibit the development 
and expression of spontaneous recurrent epileptiform discharges (SREDs) in cultured 
hippocampal neurons injured following SE-like activity in vitro.  While the neuronal 
cultures do not have true anatomical connections and do not display clinical seizures, this 
in vitro model has been routinely used to characterize biochemical, electrophysiological, 
and molecular mechanisms underlying acquired epilepsy [4,24,48,67].  Moreover, the 
SREDs demonstrate electrographic properties, neuronal population synchronicity, and 
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anticonvulsant sensitivity identical to those of epileptic seizures recorded in vivo [4,23].  
This system also allows for control of the extracellular milieu and is ideally suited to 
evaluate the effects of investigational compounds on in vitro seizure-like activity. 
   
Materials and Methods 
Reagents 
All the reagents were purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.) unless 
otherwise noted. Carisbamate was provided by Johnson & Johnson (Pharmaceutical 
Research & Development L.L.C., Titusville, NJ, U.S.A.). Carisbamate and phenytoin were 
dissolved in sterile water made slightly basic with sodium hydroxide. Phenobarbital was 
dissolved in sterile water. All stocks were made fresh daily. 
 
Hippocampal neuronal culture preparation 
All animal use procedures were in strict accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and approved by 
Virginia Commonwealth University's Institutional Animal Care and Use Committee. 
Studies were conducted on primary mixed hippocampal neuronal cultures prepared as 
described previously with slight modifications [23,24].  In brief, hippocampal cells were 
obtained from 2-day postnatal Sprague–Dawley rats (Harlan, Frederick, MD, U.S.A.) and 
plated at a density of 2 × 105 cells/cm2 onto glial beds grown on 35-mm Falcon cell culture 
dishes (Becton Dickinson and Co., Franklin Lakes, NJ, U.S.A.) previously coated with 
poly-L-lysine (0.05 mg/mL).  Cultures were maintained at 37°C in a 5% CO2/95% air 
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atmosphere and fed twice weekly with neuronal feed (minimal essential media with Earle's 
Salts, 25 mM HEPES, 2 mM l-Glutamine, 3 mM Glucose, 100 µg/mL transferrin, 5 µg/mL 
insulin, 100 µM putrescine, 3 nM sodium selenite, 200 nM progesterone, 1 mM sodium 
pyruvate, 0.1% ovalbumin, 0.2 ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone 
supplemented with 20% conditioned media).  These mixed cultures were used for 
experiments from 13 days in vitro following neuronal plating through the life of the 
cultures. 
   
Whole-cell current clamp recordings 
Whole-cell current clamp recordings were performed using previously established 
procedures [23,24].  Briefly, a cell culture dish was mounted on the stage of an inverted 
microscope (Nikon Diaphot, Tokyo, Japan) continuously perfused with physiological basal 
recording solution (pBRS) containing (in mM): 145 NaCl, 2.5 KCl, 10 HEPES, 2 CaCl2, 
10 glucose, and 0.002 glycine, pH 7.3, and osmolarity adjusted to 325 ± 5 mOsm with 
sucrose.  Patch electrodes with a resistance of 2–4 mΩ were pulled on a Brown-Flaming P-
80C electrode puller (Sutter Instruments, Novato, CA, U.S.A.), fire-polished and filled 
with a solution containing (in mM): 140 K+ gluconate, 1.1 EGTA, 1 MgCl2, and 10 Na-
HEPES, pH 7.2, osmolarity adjusted to 290 ± 10 mOsm with sucrose. Whole-cell 
recordings were carried out using an Axopatch 200B amplifier (Molecular Devices, Foster 
City, CA, U.S.A.) in a current-clamp mode. Data were digitized via Digidata 1322A 
(Molecular Devices) and transferred to VHS tape using a PCM device (Neurocorder, New 
York, NY, U.S.A.) and then played back on a DC-500 Hz chart recorder (Astro-Med Dash 
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II, Warwick, RI).  All the recordings were performed in the current-clamp mode at I = 0 
setting.  No current was injected at any stage of recording in the presence or absence of 
drugs. 
  
Hippocampal neuronal culture model of SREDs 
SREDs were induced in neuronal cultures by exposing them for 3 hrs to a solution 
containing no added MgCl2 (low Mg2+) using procedures described previously [23,24].  
Briefly, after the removal of maintenance media, neurons were gently washed with 3 × 1.5 
ml of pBRS (with or without 1 mm MgCl2) and then allowed to incubate in this solution at 
37°C under 5% CO2/95% air atmosphere. At the end of the 3 hr period, cultures were 
restored to the physiological concentration (1 mm) of MgCl2 by gently washing with 
minimum essential medium, returned to the maintenance medium, and incubated at 37°C 
under 5% CO2/95% air atmosphere. Thus, low Mg2+ treatment was carried out with pBRS 
without added MgCl2, whereas sham controls were treated with pBRS containing 1 mm 
MgCl2. 
   
Analysis of the effects of carisbamate on the in vitro development and expression of 
epileptiform discharges 
To investigate the effects of carisbamate on the generation and expression of SREDs, 
neuronal cultures were first subjected to 3 hrs of low Mg2+-induced continuous high-
frequency epileptiform activity to mimic in vivo SE. At the end of the 3 hr period, cultures 
were washed with a solution containing physiological concentrations of Mg2+ so as to 
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immediately terminate the SE-like activity [23], and the cultures were returned to 
maintenance media (neuronal feed) containing carisbamate (200 µM), phenytoin (50 µM), 
phenobarbital (50 µM), or control solution. After a 12 hr treatment period, the media 
containing drug or control solution was removed by washing the cultures with neuronal 
feed and the cultures were maintained at 37°C in a 5% CO2/95% air atmosphere. Neurons 
were patch-clamped 24 hrs following this 12 hr treatment with carisbamate, phenytoin, 
phenobarbital, or control solutions for the presence or absence of SREDs. Control neurons 
were treated with the same number of washes and media changes as the treatment cultures. 
Sham controls were also subjected to the same number of washes with respective drugs in 
a solution containing normal Mg2+ concentrations. Experiments were performed on 
multiple neurons from multiple culture plates, spread across several weeks. Concentrations 
of all the drugs chosen to study their effect on the development and expression of SREDs 
were at least twice the concentration at which they produced maximal anti-SRED effects 
based on the dose-response curves generated in our laboratory (data not shown). A higher 
concentration was chosen to maximize the effects of the agents studied and to determine if 
this agent could produce a significant reduction in epileptiform discharges. 
   
Cell death assay 
Neuronal death was assessed at the same time point as patch clamp experiments using 
fluorescein diacetate (FDA)-propidium iodide (PI) microfluorometry [24].  Three 
randomly selected fields were marked and photographed. Both fluorescent and phase 
bright images were captured. Neurons labeled with FDA or PI were quantified by means of 
   
 128 
the Ultraview image analysis software package (Perkin Elmer Life Sciences, Waltham, 
MA, U.S.A.) and the fraction of neuronal death was calculated as the number of neurons 
labeled by PI divided by the sum of the number of neurons labeled by PI and those labeled 
by FDA. Fluorescent images were compared with phase bright images to confirm that only 
pyramid-shaped neurons were counted. To quantify neuronal death with this technique, 
cells in three randomly selected fields were counted manually and averaged per culture 
(approximately 18–25 neurons per field). 
   
Data analyses 
Data are reported as mean ± SEM. Differences in percentage of neurons displaying 
SREDs, frequency and duration of SREDs, and neuronal death were examined using one-
way analysis of variance (ANOVA) followed by a post hoc Tukey test. Data were analyzed 
using SigmaStat 2.0 and graphs were generated using SigmaPlot 8.02 (SPSS, Inc., 
Chicago, IL, U.S.A.). All or no effect of a given drug on SREDs was taken as the criterion 
for its antiepileptic effect. In a given culture plate we patch-clamped three neurons before 
moving on to another plate. All experiments were performed over a period of 3 weeks. 
Depending on the number of culture plates available, we analyzed three to five culture 
plates for every condition each week. Thus, the results reported are representative of 
multiple culture plates belonging to different batches. 
   
Results  
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In vitro antiepileptic effects of carisbamate 
Whole cell current clamp recordings obtained from neurons in cultures 2 days after a 
treatment with low-Mg2+ for 3 hrs demonstrated characteristic SREDs, or in vitro seizure 
events. Three SREDs lasting between 1–2 min (Figure 6-1 B) were observed in a 
continuous 30 min recording. SREDs occurred spontaneously in the network of neurons, 
had durations between 1 and 3 min, occurred at frequencies of up to 3-4 episodes/hr and 
were observed for the life of the neurons in culture. Expansion of SREDs revealed 
characteristic paroxysmal depolarization shifts, a pathophysiological characteristic 
observed in epilepsy (data not shown, [23]). Age-matched control neurons never 
demonstrated SREDs and had "normal" baseline activity consisting of intermittent action 
potentials (Figure 6-1 A). 
   
In contrast, bath application of carisbamate (200 µM) acutely inhibited SREDs compared 
to the non-treated epileptic cultures (Figure 6-1 C).  The effect of carisbamate was fully 
reversible and SREDs returned upon washout of the drug from the culture medium (data 
not shown). Thus, carisbamate prevented SREDs in this in vitro model of seizures. Similar 
to carisbamate, bath application of clinically used AEDs, such as phenytoin (50 µM) and 
phenobarbital (50 µM), also acutely inhibited SREDs (Figures 6-1 D,E). Greater than 95% 
of the neurons exhibited evidence of an in vitro antiepileptic effect following application of 
carisbamate/phenytoin/phenobarbital. It took approximately 10–15 min for the anti-SRED 
effect to be fully manifested. In addition, there were no significant differences in 
membrane potential and input resistance between age-matched control neurons, neurons 
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exhibiting SREDs [23,157], and neurons treated with carisbamate acutely. Thus, neurons 
displaying SREDs and carisbamate-treated neurons had mean membrane potential of −64.1 
± 1.4 mV and −62.9 ± 1.1 mV and a mean input resistance of 138.5 ± 6.03 mΩ and 136.2 ± 
6.7 mΩ, respectively. These values were not significantly different from each other (n = 9, 
p = 0.5 and 0.8, respectively). 
 
Effects of carisbamate on the development and expression of SREDs 
As shown in Figure 6-2 A, in comparison to control neurons that did not manifest SREDs, 
neurons exposed to 3 hrs of low Mg2+ treatment (n = 15 neurons, 5 culture plates) 
displayed characteristic SREDs when patch clamped 36 hrs following the cessation of the 
3 hrs of SE-like treatment.  To investigate the effects of carisbamate on the development 
and expression of SREDs, hippocampal neuronal cultures were treated with carisbamate 
(200 µM) for 12 hrs after the 3 hr SE-like injury.  Thus, carisbamate was not present 
during low Mg2+ treatment but was present only after the SE-like injury (Materials and 
Methods).  Whole cell current clamp recordings from neurons (n = 18, 6 culture plates) 24 
hrs following carisbamate (200 µM) treatment were devoid of any SRED activity (Figure 
6-2 B).  The electrographic recordings did not display any SREDs, and only manifested 
occasional action potentials, resembling the recordings from sham-control neurons. 
Further, neurons displaying SREDs and neurons treated with carisbamate for 12 hrs had a 
mean membrane potential of −65.4 ± 1.2 mV and −64.6 ± 1.1 mV and a mean input 
resistance of 133.36 ± 6.6 mΩ and 131.69 ± 8.43 mΩ, respectively.  These values were not 
different from each other (n = 8, p = 0.6 and 0.8, respectively).  These results provide 
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direct evidence that cells evaluated the day after treatment with carisbamate were still free 
of in vitro seizure activity and did not develop SREDs.  Thus, carisbamate had long-lasting 
effects on the hippocampal neurons that were independent from its in vitro antiepileptic 
effects. 
  
Quantitation of the effects of carisbamate on the development and expression of 
SREDs 
Although the whole cell current clamp recordings from 18 neurons 24 hrs following 
carisbamate (200 µM) treatment were devoid of any SRED activity (Figure 6-2 B), we 
wanted to evaluate a larger population of neurons to carefully quantitate the effects of 
carisbamate on the development and expression of SREDs.  A total of 98 neurons from 
different treatment groups were analyzed.  For the studies in this paper, we only evaluated 
recordings that were maintained for over 1 hr and some recordings were held for up to 
2.5 hrs.  Recordings were made from 53 neurons in carisbamate treated groups (n = 15 
culture plates), 30 neurons from low Mg2+ alone groups (n = 10 culture plates), and 15 
neurons from sham treated (drug control) groups (n = 5 culture plates).  Greater than 97% 
of the low Mg2+ alone-treated neurons displayed SREDs.  In contrast, in the 53 neurons 
treated with carisbamate for 12 hrs after SE-like injury, 80% of the neurons (n = 42) were 
completely devoid of SREDs, and only 20% of the neurons displayed occasional 
epileptiform activity (n = 11).  No SREDs or hyperexcitability were observed in the control 
neurons. 
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We then calculated the seizure frequency by averaging total number of SREDs over 3 min 
recording periods. The SRED frequency in neurons treated with low Mg2+ alone was 8.2 ± 
3.6 episodes/30 min. In carisbamate treated cells, the SRED frequency was reduced to 0.58 
± 0.14 episodes/30 min (Figure 6-3 B).  This represented a 93% reduction in SRED 
frequency in carisbamate treated neurons.  We also compared the duration of SREDs 
between the low Mg2+ alone and carisbamate-treated groups.  The average SRED duration 
in the low Mg2+-treated group was 152.4 ± 14.13 s.  In the small percentage of neurons that 
displayed an occasional SRED in the carisbamate treated group, the average SRED 
duration was 77.6 ± 9.45 s (Figure 6-3 C).  This represented an approximately 50% 
reduction in the duration of SREDs in neurons from the carisbamate treated group.  Thus, 
carisbamate not only inhibited the development and expression of SREDs in the majority 
of neurons, but it also decreased seizure frequency and duration in the few neurons that 
still had an occasional epileptiform event. 
   
Comparison of the effects of carisbamate on the development and expression of 
SREDs with other AEDs 
As there are currently no known agents that offer an antiepileptogenic effect in vivo, there 
were no positive control drugs for comparing the ability of carisbamate to prevent the 
development and expression of SREDs. However, we utilized clinically employed AEDs 
that displayed anti-SREDs properties in our in vitro model as control conditions. Phenytoin 
(50 µM) or phenobarbital (50 µM) was included in the neuronal feed following the 3 hr 
low Mg2+ treatment (SE, Materials and Methods) for 12 hrs in an identical manner to the 
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carisbamate treatment.  Both phenytoin and phenobarbital at this concentration blocked 
SREDs, producing the same in vitro antiepileptic effects observed following treatment 
with carisbamate (Figure 6-1).  24 hrs following drug washout, neurons were patch-
clamped and observed for the presence of SREDs.  As observed earlier, low Mg2+ alone-
treated neurons displayed characteristic SREDs (Figures 6-1 B, 6-2 A, 6-4 A), whereas 
control and carisbamate treated cells were devoid of any SRED activity (Figures 6-1 A, 6-2 
B, 6-4 B).  In contrast, neurons treated with either phenytoin or phenobarbital after the SE-
like injury (n = 10 neurons, 5 culture plates) (Figure 6-1 D,E) clearly demonstrated SREDs 
similar to low Mg2+ alone-treated cells (Figure 6-4 C,D). SRED frequency in the low Mg2+ 
alone-treated group was 8.2 ± 3.6 episodes/30 min, while SRED frequency in the 
phenytoin or phenobarbital treated groups were 8.0 ± 4.0 and 7.8 ± 4.6 episodes/30 min, 
respectively.  The average SRED duration in the low Mg2+ alone-treated group was 152.4 
± 14.13 s, while the average SRED duration in the phenytoin- or phenobarbital-treated 
groups were 162.4 ± 10.03 s and 149.4 ± 12.44 s, respectively. There were no significant 
differences between low Mg2+ alone-treated and phenytoin- or phenobarbital-treated group 
for these two criteria of SREDs (n = 10, p = 0.79, 0.85 and 0.43, 0.79). Thus, phenytoin 
and phenobarbital did not prevent the development and expression of SREDs after SE-like 
injury at concentrations that were acutely antiepileptic in vitro. 
 
Carisbamate is neuroprotective 
The neuronal injury caused by the removal of extracellular Mg2+ (in vitro SE-like injury) in 
this model has been well characterized [24]. The removal of the Mg2+ block produces 
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repetitive depolarizations, resulting in prolonged activation of NMDA receptors. This 
persistent activation of NMDA receptors allows for excessive entry of extracellular 
calcium (Ca2+), resulting in excitotoxic activation of cell-death pathways and culminating 
in neuronal demise [16]. In order to investigate if carisbamate was neuroprotective, we 
evaluated the effects of carisbamate exposure after the 3 hr SE-like treatment on the 
viability of neurons. The fraction of neuronal death was evaluated using FDA-PI staining 
24 hrs following the termination of the drug or sham control treatment employing our 
previously established procedures [24].  Sham control cultures that were not exposed to 
SE-like activity had a fraction of cell death of 0.117 ± 0.006.  Low Mg2+ cultures exposed 
to 3 hrs of SE-like injury showed fraction of cell death of 0.323 ± 0.006, which was 
significantly different from sham control (n = 5; p < 0.001, one-way ANOVA, post hoc 
Tukey test, Figure 6-5).  In contrast, carisbamate (200 µM) treated cultures had fraction of 
cell death of 0.106 ± 0.005 after 3 h of SE-like injury, which was not significantly different 
from sham controls.  These results provide direct evidence that carisbamate can provide 
neuroprotection when administered after the SE-like activity is completed. 
     
Discussion 
This study provides direct evidence that the novel neuromodulator carisbamate not only 
inhibits the development and expression of SREDs but is also neuroprotective when 
administered following SE-like injury in cultured hippocampal neurons. The process of 
epileptogenesis refers to the development of spontaneous recurrent seizures in a previously 
normal brain [4,18,172].  Our model employs low Mg2+-induced continuous electrographic 
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epileptiform discharges for 3 hrs to mimic SE-like injury in vitro. Restoration of 
physiological Mg2+ concentrations terminates the high frequency epileptiform discharges 
but produces a permanent plasticity change in neuronal excitability, such that the surviving 
neurons manifest synchronized SREDs for their life in culture. Presence of carisbamate 
following SE-like injury prevented the chronic development and expression of SREDs. 
This property was unique to carisbamate, because conventional AEDs such as phenytoin 
and phenobarbital failed to prevent the development and expression of SREDs following 
neuronal injury. We studied phenytoin and phenobarbital because they represent two 
diverse mechanisms of antiepileptic action. However, it will be important to investigate if 
other AEDs prevent the development of epileptiform discharges in our model. The ability 
of carisbamate to prevent the development and expression of SREDs when administered 
after 3 hrs of continuous SE-like activity offers major implications in the use of this 
antiepileptic agent in treating SE, because this drug is not only antiepileptic, but may also 
delay the development and expression of epileptiform discharges, at least in vitro. 
 
Our results also demonstrate that control of seizures with carisbamate may also have an 
added benefit of providing a neuroprotective effect on the hippocampus. Preventing 
neuronal damage after prolonged seizures is an important therapeutic goal. Several studies 
have demonstrated that SE causes neuronal damage, memory loss, and several long-term 
plasticity changes that can result in significant mortality and morbidity [14,74,76]. This 
was an important test, because it evaluated the effects of carisbamate on neuronal death 
when the drug is administered after the injury phase of SE. To our knowledge, this is the 
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first demonstration of neuroprotection following SE-like activity in vitro. We also 
evaluated the effects of ongoing SREDs in epileptic cultures on neuronal death by 
comparing cell death using FDA-PI staining on cultures that were undergoing SREDs 
versus carisbamate-treated or control sham cultures. The results of these experiments (data 
not shown) demonstrated that the ongoing activity of SREDs did not increase cell death in 
comparison to sham control cultures when evaluated starting 2 days after induction of 
SREDs [24]. Thus, SE but not SREDs caused neuronal death in this model, and 
carisbamate was able to block the cell death caused by SE-like activity. Carisbamate was 
neuroprotective when given after SE-like injury and thus offers considerable therapeutic 
potential in preventing brain injury following SE. However, it has been recently shown that 
carisbamate reduced posttraumatic hippocampal edema without affecting neurobehavioral 
or histological outcome [182]. Future studies are needed to determine the mechanism of 
the neuroprotective action of carisbamate. 
 
A long-standing question in neuroscience has been how the initial CNS injury produces 
long-term plasticity changes that result in the development, expression, and maintenance of 
epilepsy. Emerging research has indicated that the alterations in the levels and handling of 
the ubiquitous intracellular second messenger, Ca2+, could underlie these injury-induced 
long-term plasticity changes in neuronal excitability, thus leading to the proposal of the 
Ca2+ hypothesis of epileptogenesis [4]. In concordance with this hypothesis, our laboratory 
and many others have observed alterations in Ca2+ dynamics in all three phases of 
development of acquired epilepsy [4]. Results from our laboratory have provided evidence 
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that the epileptogenic and neurotoxic effects of SE are mediated both by alterations in 
intraneuronal Ca2+ levels during and after SE and by altered Ca2+ homeostatic mechanisms 
in the injured neurons that survive SE [32,85].  It will be insightful to investigate the 
effects of carisbamate on neuronal Ca2+ dynamics and determine if this mechanism 
contributes to the ability of this drug to not only prevent the development and expression 
of SREDs but also afford neuroprotection following neuronal injury. 
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Figure 6-1.  Effects of carisbamate and other clinically used AEDs on 
SREDs in cultured hippocampal neurons.  A, current-clamp recording from a 
representative control neuron displaying baseline activity consisting of 
intermittent action potentials. B, recording from an "epileptic" neuron 3 days 
following a 3 hr exposure to low Mg2+ solution demonstrates occurrence of 
characteristic SREDs. Three SREDs or spontaneous seizure episodes lasting ~1–
1.5 min can be seen in this recording time frame. These SREDs occurred 
throughout the life of the cultures and are indicative of the pathophysiological 
"epileptic" phenotype. Effects of various AEDs on SREDs in cultured 
hippocampal neurons. Application of C, carisbamate (200 µM) or D, phenytoin 
(50 µM) or E, phenobarbital (50 µM) to the epileptic neurons abolished the 
expression of SRED activity. The solid bar above each trace represents the 
duration for drug exposure. Thus, the beginning of the bar is the point of 
addition of drug. 
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Figure 6-2.  Effects of carisbamate on the development and expression 
of SREDs. Hippocampal neuronal cultures were treated with or without 
carisbamate (200 µM) immediately following the low Mg2+ treatment. 
Drug was washed off the next day and 24 hrs later neurons were patch 
clamped. A, representative control neuron displaying characteristic SREDs 
24 hrs following the sham washout. The recording is representative of 30 
different neurons.  B, current clamp recordings from a representative 
neuron 24 hrs following carisbamate (200 µM) washout. The neuron was 
devoid of any SRED activity and manifested occasional action potentials 
resembling the recordings from sham-control neurons. The recording is 
representative of 53 different neurons. 
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Figure 6-3.  Analyses of the effects of carisbamate on the development 
and expression of SREDs.  A, SRED frequency in low Mg2+ alone-treated 
group was 8.2 ± 3.6 episodes/30 min. Phenytoin- and phenobarbital-treated 
groups had SRED frequencies of 8 ± 2 and 7.8 ± 2.2 episodes/30 min, 
respectively, while the carisbamate treated group displayed a SRED 
frequency of 0.58 ± 0.14 episodes/30 min. B, average SRED duration in 
the low Mg2+ alone treated group was 152.4 ± 14.13 s. Phenytoin and 
phenobarbital groups had average SRED durations of 162.4 ± 10.03 s and 
149.4 ± 12.44 s, respectively, while the average SRED duration of the 
carisbamate-treated group was 77.6 ± 9.45 s (*p < 0.001, one-way 
ANOVA, post hoc Tukey test). 
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Figure 6-4.  Comparison of the effects of carisbamate on the 
development and expression of SREDs with other AEDs. A, 
recordings from a low Mg2+-treated neuron displaying characteristic 
SREDs.  B, treatment with carisbamate (200 µM) following SE-like 
injury prevents the development and recurrence of SREDs. No SREDs 
are observed in this neuron even after removal of carisbamate. C and D, 
other clinically used AEDs such as phenytoin (50 µM) and phenobarbital 
(50 µM) did not prevent the development and expression of SREDs. All 
the patch clamp recordings were performed 24 h following the drug 
washout. 
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Figure 6-5.  Neuroprotective effects of carisbamate. Fraction of cell 
death was analyzed using FDA-PI staining after the removal of the 
drug. Sham control cultures were not exposed to SE, but were handled 
similar to other cultures. They displayed a fraction of cell death of 
0.117 ± 0.006. Cultures exposed to 3 hrs of low Mg2+ SE showed a 
fraction of cell death of 0.323 ± 0.006 (n = 5; *p < 0.001, one-way 
ANOVA, post hoc Tukey test). Carisbamate (200 µM) treated cultures 
had a fraction of cell death of 0.106 ± 0.005 when administered after 3 
hrs of SE-like injury. This fraction of cell death was not significantly 
different from sham controls 
. 
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Chapter 7:  The Novel Anti-Epileptic Drug Carisbamate (RWJ333369) 
Modulates Calcium and Restores Calcium Homeostatic Mechanisms in 
Hippocampal Neuronal Cultures 
 
 
Introduction 
Approximately 2% of the world’s population is affected by epilepsy, a common 
neurological condition characterized by spontaneous, recurrent seizures [81].  40% of all 
cases of epilepsy develop following some neuronal injury, such as status epilepticus (SE), 
stroke, or traumatic brain injury (TBI) and are, thus, classified as acquired epilepsy (AE) 
[81,183].  This transformation can be characterized as a progression through three stages: 
injury, epileptogenesis, and the maintenance of chronic epilepsy.  During the 
epileptogenesis phase, recurrent seizures may not be present; however, neurons are 
undergoing plasticity changes that will ultimately lead to the expression of epilepsy.  
Understanding the pathophysiological changes that occur during this process is important 
in the development of anti-epileptogenic agents to prevent the ultimate development of 
epilepsy.  While much progress has been made in the development of new anti-epileptic 
drugs (AEDs), or anti-convulsants, currently there are no therapeutics that can prevent 
epileptogenesis following neuronal injury.  Such compounds that can be administered after 
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brain injury and halt epileptogenesis are clinically very important, and the development of 
these agents represents an important area of research. 
 
Carisbamate (RWJ333369) is a novel neuromodulator that is currently in phase II clinical 
trials for the treatment of epilepsy [178,179].  It has been shown that this drug, a carbamate 
closely related to felbamate, not only demonstrates anti-convulsant properties but also 
displays a wide margin of safety in humans [178,179,181].  More recently, we have 
demonstrated that carisbamate is able to inhibit spontaneous recurrent epileptiform 
discharges (SREDs), the in vitro correlate to epilepsy, in hippocampal neuronal cultures 
[184].  In the same low Mg2+ model, we were also able to demonstrate that when given 
following low Mg2+-induced in vitro SE, carisbamate prevented the development of 
SREDs even following the removal of the drug from the system [185].  This is the first 
time a drug has been shown to be anti-epileptogenic in this in vitro model; thus, 
elucidating the mechanism of action is critical to understanding how anti-epileptogenic 
agents work.  Currently the mechanism of action behind this drug is not known so many 
groups are actively investigating potential mechanisms responsible for both its anti-
convulsive and its anti-epileptogenic properties.     
 
This study was initiated to elucidate a potential mechanism of action behind the ability of 
carisbamate to inhibit epileptogenesis in the low Mg2+, in vitro hippocampal neuronal 
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culture model of SE-induced AE.  This model is well-characterized and used widely.  
Moreover, due to several similarities between the model and both in vivo models and the 
human condition, it provides a useful tool in preliminary studies investigating 
pathophysiological mechanisms and potential therapeutics.  The changes in Ca2+ dynamics 
observed in the rat pilocarpine model of SE-induced AE are also observed in the in vitro 
model.  Essentially, it has been demonstrated that during in vitro SE, [Ca2+]i increases 
significantly.  These elevations are maintained well past the duration of the injury, and 
while they decrease over time, they remain significantly elevated for at least 48 hrs post-in 
vitro SE.  Similar changes in Ca2+ also exist in the rat pilocarpine model, wherein 
hippocampal neuronal [Ca2+]i remains elevated only in those animals that later develop 
epilepsy [32].  As an important second messenger, such long-lasting increases in [Ca2+]i 
have the potential to affect neurotransmission, gene transcription, and neuronal plasticity 
leading to the development of chronic epilepsy.  Moreover, studies that have blocked the 
elevations in [Ca2+]i by administering NMDA antagonists before SE have prevented the 
development of epilepsy; therefore, this suggests that these alterations in Ca2+ are 
responsible for epileptogenesis and the maintenance of the epileptic phenotype.  Thus, 
examining how carisbamate affects these changes in Ca2+ is important in understanding 
epileptogenesis and potentially, how this drug affects neuronal plasticity.        
 
Materials and Methods 
Reagents 
   
 148 
Carisbamate was provided by Johnson & Johnson (Pharmaceutical Research & 
Development L.L.C., Titusville, NJ, U.S.A.). Carisbamate was dissolved in sterile water 
made slightly basic with sodium hydroxide and diluted to final concentration in 
physiologic basal recording solution (pBRS).   
 
Hippocampal neuronal culture preparation 
Preparation of primary mixed hippocampal neuronal culture was performed as previously 
described [23].  In summary, hippocampal cells were isolated from 2-day post-natal 
Sprague-Dawley rats (Harlan, Frederick, MD).  Hippocampal neurons (8.75x104) were 
plated onto a glial support layer that was previously plated onto poly-L-lysine (0.05 
mg/ml) coated Lab-Tex glass chambers (Nalge-Nunc International, Naperville, IL).  
Cultures were maintained at 37°C in a 5% CO2/95% O2 incubator and fed twice weekly 
with neuronal feed containing 20% conditioned media, as described previously [23,50].  
All experiments were performed on neurons maintained for 14-17 days in vitro to ensure 
proper development.  All procedures adhered strictly to the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by Virginia 
Commonwealth University’s Institutional Animal Care and Use Committee. 
 
Ca2+ microfluorometry  
Primary hippocampal cultures were loaded with Fura-2 acetoxymethyl ester (Fura-2AM) 
and then placed on the 37°C stage of an Olympus IX-70 inverted microscope (Olympus, 
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Center Valley, PA) coupled to an ultra-high-speed fluorescence imaging system.  Ratio 
images were acquired using alternating excitation wavelengths (340/380 nm) with a filter 
wheel (Sutter Instruments, Novato, CA) and fura filter cube at 510/540 nm emissions with 
a dichroic mirror at 400 nm [94].  MetaFluor (Olympus, Center Valley, PA) was used for 
image acquisition and analysis.  Images were acquired from any given field at various time 
intervals depending on the specific experiment and background fluorescence was 
subtracted from all acquired data by imaging hippocampal neuronal cultures that were not 
loaded with Fura-2AM [94].  
 
Glutamate challenge: assessing Ca2+ homeostatic mechanisms 
In order to assess Ca2+ homeostatic mechanisms, neurons were loaded with Fura-2AM 
according to previously described protocols [50] and challenged with 50 µM glutamate for 
2 minutes.  After 2 min, the cultures were washed with pBRS to remove the glutamate.  
340/380 ratio images were captured every 30 seconds to record both the response to and 
recovery from glutamate exposure, as described previously [4].    
 
Data analysis 
Data were statistically analyzed using StatView (Version 5.0.1).  Experiments were 
repeated over a period of a few weeks so as to sample from different culture batches.  The 
significance of the data was tested by one-way analysis of variance (ANOVA), or one-way 
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repeated measures (RM) ANOVA followed by Fisher’s post-hoc test when appropriate.  P 
< 0.05 was considered significant for all data analysis. 
 
Results 
It has been demonstrated that in vitro SE causes long-lasting elevations in intracellular 
Ca2+ ([Ca2+]i).  The ability to lower [Ca2+]i post-SE to normal, baseline concentrations may 
help prevent the second messenger effects that lead to plasticity changes and the 
development of epilepsy.   
 
Carisbamate restores Fura-2 Ca2+ ratios following low Mg2+-induced in vitro SE 
During treatment with low Mg2+(in vitro SE), cells exhibited increased [Ca2+]i as indicated 
by an elevation in 340/380 ratios to approximately 0.78 (Figure 7-1).  Following the low 
Mg2+ treatment, neurons were returned to Mg2+-containing solution containing either 
carisbamate (200 µM) or vehicle at time point 0 on the x-axis.  In cells treated with the 
drug following low Mg2+, the 340/380 ratios are lowered rapidly to ratios observed in 
naïve neurons, unlike the vehicle-treated neurons, which continue to exhibit 340/380 ratios 
that are significantly elevated.  Thus, it appears that when given acutely following in vitro 
SE, carisbamate is able to significantly lower [Ca2+]i. 
 
Basal Ca2+ levels are maintained 24 hours post-carisbamate washout 
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Carisbamate, when used following in vitro SE, was able to maintain baseline [Ca2+]i for at 
least 24 hrs after drug washout.  After neurons were returned to normal, Mg2+-containing 
solution following treatment with low Mg2+, the cells displayed SREDs.  SREDs are the in 
vitro correlate to epilepsy and these ‘epileptic’ cells exhibit paroxysmal depolarization 
shifts.  Similarly to the experimental protocols used in the study that demonstrated that 
carisbamate was anti-epileptogenic (prevented the development of SREDs when 
administered immediately post-SE) [185], following 3 hrs of low Mg2+ treatment cells 
were returned to maintenance media containing vehicle or 200µM carisbamate. 12 hrs later 
the drug was washed out of the hippocampal neuronal cultures, and 24 hrs following the 
removal of the drug the neurons were imaged to determine [Ca2+]i.  At this time point, 
drug-treated neurons fail to display SREDs, in contrast to the vehicle-treated, or ‘epileptic’ 
neurons [185].  Moreover, as shown in Figure 7-2, the carisbamate-treated neurons showed 
Fura-2 ratios significantly lower than the vehicle-treated neurons that displayed SREDs, 
0.328 ± 0.025 and 0.424 ± 0.019 respectively (n=5; P<0.001, one-way ANOVA, post-hoc 
Fisher test). Moreover, the Fura-2 ratio observed in the drug-treated cells is consistent with 
that of the sham controls, 0.314 ± 0.018.  This demonstrates that caribamate, as far out as 
24 hrs post-drug washout, was able to maintain [Ca2+]i at baseline values. 
 
Carisbamate-treated neurons exhibit enhanced recovery following glutamate 
challenge 
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It has been demonstrated that following treatment with low Mg2+, ‘epileptic’ neurons that 
display SREDs also show altered homeostatic mechanisms [4].  Therefore, if these neurons 
are briefly stimulated with glutamate, they are unable to restore normal [Ca2+]i in the cell 
[4].  In contrast, naïve or sham-control neurons have intact homeostatic mechanisms and 
are thus, able to recover from such challenges [4]. 
 
Following 3 hrs of treatment with low Mg2+ (in vitro SE), cells were returned to 
maintenance media containing vehicle or carisbamate (200µM). 12h later the drug was 
washed out of the cultures and 24h post-washout the carisbamate-treated neurons were 
loaded with the Ca2+ indicator Fura-2AM.  These neurons were then subjected to glutamate 
stimulation (50µM, 2 min).  The neurons that were treated with carisbamate showed an 
increased ability to recover from this challenge when compared to vehicle-treated 
(epileptic) neurons (Figure 7-3). Glutamate elicited an increase in [Ca2+]i in both treatment 
groups. Neurons treated previously with carisbamate were able to restore [Ca2+]i to basal 
levels in 25 min (consistent with that observed in sham controls, data not shown but as 
observed previously [4]). Vehicle-treated, ‘epileptic’ neurons showed a diminished ability 
to recover from this challenge and in 25 min, [Ca2+]i is still elevated at 150% of baseline.  
Thus, SE induces long-lasting alterations in Ca2+ homeostatic mechanisms that treatment 
with carisbamate is able to restore.   
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Discussion 
The results of this study demonstrate that the novel AED, carisbamate, when administered 
immediately following in vitro SE, is able to lower [Ca2+]i to baseline concentrations 
observed in control neurons in the hippocampal neuronal culture model of SE-induced AE.  
Moreover, in order to test whether immediate treatment post-SE was able to cause more 
long-lasting changes in these neurons, the drug was washed out of the system 12 hrs post-
treatment.  Interestingly, 24 hrs after the wash-out of drug, the carisbamate-treated neurons 
appear to have normal [Ca2+]i and unaltered homeostatic mechanisms, unlike the low Mg2+ 
neurons that were not treated with the drug.  At this same time point (24 hrs following 
wash-out of drug), the neurons that were treated with carisbamate also fail to display 
SREDs.  Thus, it appears that lowering [Ca2+]i and the restoration of homeostatic 
mechanisms correlates with a positive outcome, the prevention of SRED development.  In 
the model of SE-induced AE that was used in these studies, hippocampal neuronal cultures 
were treated for 3 hrs with low Mg2+ to trigger high frequency, SE-like activity.  The 
ability to treat these neurons after an insult such as SE and prevent the process of 
epileptogenesis- wherein cells begin to express SREDs- is important in addressing the 
significant clinical challenge of developing anti-epileptogenic agents. 
 
Carisbamate was initially developed to be an effective AED that did not produce the 
unwanted side effects observed in earlier generations of carbamates such as felbamate.  
Several studies have started utilizing this drug in various models of epilepsy, and have 
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found that it displays potent neuroprotective, as well as anti-convulsant properties [178-
181].  However, despite these positive results, the mechanisms of action behind these 
properties are currently unknown.  Many groups have initiated studies aimed at better 
understanding how this drug works.  Some groups have proposed that the anti-convulsant 
effects are mediated by voltage-gated sodium channels [186] and another study has 
affirmed these results by showing that caribsmate is able to inhibit sustained repetitive 
firing (SRF), an effect thought to be dependent on voltage-gated sodium channels [184].  
However, the effect that carisbamate has on other channels has not been as thoroughly 
examined.  Moreover, no studies besides the current one have examined potential 
mechanisms of action behind its anti-epileptogenic properties in the in vitro model.  The 
ability to modulate Ca2+, while perhaps not important in contributing to the anti-convulsant 
properties of carisbamate, may prove to be an important feature in terms of preventing 
epileptogenesis.     
 
Ca2+ plays an important role as an ubiquitous second messenger; thus, alterations in [Ca2+]i 
have been shown to significantly affect cellular functions.  While it has been repeatedly 
demonstrated that injuries such as SE can cause profound injury to neuronal cells and 
trigger the activation of cell death pathways [187,188], no studies have been successful in 
preventing epileptogenesis following neuronal injury.  Studies in our lab have implicated 
Ca2+, and Ca2+ regulatory systems, as playing a key role in the development of epilepsy 
after an initial insult [32,63,85].  During neuronal injury, glutamate is released which 
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stimulates a variety of receptors, one of which is the Ca2+-permeable NMDA receptor [4].  
This event causes an acute elevation in [Ca2+]i, which is then maintained or perpetuated by 
Ca2+-induced Ca2+ release systems and inhibition of Ca2+ uptake by sarco-endoplasmic 
reticulum Ca2+-ATPase (SERCA).  Increased [Ca2+]i leads to an elevation in nuclear Ca2+ 
levels, and consequently signals the transcription of several epileptogenic/pro-apoptotic 
genes.  These events cause alterations in neuronal functions such as excitability, 
transmitter release, receptor expression, and synaptic plasticity [79].  Thus, a drug that can 
affect [Ca2+]i  and Ca2+ homeostatic mechanisms, and in doing so prevent the plasticity 
changes that lead to epilepsy, may prove to be an important step in the search for anti-
epileptogenic agents.   
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Figure 7-1.  Carisbamate restores Fura-2 Ca2+ ratios following low 
Mg2+-induced in vitro SE.  Following 3 hrs of in vitro SE (time=0), 
cells were treated with either carisbamate (200µM, clear white circles) 
or vehicle (solid black circles).  340/380 ratios were recorded every 30 
sec for 60 mins.  Carisbamate is able to significantly lower [Ca2+]i to 
levels in naïve, control neurons, whereas the vehicle-treated neurons, 
maintain persistent elevations.  *p<0.01.   
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Figure 7-2.  Basal Ca2+ levels are maintained 24 hours post-
carisbamate washout.  Carisbamate (200µM), when used 
following in vitro SE, was able to maintain baseline [Ca2+]i for at 
least 24 hrs after drug washout.  At this time point, Fura-2 ratios in 
the drug-treated group were significantly lower than the vehicle-
treated (epileptic) neurons, 0.328 ± 0.025 and 0.424 ± 0.019, 
respectively.  The Fura-2 ratio observed in the drug-treated cells 
was consistent with that of the sham controls, 0.314 ± 0.018. 
*p<0.001, n=5 plates per group. 
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Figure 7-3.  Carisbamate-treated neurons exhibit enhanced 
recovery following glutamate challenge.  Treatment with carisbamate 
(200µM) following in vitro SE restores Ca2+ homeostatic mechanisms 
for at least 24 hrs post-washout of the drug.  Carisbamate-treated 
neurons (clear white dots) show enhanced recovery from glutamate 
stimulation (50µM, 2min) when compared to vehicle-treated, 
‘epileptic’ neurons (solid black dots).  Neurons treated with 
carisbamate are able to restore [Ca2+]i to basal levels in 25min.  
Vehicle-treated (epileptic) neurons show a diminished ability to recover 
from this challenge and in 25min [Ca2+]i is elevated, 150% of baseline. 
*p<0.05, n=5 plates per group. 
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Chapter 8:  Discussion 
 
 
The results from these studies suggest that the Ca2+ plateau that exists in the in vivo 
pilocarpine model of SE-induced AE is also observed in the in vitro, low Mg2+ model.  It 
appears that SE causes a tremendous increase in [Ca2+]i which decreases slowly over time, 
but overall is maintained for at least 48 hrs post-SE.  These sustained elevations in [Ca2+]i 
may be responsible for long-term plasticity changes, ultimately leading to the development 
of SREDs, or in vitro epilepsy.  Understanding the physiology behind this elevation in Ca2+ 
may offer new therapeutic targets to provide neuroprotection and, potentially, prevent 
epileptogenesis following neuronal injuries such as SE.   
 
It has been demonstrated that NMDA receptors are largely responsible for the Ca2+ influx 
into the cell during excitatory events such as SE.  Studies have demonstrated that pre-
treatment with an NMDA antagonist prior to SE inhibited the long-lasting elevations in 
[Ca2+]i observed post-SE, improved the outcome of SE, and prevented the development of 
epilepsy [41,43].  However, from a clinical standpoint, treating a patient prior to neuronal 
injury in the hopes of preventing epileptogenesis is not a feasible approach.  Thus, the 
downstream consequences of NMDA receptor-mediated increases in [Ca2+]i remain an 
important area of research in the development of potential agents to halt the development 
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of AE.  The period between the neuronal injury and the actual development of chronic 
epilepsy represents a potential therapeutic window of opportunity wherein the plasticity 
changes that lead to epilepsy may be inhibited.   
 
Thus, our approach was to examine the period between SE and chronic epilepsy to 
determine which systems contribute to the alterations in [Ca2+]i and to test whether 
manipulating these systems pharmacologically could halt epileptogenesis.  The in vitro 
hippocampal neuronal culture model provides an excellent tool for this endeavor in that, 
unlike in vivo systems, high-throughput screenings of various drugs could be performed 
under the strict environmental control to prevent confounders.  Moreover, multiple assays 
could be performed to determine how each drug affected Ca2+ regulatory systems, cell 
viability, [Ca2+]i, and the development of SREDs.  Therefore, the observation that the in 
vitro model mimics the in vivo model in terms of Ca2+ changes is an important finding that 
will aid in the testing of new therapeutic approaches before commencing such studies in a 
more complex in vivo model.   
 
Several studies have examined various regulators of intracellular Ca2+ at myriad time 
points before, during, and after SE.  These regulators include CICR systems (IP3 and 
RyR), Ca2+ binding proteins, Ca2+-regulated enzymes, and Ca2+ channels on the cell 
membrane.  In these studies, we focused on the RyR, a tetrameric Ca2+ channel present on 
the endoplasmic reticulum.  This channel is able to gauge [Ca2+]i and then release Ca2+ 
from intracellular stores based on the cytoplasmic concentration.  Studies on the RyR have 
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utilized dantrolene, a pharmacological inhibitor of the receptor, as a tool to investigate the 
role of the channel in several pathologies.  In the field of epilepsy, several groups have 
used dantrolene prior to the inciting injury to demonstrate that treatment with this drug 
decreases neuronal cell death [97].  Two studies have demonstrated in both animal and 
slice models that dantrolene protects neurons from kainic acid-induced apoptosis, thus 
suggesting that RyRs may play a role in mediating cell death triggered by kainic acid 
[189,190].  In addition, Pelletier et al. demonstrated that RyRs are involved in cell death 
produced in a tetanic stimulation in vitro model of seizures [191].  Other labs have shown 
that dantrolene can prevent the acquisition of amygdaloid kindling, another model of 
acquired epilepsy [105].  While these studies have made novel findings regarding the role 
of RyR in seizure-induced cell death, no study has examined whether dantrolene could be 
neuroprotective when given post-neuronal injury and if so, whether this neuroprotection 
could also contribute to anti-epileptogenic properties.   
 
One group has performed several interesting studies in a model of ventricular arrhythmias 
in the heart and has demonstrated that increased phosphorylation of the RyR can cause 
them to be “leaky” and release more calcium into the cytoplasmic space [99,100].  This 
leak leads to the arrhythmia and can be controlled by treatment with a benzothiazepine, 
which stops the leak by increasing the affinity of a protein, calstabin with the receptor 
[100].  We demonstrated in the in vivo pilocarpine model that the expression of RyR does 
not change during SE, or at 1 hr, 1 day, 1 wk, or 7 wks post-SE.  Thus, we hypothesized 
that SE triggered an increase in phosphorylation of the receptor, thereby leading to 
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increased Ca2+.  This hypothesis was confirmed with western blot using an antibody for the 
phosphorylated form of the receptor.  We demonstrated that in the pilocarpine model of 
SE-induced AE, during the period of epileptogenesis hippocampal neurons show a marked 
increase in the phosphorylated form of the receptor.  This may potentially explain how 
dantrolene, a RyR inhibitor, was effective in lowering Ca2+ to baseline levels and 
preventing epileptogenesis.  The similarities between the ventricular arrhythmia model and 
epilepsy are striking: both are disorders of cellular hyperactivity triggered by ionic 
imbalances, RyR are important components of both cardiac cells and neurons, and 
benzothiazepines effectively treat the arrhythmias and benzodiazepines are the most 
prevalent treatment for epilepsy.  Thus, these studies in cardiac tissue support our 
hypothesis and also suggest that Ca2+ dysregulation could be a result of alterations to the 
RyR. This represents an interesting and novel area of future research, with clinically 
relevant implications in both the fields of neurology and cardiology.   
 
These studies demonstrating the role of RyR in ventricular arrhythmias and in seizure-
induced cell death served to bolster our own studies.  The in vitro, low Mg2+ model was 
utilized to determine if treatment with dantrolene following SE could lower [Ca2+]i and 
prevent the development of SREDs.  In this model, we observed that dantrolene is able to 
lower [Ca2+]i to concentrations observed in control neurons, maintain these baseline levels, 
offer neuroprotection, and inhibit the development of SREDs.  These results, in 
combination with the results from other studies, make dantrolene a potential therapeutic 
candidate to be tested in an in vivo model.   
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Our studies have also shown that the novel AED, carisbamate, appears to block SREDs 
when used on “epileptic” neurons and prevents the development of SREDs when 
employed immediately post-SE.  We found that the drug had to be present in the cultures 
to inhibit SREDs; the episodes returned following wash-out of the drug.  Interestingly, 
however, when cultures were treated with the drug for 12 hrs after low Mg2+ and examined 
24 hrs after wash-out of the drug, the neurons failed to display SREDs.  We also 
demonstrated that this drug not only lowered [Ca2+]i post-SE but was also able to restore 
Ca2+ homeostatic mechanisms.  This is the first account of this drug exhibiting anti-
epileptogenic properties and further studies are being conducted to determine if similar 
properties exist when used in vivo.  We are interested in more thoroughly examining how 
this drug affects regulators of intracellular Ca2+ release such as the RyR and IP3R.  
 
We have also utilized another commonly used AED, levetiracetam.  No mechanism of 
action is known for this drug, even though it is used frequently in clinical settings [110].  It 
is known that levetiracetam does not directly affect GABAergic neurotransmission or 
interact with the benzodiazepine binding site [111-113,192].  Thus, the effect of 
levetiracetam on Ca2+ and Ca2+ regulatory systems proved to be an interesting, unexplored 
potential mechanism of action.  We demonstrated in hippocampal neuronal cultures that 
this drug did not affect baseline [Ca2+]i in naïve neurons; however, when RyR and IP3R 
were over-stimulated, the drug inhibited CICR mediated through both of these systems.  
The ability to modulate Ca2+ levels inside hippocampal neurons is an important 
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characteristic, and may make the drug an ideal candidate in neuroprotection following 
neuronal injury.   
 
All of these studies have aimed at modulating [Ca2+]i, and in doing so, determining the role 
that various calcium regulatory systems have in epileptogenesis and, to some extent, 
neuronal plasticity.  The question of how Ca2+ affects plasticity is of utmost importance in 
understanding basic neuronal functions such as learning and memory, as well as long-term 
neuronal adaptations.  Moreover, the observation that elevations in [Ca2+]i are maintained 
post-SE in animals that develop epilepsy is not limited to  models of SE-induced AE.  
Other conditions such as stroke and TBI can also lead to the development of chronic 
epilepsy and alterations in [Ca2+]i have been observed in these models.  Finding common 
pathophysiologic mechanisms that lead to the development of a single phenotype—
epilepsy—following distinct injuries is important in understanding neuronal plasticity and 
in creating new treatments to prevent epileptogenesis.  Each of these injuries, while 
resulting from different etiologies, is excitotoxic and has been shown to trigger the massive 
release of glutamate, activation of NMDA receptors, and finally, influx of Ca2+ into the 
cell [4].  As a ubiquitous second messenger, this increase is enough to trigger significant 
downstream effects that can affect neurotransmission, transcription, cell death pathways, 
and ultimately, the fate of the neuron.  Therefore, the examination of Ca2+ dynamics in 
various models of injury-induced epilepsy may be of great clinical importance and may aid 
in our understanding of the precise role between Ca2+ and epileptogenesis.   
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Currently, approximately 30% of epileptic patients are resistant to conventionally used 
AEDs [72,84]; therefore, new treatment modalities are needed.  In the development of new 
AEDs, many research groups screened large numbers of drugs in in vivo models in the 
hopes that they would find potential therapeutic agents.  Once drugs were found that 
displayed these properties, the cellular and molecular mechanisms behind the anti-
convulsant action were studied.  We are only now starting to understand the specific effect 
that these agents have on individual channels, receptor expression, and myriad cellular 
processes.  While these studies contributed greatly to the current body of knowledge on 
epilepsy, such massive screening efforts are not necessarily the most appropriate or 
efficient in the search for anti-epileptogenic agents.  Research groups studying anti-
epileptogenic drugs are focusing on pathophysiological mechanisms as a means of better 
understanding the process of epileptogenesis and as targets for therapeutics [193].  This 
approach has led to a significantly more thorough understanding of mechanisms of 
excitability and plasticity and the clinical implications of utilizing these studies to affect 
patient care are tremendous.  Thus, observations such as changes in Ca2+ and Ca2+ 
homeostatic mechanisms represent a clinically interesting area of future study with 
therapeutic implications. 
 
It should be noted that while many Ca2+ channel antagonists have been shown to exhibit 
anticonvulsive properties or potentiate the effects of AEDs both in experimental models 
and in clinical trials [90,91], there are also several reports that other Ca2+ channel inhibitors 
are completely ineffective [91].   Even less work has been done examining the effect of 
   
 166 
Ca2+-modifying agents in models of epileptogenesis, and the data demonstrating the anti-
convulsive properties of these drugs suggests that numerous types of inhibitors will have to 
be tested.  One study has shown that the NMDA antagonist, MK-801, was effective in 
decreasing the number of animals that developed chronic epilepsy following electrically-
induced SE [43].  However, in the kainic acid-induced SE model, MK-801 did not prevent 
the development of epilepsy [92].  Conflicting results between different models of 
epileptogenesis have made the search for new therapeutics challenging [93] and have 
underscored the importance of utilizing several different models of epileptogenesis.     
 
Studies aimed at discerning whether lowering Ca2+ to basal levels can diminish or halt the 
process of epileptogenesis may be of importance.  The long-lasting Ca2+ plateau observed 
post-injury appears to be controlled by a multitude of channels, Ca2+ binding proteins, and 
other regulators.  Currently, Ca2+ modifying agents have been employed for other 
pathologies of the CNS.  For example, the NMDA antagonist, memantine, has been 
utilized in patients with Alzheimer’s disease [89].  Interestingly, one Phase II clinical trial 
administered the Ca2+-chelating agent, DP-BAPTA, to patients following stroke and found 
that this drug improved the National Institutes of Health stroke scores with no major 
cardiovascular or neurological side effects even at the highest dose tested [88].  The ability 
to modulate Ca2+ without causing long-lasting, severe side effects is important.  Since Ca2+ 
is found ubiquitously in the body and is necessary for many cellular processes, the 
potential side effects of altering Ca2+ pharmacologically could be tremendous and thus, 
represent a major hurdle in the utilization of Ca2+ modifying drugs.  The ability to 
   
 167 
synthesize these observations on altered Ca2+ dynamics with those from molecular-genetic 
studies identifying potential genes involved in epilepsy could provide novel insight in the 
generation of new anti-epileptogenic targets. 
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Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J. Development of the calcium plateau 
following status epilepticus: the role of calcium in epileptogenesis. Review. Expert Rev 
Neurother, 9(6):813-24,  June, 2009. 
 
Deshpande, L.S., Nagarkatti, N., Ziobro, J.M., Sombati, S., Delorenzo, R.J. Carisbamate 
prevents the development and expression of spontaneous recurrent epileptiform discharges 
and is neuroprotective in cultured hippocampal neurons. Epilepsia, 49(10):1795-802, Oct, 
2008. 
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Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J. Levetiracetam inhibits both ryanodine 
and IP3 receptor activated calcium induced calcium release in hippocampal neurons in 
culture. Neurosci Lett, 436(3):289-93, May, 2008.  
 
Deshpande, L.S., Nagarkatti, N., Sombati, S., DeLorenzo, R.J. The novel antiepileptic drug 
carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure 
discharges and blocking sustained repetitive firing in cultured hippocampal neurons. 
Epilepsy Res, 79(2-3):158-65, May, 2008. 
 
Deshpande, L.S., Blair, R.E., Nagarkatti, N., Sombati, S., Martin, B.R., DeLorenzo, R.J. 
Development of pharmacoresistance to benzodiazepines but not cannabinoids in the 
hippocampal neuronal culture model of status epilepticus.  Exp Neurol, 204(2):705-13, 
Apr, 2007. 
 
Boyson, J.E., Nagarkatti, N, Nizam, L, Exley, M.A., Strominger, J.L.  Gestation stage-
dependent mechanisms of iNKT cell-mediated pregnancy loss.  PNAS, Mar 14, 2006. 
 
Nagarkatti, N, Davis, B.A. Role of Fas and Fas Ligand in the Killing of Tumor Cells by 
Anti-Cancer Drugs.  Cancer Chemother & Pharmacol, 51(4): 284-90, Apr, 2003. 
 
Nagarkatti, N.  Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an 
important role in successful chemotherapy.  Cancer Immunol and Immunother, 49: 46-55, 
Apr, 2000. 
 
 
Book Chapters 
Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J. The Role of Calcium in Mediating 
Neuronal Plasticity in Epileptogenesis. Encyclopedia of Basic Epilepsy Research. Ed. 
Philip Schwartzkroin. 3 vols. Elsevier Ltd. 
 
 
International Conferences 
 
Invited to attend National Institute of Neurological Disoders (NINDS)/Association of 
University Professors of Neurology (AUPN)/American Neurological Association (ANA) 
course, “Combining Clinical and Research Careers in Neuroscience”- Washington D.C. 
(May 29-30, 2009) 
 
Invited Speaker at the “Internet Generation Meets the 68 Generation Session” of the 
Information Society Technologies Meeting - Nice, France (November 6-8, 2000) 
 
Invited Presenter at the 2nd annual Asian Pacific Economic Cooperation (APEC)/Asian 
Youth Science Festival (AYSF) - Singapore (July 24-August 4, 2000) 
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Invited Presenter at the Nobel Foundation’s Nobel Week - Stockholm, Sweden (December, 
1999) 
 
Selected Presenter at the 4th International Conference of the Asian Clinical Oncology 
Society - Bali, Indonesia. “Fas-Fas ligand interactions play an important role in successful 
therapy of cancer.” (August 3-8, 1999) 
 
 
Abstracts/Meetings 
 
Nagarkatti, N., Blair, R.E., DeLorenzo, R.J. The role of leaky ryanodine receptors in the rat 
pilocarpine model of acquired epilepsy. Society for Neurosciences Meeting, Chicago, IL, 
October 17-21, 2009. 
 
Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J. The prevention of epileptogenesis 
through calcium modulation in a hippocampal neuronal culture model of status epilepticus-
induced acquired epilepsy.  Virginia Academy of Sciences, Richmond, VA, May 28-29, 
2009. 
 
Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J. The generation and maintenance of a 
long lasting calcium plateau in cultured hippocampal neurons following in vitro status 
epilepticus. American Epilepsy Society Meeting, Seattle, WA, Dec. 5-9, 2008. 
 
Nagarkatti, N., Deshpande, L.S., Ziobro, J.M., DeLorenzo, R.J. Carisbamate exhibits anti-
epileptogenic properties mediated through calcium modulation in cultured hippocampal 
neurons. Society for Neurosciences Meeting, Washington D.C., Nov. 15-19, 2008. 
 
 Nagarkatti, N., Carter, D.S., Deshpande, L.S., Blair, R.E., DeLorenzo, R.J. The inhibition 
of the injury-induced calcium plateau through modulation of intracellular calcium stores in 
an in vitro model of acquired epilepsy. Watts Day Symposium, Richmond, VA, Oct. 30, 
2008. 
 
Nagarkatti, N. and DeLorenzo, R.J.  Levetiracetam inhibits both ryanodine and IP3 
mediated calcium induced calcium release in hippocampal neurons in culture. American 
Epilepsy Society Meeting, Philadelphia, PA, Nov. 30-Dec. 4, 2007. 
 
Nagarkatti, N., Deshpande, L.S., Blair, R.E. and DeLorenzo, R.J.  The role of the injury-
induced calcium plateau during epileptogenesis in mediating neuronal plasticity changes 
and the development of acquired epilepsy.  Society for Neurosciences Meeting, San Diego, 
CA, Nov. 3-7, 2007. 
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Nagarkatti, N. and DeLorenzo, R.J. The effect of levetiracetam on IP3 and ryanodine 
receptor-mediated calcium induced calcium release in hippocampal neuronal culture. Watts 
Day Symposium, Richmond, VA, Oct. 16, 2007. 
 
Nagarkatti, N., Deshpande, L.S., Blair, R.E., Sombati, S., Martin, B.R., DeLorenzo, R.J.  
Treatment of benzodiazepine-resistant status epilepticus (SE) through the use of 
cannabinoid CB1 agonists in the hippocampal neuronal culture model of SE. American 
Society of Clinical Investigators Meeting, Chicago, IL, April 13-15, 2007. 
 
Nagarkatti, N. and DeLorenzo, R.J.  Development of pharmacoresistance to 
benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status 
epilepticus.  Watts Day Symposium, Richmond, VA, Oct. 23, 2006. 
 
 
Awards and Honors 
 
• Awarded Philanthropic Educational Organization (PEO) Scholar Award, $15,000 (May 
2009) 
• First place winner (Best Student Paper) at Virginia Academy of Sciences (VAS) 
Meeting (May 2009)  
• Awarded American Heart Association’s pre-doctoral fellowship (July 2008) 
• Recipient of Sigma Xi Grant in Aid of Research (October 2002) 
• Featured in Teen People magazine - “20 teens who will change the world” (February 
2000) 
• Winner of Pinnacle Award (Grand Award) $40,000 (Intel Young Scientist Scholarship) 
at the 1999 Intel International Science and Engineering Fair (ISEF) held in 
Philadelphia, out of 1179 participants from 40 countries. 
• Winner at ISEF of Glenn T. Seaborg Award (2nd Grand Award)- Trip to Nobel Prize 
Ceremonies in Stockholm, Sweden (December 1999) 
• Winner at ISEF of the Office of Naval Research Naval Science Award $8000 (1999) 
 
 
Leadership Positions 
 
• American Physician and Scientist Association (APSA) – Institutional Representative 
(2007-2009); Annual Meeting Planning Committee (2008-2009). 
• Virginia Commonwealth University (VCU) Women in Science (WIS) – Vice-President 
Community Outreach (2008-2009) 
• Virginia Commonwealth University (VCU) Graduate School Mentoring Program 
(GSMP) – Mentor to Undergraduate (2008-2009) 
• Virginia Commonwealth University (VCU) MD/PhD Program – President (2007-2008) 
• Virginia Commonwealth University (VCU) Student International Health Organization 
(SIHO) - Vice-President for Campus Awareness (2005-present) 
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• VCU Hematology/Oncology Interest Group Cancer Day 2005 - organizer (March 
2005) 
• VCU Women in Medicine group - active member (2004-present) 
• International Health Organization (IHO) - Representative on the Board. IHO is an 
NGO that works with health in developing countries, primarily in South Asia (2001-
2003) 
• Harvard University South Asian Association (SAA) - President, Publicity Chair, 
Freshman Representative.  SAA is the 2nd largest cultural organization at Harvard 
University; consists of over 200 members (2001-2003)  
• AIDS in India Conference - Organizer. Harvard School of Public Health (December 6, 
2001) 
 
Volunteer Work 
 
• Organizer- Cinderella Dreams Dress Drive (VCU) (2009) 
• Organizer- Women in Science Medical Career Day for middle and high school girls 
(VCU) (2008-09) 
• Organizer- Toys for Tots Drive (VCU) (2008) 
• Crossover Clinic (2006) 
• Organizer- National Gandhi Day of Service (NGDOS) (2002)   
• Harvard University’s Refugee Youth Tutoring Program (2001) 
 
Membership in Professional Societies 
 
• Society for Neurosciences- Student member (2008-present). 
• American Physician Scientist Association (APSA) (2006-present) 
• American Academy for the Advancement of Science (AAAS)/Science Program for 
Excellence- Sponsored member (2006, 2007). 
 
 
 
 
